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GLOSSARY  
   
As used in this thesis: words, terms, abbreviations, acronyms, phrases  
 
ADL(s) 
 
Activities of daily living 
ATC Anatomical Therapeutic Chemical – Classification system 
for drugs controlled by the WHO Collaborating Centre 
for Drug Statistics Methodology  
 
CCI 
 
Charlson Comorbidity Index 
CofC 
 
continuity of care 
CofCP 
 
Continuity of Care Project 
cohort 
 
group with statistical similarities 
COOP charts 
 
Dartmouth Co-operative Functional Assessment charts 
COOP/WONCA charts Dartmouth Co-operative Functional Assessment/World 
Organisation of National Colleges and Academics charts 
 
CPS 
 
Cognitive Performance Scale 
CRQ 
 
Chronic Respiratory Questionnaire 
Day Only (DO) patients 
 
In Australia: Patients admitted and discharged in one day 
DDI(s) 
 
Drug to drug interaction(s) 
DRG 
 
Diagnosis related group or grouping 
 
x 
Glossary  
GLOSSARY continued 
 
 
DRP(s) 
 
Drug related problem(s) 
DVA 
 
Australian Government Department of Veterans’ Affairs 
effect size measure of the strength of the relationship between two 
variables 
 
empirical 
 
based on real experience or scientific experiment (rather 
than theory or secondary data analysis) 
 
EQ-5D 
 
 
EuroQol Group Health Standard 
explicit 
 
clear, obvious, definite and unqualified 
face value 
 
stated value, seeming apparent worth 
GP(s) 
 
General Medical Practitioner(s) 
HAD 
 
Hospital Anxiety and Depression scale 
HIC 
 
Australian Health Insurance Commission 
HMR Home Medicines Review, medication review conducted 
in the patient’s home 
 
HMR Report group 
 
 
Minority subgroup within the CofCP cohort 
HCP 
 
Healthcare professionals 
HRQL 
 
Health Related Quality of Life 
IADL 
 
Instrumental Activities of Daily Living 
ICD - 10 International Statistical Classification of Diseases and 
Related Health Problems, 10th Revision  
 
implicit 
 
understood, implied, contained, not stated directly in what 
is expressed 
 
integrated 
 
combining expertise, people, or ideas of different types in 
one effective unit, group, or system 
 
IQR 
 
Interquartile range  
LOS 
 
Length of stay in hospital 
Glossary Page xi 
 
GLOSSARY continued 
 
MacNewQLMI 
 
MacNew Quality of Life after Myocardial Infarction 
MBS 
 
Australian Medicare Benefits Scheme 
medication drug or medicine used to treat illness, used predominantly 
as an adjective/adverb in this thesis e.g. medication 
review 
 
MI 
 
 
myocardial infarction 
MONICA Multinational MONItoring of trends and determinants in 
CArdiovascular disease 
 
nCPAP 
 
 
nasal continuous positive airway pressure 
NHP 
 
Nottingham Health Profile 
non-HMR Report group 
 
Majority subgroup within the CofCP cohort 
NSW 
 
State of New South Wales in Australia 
NZ 
 
New Zealand 
optimal care 
 
best possible care for individual patient 
patient-nominated 
 
patient’s choice 
PBS 
 
Australian Pharmaceutical Benefits Scheme 
Polymorbidity 
 
 Many diseases 
polypharmacy concurrent and active daily consumption of many drugs 
(≥5 drugs )  
 
potential 
 
 
probable, but as yet not actual 
Primary care In Australia: care delivered in the community e.g. GP 
care 
QOL 
 
quality of life 
real 
 
physically existing, not artificial, verifiable 
representativeness truly/genuinely representative.  Typical of people or 
things in group 
 
Glossary Page xii 
 
GLOSSARY continued 
 
RQLQ 
 
Respiratory Quality of Life Questionnaire 
SDM 
 
Shared decision making 
Secondary care In Australia: healthcare delivered in non-acute care 
hospital or institution e.g. in nursing homes 
 
Short Stay patients In Australia: Patients who stay a few (e.g. 1-3)  nights in 
hospital 
 
SF-12, 36 
 
Medical Outcomes Study 12 or 36 item Short-form 
Health Survey 
 
SIP 
 
 
Sickness Impact Profile 
SPPB Physical Performance Battery score 
 
SPSS 
 
 
Statistical Package for the Social Sciences  
Tertiary care 
 
In Australia: healthcare delivered in an acute care hospital 
PIP(s) 
 
Potentially Inappropriate – Prescriptions;  Prescribing,  
Quaternary care In Australia: healthcare delivered by a tertiary care 
hospital in a consulting specialty e.g. cardiovascular 
disease.   
 
USA 
 
 
United States of America 
WMP 
 
Westmead Medicines Project 
WSAHS 
 
Western Sydney Area Health Service 
WSDGP 
 
Western Sydney Division of General Practice 
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1.0  CONTINUITY OF INTEGRATED PATIENT CARE: 
A patient centred study of medication management 
 
1.1  RESEARCH INTRODUCTION 
 
This research is about enhancing the continuity of patient care.  It focuses on 
medication management at the time of patient discharge from a cardiology unit in an 
Australian acute care hospital.  That is, during the time of the patients’ transition 
from tertiary to primary care.  The philosophical concept underpinning the research 
is centred on continuity of patient care which is defined, and then described, in the 
context of each chapter study undertaken.   
 
The main aim of the overall research was to conduct an original, empirical research 
project to identify, characterise, and investigate a cohort of patients in need of 
ongoing care after discharge.  Those subjects recruited into the Continuity of Care 
Project were 281 acute on chronic, cardiovascular patients.  In this research, the 
individual chapter studies investigated the need for continuity of care by analysing 
the quality of prescribing recorded at hospital discharge and at medication review in 
the community.   
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1.2  THESIS OUTLINE 
 
1.2.1 BACKGROUND TO THE EMPIRICAL RESEARCH 
 
Between 2004-2005 an empirical research project, called the Westmead Medicines Project 
(WMP), primarily involving pharmacists and ‘Continuity of Care’ (CofC), was conducted.  
The WMP and its subjects were included in the research reported in this thesis as part of an 
empirical study called the Continuity of Care Project (CofCP) implemented between [2004] 
2005-2007.1  The project was implemented in the acute care cardiology unit of Westmead 
Hospital in Sydney, Australia.   
 
In both studies, a Home Medicines Review (HMR) service referral by the patients’ 
general practitioners (GPs) was requested by the researcher for all recruited subjects.  Most 
of the subjects were not referred by their GP for the service.1  After the extension of 
existing WMP protocols and all ethics approvals, further recruitment of patients established 
the CofCP cohort of 281 patients.   It was proposed for investigation in the CofCP, that 
those patients not referred for an HMR service were disadvantaged in regard to the 
continuity and quality of their ongoing care after discharge back into the community.   
 
1.2.2 DEFINING CofC THROUGHOUT THE THESIS 
 
After the conclusion of the WMP, the conceptual and operational approach to defining and 
recognizing continuity of care (CofC) remained unclear.1  The complex nature of defining 
or explaining the phrase in the context of its use was evidenced from the systematic review 
conducted for this CofCP research.2  The published review is included as Chapter 2 in this 
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thesis.  Importantly, the review found that CofC in research involving pharmacists and their 
practice excluded disadvantaged patients, and care was not usually integrated across the 
involved healthcare professionals.  Further, and noted with professional concern, the 
research reviewed excluded patients most in need of continuity of care.  Following the 
systematic review, the lack of consensus on defining CofC was discussed in a commentary 
which is included in Chapter 2.  The commentary explained the development of the 
working definition used in the systematic review process and the reasons why CofC is 
defined and interpreted in the context of the research reported in the separate chapter 
studies.  
 
1.2.3 BACKGROUND TO THE CHAPTER STUDIES 
 
To pursue the proposal that most of the CofCP cohort had been disadvantaged in 
their transfer from hospital to the community, the personal characteristics, clinical status 
and quality of life (QOL) factors for the cohort were established at two points in time.3  The 
Dartmouth Co-Operative (COOP) QOL charts were utilized for the survey of these 
factors.4-6  Along with the availability to the researcher of an HMR report for 79 patients, 
these characteristics and factors divided the CofCP cohort (n=281) into two subgroups: the 
HMR Report group (n=79) and the non-HMR Report group (n=202). 
 
In the literature, there is no hesitation in identifying the period associated with 
patient transfer from secondary to primary care as a time requiring attention to discharge 
regimen and unmet health needs.7-11  In Australia, written discharge summaries include 
discharge regimen and are the responsibility of the hospital medical team prior to discharge 
dispensing by hospital pharmacists.1,12  Both these duties afford the opportunity for 
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medication reconciliation prior to discharge and for the timely prevention of drug related 
problems (DRPs) after discharge.13-14   
 
Drug related problems which are diverse in nature, are described in many ways and 
are widely reported in the literature to be exacerbated by polypharmacy.15-16  The literature 
supports the completion and accuracy of discharge summaries as crucial components of 
successful handover of information for the patient and for healthcare providers in the 
community.17-19   
 
In Australia, patients can be advised to hand deliver their discharge summaries 
directly to their GP within 3 days of discharge.1,17  This process facilitates continuity of 
care, the opportunity for medication reconciliation by the GP and at the GPs’ discretion, 
referral for a Home Medicines Review (HMR) service.20-22  This service requires an 
integration of care by the patients’ GP, community pharmacy and accredited HMR 
pharmacists for continuity in medicines management, patient education and safety.23   
 
After discharge, HMR is an additional opportunity for reconciliation of medicines 
actually consumed in patients’ homes and for identification of patients’ DRPs.21,24 Taking 
into account pharmacy records, hospital discharge summaries and GP’s referral forms, 
accredited pharmacists can report on the patients’ actual or potential drug related problems 
regardless of the sources or nature of drug prescriptions.25-27  
 
It is suggested that any problems in the quality of medication management can be 
identified by the assessment of patients’ drug regimens at hospital discharge, and post 
discharge at HMR service in the community.  Discharged patients who were referred for 
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HMR, had the advantage of ongoing identification of the source and type of any DRPs or 
any potentially inappropriate prescribing (PIP) of their drug regimens.28   
 
A published paper on identification of DRPs for the HMR Report group is included 
as Chapter 4.8  Hence, after identification of any DRPs or PIP at HMR service, these 
patients also had the advantage of the accredited pharmacists’ reports for discussion with 
their GPs.  In Australia, resolution of actual or potential prescribing problems is 
predominantly the domain of the patients’ GPs.  Meanwhile, international and 
multidisciplinary researchers have developed and validated several tools for the 
identification of PIP by informed healthcare professionals.29-32 
 
To ensure a comprehensive assessment of the drug regimen for the patients who 
were referred for HMR service, two diverse tools for assessment of PIP were applied and 
repeated at two points in time.33-34  Beers explicit criteria (Fick et al. 2003) which were well 
validated internationally, were utilised alongside explicit and implicit, appropriate 
prescribing indicators customized by Basger et al. (2008) for the Australian healthcare 
environment.35-37 
 
1.2.4 RESEARCH QUESTIONS 
 
Across the chapter studies it was proposed that the majority of CofCP patients not referred 
for HMR service were disadvantaged by the lack of CofC arising from the missed 
opportunity for medication management post discharge.3  To test this proposal, any 
differences in the personal and clinical characteristics and discharge regimens between the 
two subgroups were examined.38-41  To identify any differences, the full cohort’s 
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characteristics were examined.  Further their discharge regimens were determined and 
analysed for PIP by the application of Beers criteria.36   
In 2008, Fourrier-Réglat et al. investigated any impact on cardiovascular patients 
from their prescriber’s response or non-response to a survey on their care.  On assessing the 
representativeness of one patient group to another, Fourrier-Réglat et al. could find no 
evidence of a difference between their patient groups.42  To determine patient 
representativeness, these researchers reported on the patients’ personal and clinical 
characteristics and drug regimens.  In this research, the representativeness and significance 
of outcomes for the minority subgroup of patients referred for medication review, to the 
majority subgroup of patients not referred, was investigated. 
 
Hence, it is proposed that this research will address: 
• What is the meaning of ‘Continuity of Care’ (CofC)? 
• Did patients need CofC after hospital discharge? 
• Why did patients need CofC after discharge? 
• Were all patients in need of CofC? 
• Can the CofC needs of a minority subgroup of patients predict those of the 
majority subgroup? 
• How can CofC be integrated and practiced on, and after discharge? 
 
The research documented in this thesis is directed towards answering these 
questions to add knowledge and to inform professional healthcare practice for the 
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enhancement of ongoing patient care in medication management.  That is, to evidence any 
need for improved continuity of patient care after their discharge from hospital. 
 
 
1.3 PRIMARY RESEARCH AIM 
 
 To investigate the need for safer clinical management of medications for 
beneficial continuity and integrated patient care on and after hospital discharge. 
 
1.3.1 RESEARCH OBJECTIVES 
 
To achieve the primary research aim by: 
1) Developing an approach to defining the phrase ‘Continuity of Care’ so its use in any 
context, was meaningful and transparent.  
2) Conducting a real world, empirical research project in a large, acute care teaching 
hospital.  
3) Identifying and taking into account the patients’ personal and clinical 
characteristics, and responses to quality of life surveys.  
4) Analysing any identified drug related problems (DRPs), polypharmacy or exposure 
to potentially inappropriate prescribing (PIP) at discharge and in the community. 
5) Determining, analysing and comparing any specific drugs identified as PIP in the 
full cohort’s drug regimens.  
6) Investigating whether minority subgroup outcomes can be extrapolated to predict 
the medication management necessary for safe, continuous patient care. 
Chapter 1 Introduction, Thesis Outline and Primary Aim Page 10 
 
7) Recommendations for transferring the research and process outcomes into practice. 
 
 
1.4 THESIS FORMAT 
 
The format includes two chapters comprised of peer reviewed, published papers and two 
chapters formatted for publication.  Hence all chapters have been formatted by the inclusion 
of chapter references and appendices immediately following the relevant chapter. 
 
1.4.1 CHAPTER FORMAT – Figure 1.1 
 
Chapter 1.0  Introduction, thesis outline and primary aim.  
 
Chapter 2.0  Systematic review of the international literature questioning what 
pharmacists as researchers, meant by ‘Continuity of Care’.  This chapter consists of a 
published paper entitled:  “Quality Patient Care and Pharmacists’ Role in Its Continuity – A 
Systematic Review”.  This is followed by a commentary, prompted by the review paper, on 
what researchers and communicators mean by the concept and phrase “Continuity of Care”. 
 
Chapter 3.0  Describes the empirical research which recruited 281 cardiovascular patients 
who participated in the Continuity of Care Project (CofCP).  This chapter also builds the 
personal, clinical and drug-related profile of the cohort.  In addition a quantitative 
assessment of 9 health-related quality of life (HRQL) variables for the full cohort, was 
Chapter 1 Introduction, Thesis Outline and Primary Aim Page 11 
 
conducted at 2 points in time.  The availability of reports generated from referral of patients 
for Home Medicines Review (HMR) service divided the cohort into two subgroups. 
 
Chapter 4.0  Investigates the number and nature of drugs, diagnoses and drug related 
problems (DRPs) identified from HMR reports written on the HMR service conducted for 
the HMR Report group.  This chapter consists of a published paper entitled: “Drug related 
problems after discharge from an Australian teaching hospital.” 
 
Chapter 5 0  Is formatted for publication and investigates the severity ratings of drugs, 
instances of PIP and the source (when and where) of the prescribing.  Internationally 
developed Beer’s explicit criteria are applied to the drug regimen of the HMR Report group 
to determine any significant differences in PIP between discharge and HMR service. 
 
Chapter 6.0  Is formatted for publication and identifies instances of PIP and the source of 
prescribing.  Developed in Australia, Basger indicators are applied to the drug regimens of 
the HMR Report group to determine any significant differences between discharge and 
HMR service.  The application of the customized Australian indicators augments the 
outcomes of the internationally developed Beers criteria. 
 
Chapter 7.0  Establishes the number and nature, by active ingredient, of the full cohort’s 
discharge regimen at discharge.  Beers criteria were applied for identification of PIP in the 
full cohort’s discharge regimen.  The representativeness, of the HMR Report group (n=79) 
to the non-HMR Report group (n=202) in PIP of specific discharge drugs, was determined 
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to further indicate the extent to which the full cohort would be exposed to PIP after hospital 
discharge.  
 
Chapter 8.0  Synthesises the concepts, empirical research processes and data analyses of 
the CofCP.  Through the research objectives, this chapter summarises the outcomes and 
impact of the research findings for the HMR Report group, non-HMR Report group and 
CofCP cohort.  The extrapolation of data outcomes and generalisation of process outcomes 
is discussed.  From the outcomes of the data analysis and research processes, 
recommendations for practice and further research are proposed. 
 
Chapter 9.0  Addresses the primary research aim and conclusions are made on the need 
for  safer  clinical  management  of medications  for  the patients’  improved and  integrated  
continuity of care after discharge. 
Chapter 1 Introduction, Thesis Outline and Primary Aim Page 13 
 
1.5 CHAPTER REFERENCES  
1 Chen TF, Brien JE, Whitehead P, Ng K, Ellitt GR. From hospital to community: a 
multidisciplinary "continuity of care" model for cardiovascular patients involving 
community pharmacists. Funded projects, Research & Development Grants 
Program 2005. http://www.guild.org.au/research/funded_projects.asp  (accessed 1 
Jun. 2011) 
 
2 Ellitt GR, Brien J-aE, Aslani P, Chen TF. Quality Patient Care and Pharmacists' 
Role in Its Continuity - A Systematic Review. Ann Pharmacother 2009 
April;43(4):677-91. doi:10.1345/aph.1L505   
 
3 Preen DB, Bailey BES, Wright A, et al. Effects of a multidisciplinary, post-
discharge continuance of care intervention on quality of life, discharge satisfaction, 
and hospital length of stay: a randomized controlled trial. Int J Qual Health Care 
2005 2005;17(1):43-51. doi:10.1093/intqhc/mzi002   
 
4 Eaton T, Young P, Fergusson W, Garett JE, Kolbe J. The Dartmouth COOP 
Charts: A Simple, reliable, valid and responsive quality of life tool for chronic 
obstructive pulmonary disease. Qual Life Res 2005;14:575-85. 
doi:10.1007/s11136-004-0624-2   
 
5 Dartmouth Medical School, Department of Community and Family Medicine. The 
Dartmouth Primary Care Cooperative ("COOP") Information Project. InterStudy 
Quality Edge 1990;1(1):33-40.    
 
6 Bentsen BG, Natvig B, Winnem M. Questions you didn't ask COOP/WONCA 
Charts in clinical work and research. Fam Pract 1999;16(2):190-95. doi: 
10.1093%2Ffampra%2F16.2.190   
 
7 Callen J, McIntosh J, Li J. Accuracy of medication documentation in hospital 
discharge summaries: A retrospective analysis of mediction transcription errors in 
manual and electronic discharge summaries. Int J Med Inform 2010;79:58-64. 
doi:10.1016/j.ijmedinf.2009.09.002   
 
8 Ellitt GR, Engblom E, Aslani P, Westerlund T, Chen TF. Drug related problems 
after discharge from an Australian teaching hospital. Pharm World Sc  
2010;32:622-30. doi:10.1007/s11096-010-9406-9   
 
9 Grimmer KA, Moss JR, Gill TK. Discharge planning quality from the carer 
perspective. Qual Life Res 2000;9:1005-13.    
 
10 Hugtenburg JG, Borgsteede SD, Beckeringh JJ. Medication review and patient 
counselling at discharge from the hospital by community pharmacists. Pharm 
World Sci 2009;31:630-37. doi:10.1007/s11096-009-9314-z  
 
11 Letrilliart L, Hanslik T, Biour M, et al. Post discharge adverse drug reactions in 
primary care originating from hospital care in France: a nationwide prospective 
study. Drug Saf 2001;24(10):781-92  
 
Chapter 1 Introduction, Thesis Outline and Primary Aim Page 14 
 
12 Grimes TC, Duggan CA, Delaney TP, et al. Medication details documented on 
hospital discharge: cross-sectional observational study of factors associated with 
medication non-reconciliation. Br J Clin Pharmacol 2010;71:449-57. 
doi.10.1111/j.1365-2125.2010.03834.x   
 
13 Faulx MD, Francis GS. Adverse Drug Reactions in Patients with Cardiovascular 
Disease. Curr Probl Cardiol 2008;33:703-68. doi:101016./j.cpcardiol.2008.08.002   
 
14 Straubhaar B, Krähenbühl S, Schlienger RG. The Prevalence of Potential Drug-
Drug Interactions in Patients with Heart Failure at Hospital Discharge. Drug Saf 
2006;29(1):79-90. doi.10.2165%2F00002018-200629010-00006   
 
15 Bjerrum L, Søgaard J, Hallas J, Kragstrup J. Polypharmacy: correlations with sex, 
age and drug regimen. Eur J Clin Pharmacol 1998;54:197-202. 
doi.org/10.1007%2Fs002280050445   
 
16 Jyrkkä J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Patterns of Drug Use 
and Factors Associated with Polypharmacy and Excessive Polypharmacy in Elderly 
Persons. Drugs Aging 2009;26(6):493-503. doi.org/10.2165%2F00002512-
200926060-00006   
 
17 Alderton M, Callen J. Are general practitioners satisfied with electronic discharge 
summaries? Health Inf Manag J 2007;36(1):7-12. Print ISSN 1833-3583; On-line 
ISSN 1833-3375   
 
18 Bergkvist A, Midlov P, Hoglund P, et al. Improved quality in the hospital 
discharge summary reduces medication errors - LIMM: Landskrona Integrated 
Medicines Management. Eur J Clin Pharmacol 2008;65(10):1037-46. doi: 
10.1007/s00228-009-0680-1   
 
19 Coiera E. Do we need a national electronic summary care record? Med J Aust 2011 
17 January;194(2):90-92.    
 
20 Roughead EE, Barratt JD, Ramsay E, et al. The Effectiveness of Collaborative 
Medicine Reviews in Delaying Time to Next Hospitalisation for Patients 
WithHeart Failure in the Practice Setting - Results of a Cohort Study. Circ Heart 
Fail 2009;2:424-28. doi:10.1161/CIRCHEARTFAILURE.109.861013   
 
21 Sorensen L, Stokes JA, Purdie DM, et al. Medication management at home: 
medication-related risk factors associated with poor health outcomes. Age Ageing 
2005 Nov;34(6):626-32. http://dx.doi.org/10.1093/ageing%2Fafi202   
   
 
22 Wong JD, Bajcar JM, Wong GG, et al. Medication reconciliation at hospital 
discharge: evaluating discrepancies. Ann Pharmacother  2008 Oct;42(10):1373-9.    
 
23 Bergkvist A, Midlov P, Hoglund P, Larsson L, Eriksson T. A multi-intervention 
approach on drug therapy can lead to a more appropriate drug use in the elderly. 
LIMM-Landskrona Integrated Medicines Management. J Eval Clin Pract 
2008;15:660-67. doi: 10.1111/j.1365-2753.2008.01080.x   
 
Chapter 1 Introduction, Thesis Outline and Primary Aim Page 15 
 
24 Mant A, Kehoe L, Cockayne NL, Kaye KI, Rotem WC. A Quality Use of 
Medicines program for continuity of care in therapeutics from hospital to 
community. Med J Aust 2002;177(1):32-34.    
 
25 Bregnhøj L, Thirstrup S, Kristensen MB, Bjerrum L, Sonne J. Prevalence of 
inappropriate prescribing in primary care. Pharm World Sc 2007;29:109-15. 
doi:10.1007/s1109-007-9108-0   
 
26 Walraven Cv, Mamdani M, Fand J, Austin PC. Continuity of Care and Patient 
Outcomes After Hospital Discharge. J Gen Intern Med 2004;19:624-31. 
http//:www.doi:10.1111/j.1525_1497.2004.30082.x  (accessed 28 June 2010) 
 
27 Yu K, Nguyen A, S.Shakib, et al. Enhancing continuity of care in therapeutics: 
development of a post-discharge home medicines review model. J Pharm Pract  
Res 2007;37:23-26.    
 
28 Liu GG, Christensen DB. The Continuing Challenge of Inappropriate Prescribing 
in the Elderly: An Update of the Evidence. J Am Pharm Assoc 2002;42(6):847-57. 
doi.org/10.1331%2F108658002762063682   
 
29 Avery AJ. Appropriate prescribing in general practice: development of the 
indicators. Qual Health Care 2009;7:123. doi:10.1136/qshc.7.3.123   
 
30 Batty GM, Grant RL, Aggarwal R, et al. Using prescribing indicators to measure 
the quality of prescribing to elderly medical in-patients. Age and Ageing 
2003;32:292-98. http://dx.doi.org/10.1093/ageing%2F32.3.292 (accessed 30 June 
2010) 
 
31 Schumock GT, Walton SM, Park HY, et al. Factors that Influence Prescribing 
Decisions. Ann Pharmacother 2004;38:557-62. doi: 10.1345/aph.1D390   
 
32 Steinman MA, Rosenthal GE, Landefeld S, Bertenthal D, Kaboli PJ. Agreement 
Between Drugs-toAvoid Criteria and Expert Assessments of Problematic 
Prescribing. Arch Intern Med 2009;169(14):1326-32.    
 
33 Levy HB, Marcus E-L, Christen C. Beyond the Beers Criteria: A comparative 
Overview of Explicit Criteria. Ann Pharmacother 2010;44:1968-75. 
doi.10.1345/aph.1P426   
 
34 vanderHooft CS, 'tJong GW, Dieleman JP, et al. Inappropriate drug prescribing in 
older adults: the updated 2002 Beers criteria - a population-based cohort study. Br J 
Clin Pharmacol 2005;60(s):137-44. doi:10.1111/j.1365-2125.2005.02391   
 
35 Basger BJ, Chen TF, Moles RJ. Inappropriate Medication Use and Prescribing 
Indicators in Elderly Australians - Development of a Prescribing Indicators Tool. 
Drugs Aging 2008;25(9):777-93. doi:10.2165/00002512-200825090-00004    
 
36 Fick DM, Cooper JW, Wade WE, et al. Updating the Beers Criteria for Potentially 
Inappropriate Medication Use in Older Adults. Arch Intern Med 2003;163:2716-
24. doi:10.1001/archinte.163.22.2716   
 
Chapter 1 Introduction, Thesis Outline and Primary Aim Page 16 
 
37 Fick DM, Mion LC, Beers MH, Waller JL. Health Outcomes Associated with 
Potentially inappropriate Medication Use in Older Adults. Res Nurs Health 
2008;31:42-51. http://dx.doi.org/10.1002/nur.20232  (accessed 30 June 2010) 
 
38 Barry PJ, O'Keefe N, O'Connor KA, O'Mahony D. Innapropriate prescribing in the 
elderly: a comparison of the Beers criteria and the improved prescribing in the 
elderly tool (IPET) in acutely ill elderly hospitalized patients. J Clin Pharm Ther 
2006;31:617-26.    
 
39 Egger SS, Bachmann A, Hubmann N, Schlienger RG, Krähenbühl S. Prevalence of 
Potentially Inappropriate Medication Use in Elderly Patients - Comparison between 
General Medical and Geriatric Wards. Drug Aging 2006;23(10):823-37. 
doi.10.2165/00002512-200623100-00005   
 
40 Hayes BD, Klein-Schwartz W, Barrueto F. Polypharmacy and the Geriatric Patient. 
Clinics Geriatric Medicine 2007;23:371-90. doi:10.1016/j.cger.2007.01.002   
 
41 Rigler SK, Jachna CM, Perera S, Shireman TI, Eng ML. Patterns of Potentially 
Inappropriate Medication Use Across Three Cohorts of Older Medicaid 
Receipients. Ann Pharmacother 2005 July/August;39:1175-81. 
doi:10.1345/aph.1E581   
 
42 Fourrier-Réglat A, Droz-Perroteau C, Bénichou J, et al. Impact of prescriber 
nonresponse on patient representativeness. Epidemiol 2008;19(2):186-90. doi: 
10.1097/EDE.0b013e31816362e9   
 
Chapter 2 Systematic Review and Commentary – Continuity of Care Page 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2.0 
Systematic Review of the Literature 
and Commentary 
 
Pharmacists’ Role in Continuity of 
Quality Patient Care  
Chapter 2 Systematic Review and Commentary – Continuity of Care Page 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Chapter 2.0 Flowchart
CHAPTER 2.0 
Systematic Review of the Literature and 
Commentary 
 
Pharmacists’ Role in Continuity of Quality Patient Care  
 
DEFINING AND APPLYING ‘CONTINUITY OF CARE’ 
(CofC) 
“What published research centered around the concept of CofC 
and how were pharmacists with multidisciplinary health care 
professionals (HCP) involved as interventionists?” 
Review Process 
*Peer-review of retrieved articles 
*Development Relevance Quality Assessment Tool 
*1st and 2nd Relevance Quality Testing 
*Development Working Definition of CofC 
SEARCH 
Research Components 
*Random Control Trials (RCTs) 
*Clinical Control Trials (CCTs) 
*Retro/Prospective or crossover 
    studies 
*Multidisciplinary HCP involvement 
Concept of Continuity of care 
*Concept synonyms: seamless, 
    continuous, ongoing care 
*Barriers to care 
*Definitions &Themes of CofC 
*Practising Pharmacists/Pharmacies 
*Patients most in need of continuity of care were disadvantaged 
by exclusion criteria 
 
*The involvement of multidisciplinary HCPs was beneficial 
 
*There was no consensus on the definition of Continuity of Care 
 
*The working definition of CofC provided a ready and practical template 
for describing the concept  
SELECTION 21 ARTICLES FOR REVIEW 
Data Extraction 
Data Synthesis 
SUMMARY of OUTCOMES 
Heterogeneity of studies 
Chapter 2 Systematic Review and Commentary – Continuity of Care Page 19 
 
CHAPTER 2.0 SYSTEMATIC REVIEW OF THE LITERATURE: 
 
DEFINING AND APPLYING ‘CONTINUITY OF CARE’ (CofC) 
 
 
2.1 CHAPTER SUMMARY 
‘Continuity of Care’ is a pivotal concept and aim throughout this thesis, therefore the 
phrase required explanation.  Reporting of diverse research topics in peer reviewed 
literature constantly utilised the phrase and its use was varied and unexplained in claims of 
high quality, professional healthcare practice across all disciplines.   Definition, 
description or explanation of the concept in the context in which it was used was rare.  
Hence, as a claim for excellence in practice or as a research goal in infinite circumstances, 
no one definition could suffice.  In this chapter, a systematic review of the literature was 
conducted to clarify the meaning of the phrase and how it was applied in research 
conducted by pharmacists alone, or with multidisciplinary healthcare professionals 
(HCPs).  For the review process it was necessary to develop a relevance quality assessment 
tool and a working definition of continuity of care.   Further, this chapter addresses the 
overall thesis research question of ‘What is Continuity of Care’?   
 
2.2 WORKING DEFINITION  
CONTINUITY OF CARE is a perception of quality health care resulting from the ongoing 
management of issues which cause disruption to optimal patient care. 
 
2.3 PUBLICATION NOTE.  The following paper is cited in subsequent chapters as: 
Ellitt GR, Brien JE, Aslani P, Chen TF. Quality Patient Care and Pharmacists’ Role in Its 
Continuity – A Systematic Review. Ann Pharmacother 2009:43:677-91. doi: 
10.1345/aph.1L505 
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With regret, and to respect our publishers we have not reproduced the full 
manuscript for e-digitization and manuscript pages 23-35 have been deleted.  This 
complete paper is freely available on line and the contents of the paper constitute 
a background to the use of the developed ‘working definition’ of continuity of care 
throughout the thesis.  The authors apologise and encourage readers to access 
the information rich paper, please. 
 
 
PUBLICATION NOTE.  Ellitt GR, Brien JE, Aslani P, Chen TF. Quality Patient Care 
and  Pharmacists’  Role  in  Its  Continuity  –  A Systematic Review.    Ann  Pharmacother  
2009:43:677-91. doi: 10.1345/aph.1L505 
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2.4  COMMENTARY ON ‘CONTINUITY OF CARE’  
 
2.4.1 WORKING DEFINITION FROM SYSTEMATIC REVIEW: 
CONTINUITY OF CARE is a perception of quality health care resulting from the ongoing 
management of issues which cause disruption to optimal patient care.1 
 
2.4.2 COMMENTARY SUMMARY 
After publication of the systematic review assessing pharmacists’ roles in the continuity of 
quality patient care, the above working definition developed for that review, was shown to 
provide a ready and practical baseline for that purpose.  The working definition of 
continuity of care (CofC) was developed from broad searches of the literature.  It required 
an initial indication of whose perception of quality healthcare was being defined.  This was 
followed by the inclusion of three other important components: ongoing management; 
management of issues; and optimal care.   
 
While utilising the working definition it became clear that no one definition would 
suffice to cover the broad, complex and professionally diverse application of the concept 
in healthcare research and communication.  Hence, it was proposed the working definition 
was used as a template which was followed by a description of the four components in 
terms of the research or message rendered.  That is, the template was used as a basis for 
the meaningful description of CofC in the context of its use. 
 
2.4.3 THE CONCEPT OF CONTINUITY OF CARE 
 There is no doubt about the importance of ‘continuity of care’ in healthcare as a 
concept, an expression of professional achievement, significant research outcome or as a 
model of optimal patient care.2-3  Despite the importance of continuity of care, there 
appears to be no consensus on the definition or application of the phrase.4-5 
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 The vast number of articles retrieved with ease, when searching the literature for the 
phrase ‘continuity of care’, suggests that the term is in common use in all forms of 
research and communication within the healthcare professions.1,4,6-7  Use of the phrase was 
found to be made by most professions in a diverse range of settings, but always in relation 
to care delivered over a long period of time.  Further, the phrase has been used to describe 
the care of patients in most diagnosis related groups (DRGs) from a variety of societies 
and cultures.8-9  Despite common usage, few articles defined the phrase and in those few, 
no two definitions were alike. 
 
 In general, in the few articles where the phrase was defined and where a claim for 
attainment of CofC or ‘seamless’ care was made, the definitions seemed narrow, 
prescriptive and exclusive.10-12  These definitions implied an exclusivity for CofC to the 
authors’ profession, to their own health care setting and/or to patients in (only) their care 
for a specified, long period of time.10 
 
 Beside well known factors such as a long time period and knowledge of the patient’s 
medical history, other less obvious factors influence CofC but are rarely explained when 
the phrase is used. These include, for example: the need for a patient focus; the quality of 
care; the quality of research evidence; the geography and religion of the care setting.  In 
the literature, cultural and ethical aspects of health care settings were found to be factors 
which were integral to the context in which the phrase was used.13-14 
 
 When these factors were addressed, culture and ethics were described as being separate 
and unique, and not as being integral to CofC.  For example, there has been significant 
criticism about the movement of primary (medical) care towards specialization and the 
way in which it undermined the patients’ CofC especially when patients were from 
minority cultural groups.13  Other articles discussed the ethics of fee-for-service systems 
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where uninsured patients were refused treatment or patients in managed care systems felt 
abandoned and frustrated where CofC was concerned.  Contextual factors such as culture 
and ethics were even more rarely reported when found to be barriers to the quality of the 
patients’ CofC.15-18 
 
 It was challenging to adequately include, in one description, the vast number of 
components which could comprise continuity of care. The expression is comfortably 
adopted and utilized by so many professionals in so many ways to indicate so many 
different ideas.  Hence, how could CofC communication by healthcare professionals be 
unambiguous, or research findings described as ‘enhancing continuity of care’, be 
validated or interpreted unambiguously?  
 
2.4.4 DEFINING CONTINUITY OF CARE 
In an effort to find a standard or benchmark for professional communication and research 
outcomes, after conducting the systematic review in this chapter, it was concluded that no 
one fixed definition of continuity of care could suffice.19 As a starting point for clarity, it is 
proposed that the working definition of CofC developed for the review, be used as a 
generic template on which particular components of the CofC research or message were 
described.  The template included four main components consisting of:  
1) a perception of quality healthcare;  
2) ongoing management;  
3) management of disruptive issues; and  
4) optimal patient care. 
 
 In the systematic review of the literature on how pharmacists contributed to patients’ 
continuity of care, the proposed template was used to assess descriptions of CofC.1  Of the 
twenty one articles reviewed, eleven articles clearly contained the words or the phrase 
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‘continuity of care’ or one of its synonyms however, only the three following studies 
offered any explanation of the concept in the context of their studies.   
 
 Bolas et al, (2004) in Northern Ireland, stated the clear benefits of achieving seamless 
pharmaceutical care which they defined as “concerned with the transfer of patients 
between primary and secondary sectors without loss of continuity…..”20  They added that 
few pharmacy services were able to deliver that type of care and that communication and 
timely information exchange were the most important components of seamless care. 
 
 Nickerson et el. (2005) in Canada, defined seamless care in the profession of pharmacy 
as continuity of care delivered ‘across the spectrum of caregivers and their 
environments’.12  In addition, to improve medication use, it was stated that pharmacy care 
should be un-interrupted as pharmacists take responsibility for patient care as it is passed 
from one professional to the next. These researchers named ‘medication reconciliation’ as 
an important subset of seamless care.  
 
Kuehl et al. (1998) in the USA, commented that ‘continuity of care’ had been 
repeatedly re-defined and even though the term was increasingly more relevant to 
pharmacy practice, an applicable definition was lacking.21  Kuehl described the term as 
including information exchange, coherent provider/consumer relationships, sharing of 
professional knowledge and patient interaction across healthcare systems.  It was also 
suggested that patient interaction alone, even with a knowledgeable healthcare 
professional, did not totally define the concept. 
 
The above three examples from the systematic review showed the template’s utility 
and flexibility as a baseline on which to assess the concept in the context of its use.  In the 
examples it was assumed, and not reported, that readers would know whose perception of 
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quality healthcare was being researched in patient transfer between primary and secondary 
sectors; across the spectrum of caregivers; or across healthcare systems.  
 
 It was reported that ongoing management could be achieved by ‘transfer without loss 
of continuity’; and ‘uninterrupted pharmacy care’.  Management of disruptive issues was 
implied by the achievement of communication and timely information exchange; taking 
responsibility for patient care; and providing coherent consumer relationships.  Optimal 
patient care was implied by the conduct of medication reconciliation; and the clear benefits 
of achieving seamless care. The template accommodated these specialised descriptions of 
CofC in the context of three very different research studies.  However, none of the 
examples included all four of the proposed components. 
 
Further, it is noteworthy that none of the twenty one reviewed studies suggested 
fragmentation of the concept into different types of CofC (e.g. interpersonal, relational, 
organisational, or informational continuity), which was identified in abundant medical and 
nursing literature.4,19,22  The lack of CofC fragmentation suggested a tendency to intra-
disciplinary consensus between pharmacists from seven different countries, in twenty one 
disparate studies.  The pharmacists, by chance, used the same general expression of the 
concept in their studies and CofC was not broken up into several different types of 
continuity. 
 
 In an editorial on the systematic review of CofC in this chapter, Murray M (2009) 
suggested that healthcare professionals ‘Keep it simple” when discussing CofC.23  These 
comments were consistent with the proposed non-fragmentation of the concept into many 
different types.  In the literature, the four components of the template were repeatedly 
reported to be necessary for successful continuity of patient care.24-31  It is suggested that 
the components are not negotiable in describing the phrase.  However, the template allows 
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flexibility in the way components are included to describe the concept.  That is, 
descriptions could include interpersonal, relational, organization or informational care as 
optimal for the patient.32  
  It is intended that the generic template be customized so the meaning of each 
component is clarified.  That is, it was recorded whose perception of quality healthcare 
was envisaged; what form the ongoing management takes in a particular setting; how 
management of disruptive issues is proposed; and what care is seen as optimal for the 
patient.  The four generic components have been derived from the plethora of opinions and 
descriptions in the literature and are commonplace factors expected in professional 
healthcare practice.30,33  The concept of ‘continuity of care’ seems to be idealised and 
generalised, but claims of its attainment were not reported as patient centred and 
meaningful in a specific context.   
 
 Hence, only the users of the phrase ‘continuity of care’; in any study or message, could 
answer the question of what was meant by the phrase at the time of its use.  If no 
explanation or description in the context of the message was provided, then an accurate 
interpretation by the reader or listener could not be expected.  If the meaning was reported 
as suggested, the receiver of the message could decide how far the proffered description of 
CofC was acceptable, adequate and applicable within their own ethical, research or 
practice ethos. For the patients’ welfare, communication should be less ambiguous. 
 
It is accepted that consensus on one definition of CofC is unlikely, but inclusion of 
the intended meaning of the phrase in context, would reduce the ambiguity of its use.  To 
this end in the following chapters, the concept of CofC was defined by the same template 
but was described in the context of the overall thesis or in the context of each of the 
separate studies of which the thesis was comprised. 
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CHAPTER 3.0  CONTINUITY OF CARE PROJECT and SUBJECT  
 
CHARACTERISTICS 
 
3.1  CHAPTER SUMMARY 
This chapter introduces the empirical Continuity of Care Project (CofCP), characterises 
the patients recruited, describes the implementation of the CofCP and justifies the 
division of the cohort into subgroups.  The cohorts’ characteristics of age, gender, 
length of stay (LOS) and number of prescriptions are assessed along with the outcomes 
of a Health Related Quality of Life (HRQL) survey at discharge and post discharge.   
 
At these two points in time, the cohorts’ personal and clinical characteristics 
were also compared to ascertain any differences between HRQL survey responders and 
non-responders.  Justification for the division of the cohort into the non-HMR Report 
group (n=202) and HMR Report group (n=79) is reported, as is the representativeness 
of the minority subgroup in the above variables.  Description of the project 
implementation and cohort characteristics in this chapter precedes investigations into 
the patients’ medication management for continuity of care in the following chapters.  
 
3.2  BACKGROUND TO CONTINUITY OF CARE PROJECT (CofCP) 
A previous study known as the Westmead Medicines Project (WMP) was conducted in 
the cardiology unit of Westmead Hospital which is a major teaching hospital in Sydney, 
Australia.  The WMP tested a multidisciplinary ‘continuity of care’ model for 
cardiovascular patients, involving community pharmacists.  Referral for Home 
Medicines Review (HMR) services by the patients’ general medical practitioners (GPs) 
after discharge, was requested for all subjects.  After referral, the involvement of 
pharmacists combined the patients’ community pharmacies and accredited pharmacists 
as providers of the HMR services after hospital discharge.   
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By the final date of funding for the WMP and report to the Pharmacy Guild of 
Australia, the recruitment of 176 patients and collection of 46 HMR reports was 
achieved.  The original WMP research design had been approved by 4 institutional 
ethics boards for the recruitment of 280 subjects and subsequently, these boards 
approved an extension of time to complete patient recruitment and follow up.   
 
An additional 105 patients were recruited under WMP protocols and conditions, 
and all details appear in the methods section of this chapter.  The full cohort of patients 
(n=281) and their data sources, constituted the subjects and resources for the Continuity 
of Care Project (CofCP) on which studies in this, and the following chapters are 
focussed.  
 
3.3  INTRODUCTION TO THE CONTINUITY OF CARE PROJECT (CofCP) 
 
3.3.1  CONTINUITY OF CARE 
The concept of continuity of care (CofC) is important and is upheld by most 
professional practitioners from internationally diverse cultures and healthcare 
environments.1-4 While there is ready acceptance and common use of the phrase, there is 
no consensus on the definition of the concept.5   
 
More often than not, CofC is not defined or explained in the context of the 
situation or research in which the phrase is used.5-8  There is however, no disagreement 
that continuity in patient safety and quality of care is most at risk on transfer from one 
healthcare sector to another.  Several researchers concluded that clear and accurate 
communication between healthcare professionals was vital to patient safety and care. 9-
13 Wenger and Young (2007) equated safety and quality of care with having patient 
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focussed communication with a dedicated primary care physician after hospital 
discharge.14   
 
 
3.3.2  HOSPITAL DISCHARGE    
However, Shakib et al (2009) found the opportunity for effective communication with 
the patients’ GPs through discharge summaries, was ‘spurned’ in Australia by hospital 
medical staff.15  Research by Richardson and McKie (2008) found a proposal for 
improved supervision and support of junior doctors was rated highest overall in their 
investigation of options for reducing adverse events in Australian hospitals.16  These 
same junior doctors are generally responsible for the documentation of hospital 
discharge summaries which are often computer printed after manual input for hand 
delivery, by the patient, to their local GP.17-19  
 
 In 2001, Australian researchers reviewed the reliability, delivery timeliness and 
accuracy of discharge summaries and found only 27.1% of the patient-nominated GPs 
received summaries and 36.4% of discharge summaries contained errors.17  In 2011, 
Swiss researchers targeted omitted and unjustified drugs recorded in 577 discharge 
summaries.  They found that 32% of omissions and 16% of the unjustified drugs 
identified, were potentially harmful.20 
 
Responsible patient discharge from an acute care hospital back into the 
community relies heavily on the provision of accurate clinical documentation, patients’ 
health needs and education on their drug regimen.21-23  Comprehensive discharge 
summaries are a base line for recognition of change in patients’ health status, medical 
treatment and pharmacotherapy, post discharge.24  As such, discharge summaries can 
efficiently transfer patient information.25-26  Internationally, the literature shows 
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discharge summaries are recognised as an important link in communication between 
hospitals and healthcare practitioners in the community.27-32 
 
 
3.3.3  HOME MEDICINES REVIEWS 
 
In general, diligent communication would effectively maintain information exchange 
between hospital medical staff and patients’ GPs for the successful integration of 
tertiary and primary care.14,33-34 In particular, information exchange between healthcare 
professionals is pivotal to the accuracy and relevance of all forms of post discharge 
medication reviews by pharmacists.35-36   
 
In comparison to Australia, international primary care services which include 
medication review and reconciliation; vary in name, process, involved healthcare 
professional (HCP) and patient interview location.35,37-40  When investigating patients’ 
self efficacy after medication review services, Canadian and UK researchers concluded 
that medication review by pharmacists did not necessarily lead to health gains or cost 
effectiveness.  The international researchers claimed pharmacists’ advice had the 
potential to “undermine and threaten the patients’ assumed competence, integrity, and 
self governance.” (pp110579)42-44   
 
In Australian HMR services, GPs are requested to document their patients’ 
current diseases and prescribed drugs on referral forms to inform pharmacists prior to 
their provision of the service.  Also, as the service name implies, HMRs are conducted 
in the patients’ homes where accredited pharmacists have access to all medications the 
patient is currently consuming.18  As a service requirement, pharmacists report back to 
the referring GP on the patients’ health status and any potential drug related problems 
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identified.39,45-46  Also during HMR, pharmacists exchange information with patients to 
encourage adherence to prescribed drug regimen.47-48 
 
Although there have been reports of slow uptake of HMR in Australia by GPs, 
no reports of potential, detrimental outcomes from the service have been published.36,48-
50 Australian research shows multidisciplinary HMR services can address drug related 
problems; improve the appropriateness of prescribing; warfarin management; regimen 
adherence and the timely identification of potentially inappropriate medications post 
discharge.48,50-54  Australian researchers have also shown how continuity of care 
intervention by multidisciplinary teams of primary care providers can positively affect 
the patients’ quality of life (QOL) post discharge.55 
 
3.4  PERSONAL CHARACTERISTICS OF THE PROJECT COHORT 
 
In this chapter the personal characteristics of the study cohort (n=281 patients) were 
assessed as a prelude to the identification, in the following chapters, of any drug related 
problems experienced by the cohort.  Preen et al. (2005) claimed that an 
acknowledgement and consideration of the influence of human factors such as age, 
gender and QOL, on drug related research validity and on the patients’ continuity of 
care, was essential.55 
 
For patients with primary or co-morbid cardiovascular disease, the literature on 
QOL research is vast, geographically and culturally diverse, and published by many 
healthcare disciplines.  Age and gender are routine inclusions in QOL investigations.  
Further, QOL research can be conducted at primary care/community and or 
hospital/clinical research sites.  In addition, the increasing importance of quantifying the 
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impact of all HRQL interventions has realised an extensive array of QOL measurement 
charts, questionnaires, health surveys, scales, indexes and programmes.56-57  From a 
literature search, international research into HRQL has been compared with Australian 
and New Zealand (NZ) research as these two countries have many geographic, cultural, 
social and (in particular) healthcare system similarities. 
 
3.4.1.  JUSTIFICATION FOR ASSESSMENT OF QOL AS A PATIENT  
CHARACTERISTIC 
 
3.4.1.1  QOL International Perspective: Primary Care/Community  
 
Environment 
 
In Norway, Stavem and Jodalem (2002) assessed the reliability, construct and 
discriminant validity of the Dartmouth Co-operative Functional Assessment; World 
Organisation of National Colleges and Academics (COOP/WONCA) charts against the 
EuroQol Group Health Standard (EQ-5D) and Respiratory Quality of Life 
Questionnaire (RQLQ) in a respiratory outpatient clinic.  These researchers found the 
reliability of the COOP/WONCA items were acceptable for group level use, but were 
lower than recommended reliability for individual patient use.58  Benetti et al.(2010) in 
Brazil, ran a community exercise programme for cardiorespiratory fitness and QOL 
improvement after myocardial infarction (MI) using the MacNew Quality of Life after 
Myocardial Infarction (MacNewQLMI) scale and found greater intensity exercises 
increased functional capacity and QOL after MI.59   
 
Landi et al. (2007) in Italy, researched the impact of inappropriate drug use, 
identified by Beers criteria for subjects ≥65 years of age.  The researchers assessed 
physical performance and functional status in the elderly from a mountain community.  
Measurement of QOL utilised the Cognitive Performance Scale (CPS), Physical 
Performance Battery Score (SPPB) and Instrumental Activities of Daily Living (IADL) 
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scale.  Landi et al. found the mean age of his subjects was 85 years and that amongst 
these ‘frail-old subjects’, the use of inappropriate drugs is associated with impaired 
physical performance.60 
 
3.4.1.2  QOL Australian and New  Zealand Perspective: Primary  
 
 
Care/Community Environment 
 
In a NZ primary care environment, Eaton et al. (2005) compared the COOP charts, 
Chronic Respiratory Questionnaire (CRQ), Medical Outcomes Study 36 item Short-
form Health Survey (SF-36) and Hospital Anxiety and Depression (HAD) scale.  Eaton 
et al. found many HRQL tools were not user-friendly in the clinic setting and the COOP 
charts were simple, reliable, valid and responsive.61  Further HRQL research was 
conducted by Krass et al. (2011) in a community pharmacy Diabetes Medication 
Assistance Service and Clarke et al. (2009) in a Fenofibrate Intervention and Event 
Lowering in Diabetes study.  Both research teams utilized clinical and the EQ-5D for 
QOL outcome measurement.  Krass et al. found the diabetes service would reduce 
diabetes-related complications and cardiovascular risk.62  Clarke  et  al.  found  EQ-5D  
was  an  independent  predictor  of  mortality  risk,  diabetes  complications  and  future 
vascular events.56 
 
3.4.1.3  QOL  International  Perspective:  Hospital/Clinical Environment 
 
In a Spain, Parra et al. (2011) assessed the impact of nasal continuous positive airway 
pressure (nCPAP) in first time ischaemic stroke patients in seven acute care teaching 
hospitals.  The Barthel Index, Canadian Scale, Rankin Scale and SF-36 were repeated 
over 24 months and patient age, gender, number of drugs and hospital length of stay 
(LOS) were included variables.  Parra et al. found nCPAP accelerated neurological 
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recovery and delayed cardiovascular events, although improved survival and QOL was 
not shown.63 
 
Researchers from the United Kingdom and Norway combined to systematically 
review fifteen HRQL instruments and assessed older people whose specific co-
morbidities included chronic heart disease and stroke.  Of the fifteen instruments the 
most extensive evidence for reliability, validity and responsiveness was found for the 
SF-36, COOP charts, EQ-5D, Nottingham Health Profile (NHP), and Sickness Impact 
Profile (SIP).  Age, gender and LOS characterised the patients and the effect size 
statistic was claimed to be the most common method of providing a standardised unit of 
expression of the size and meaning of score change.64 
 
3.4.1.4  QOL Australian/New Zealand Perspective: Hospital/Clinical 
 
 
Environment 
 
In an Australian/New Zealand (NZ) healthcare environment Dixon et al. (2001) tested 
the independent predictive qualities of a ‘heart-specific’ QOL measurement in cardiac 
emergency, hospital admissions.  The MacNew Instrument (previously known as the 
QLMI) measured QOL, Charlson Comorbidity Index (CCI) determined clinical status, 
and prognostic factors included age, gender and LOS.65  Dixon et al. found global QOL 
scores predicted mortality and cardiovascular morbidity; and that emotional, physical 
and social domains predicted adverse outcomes post discharge.   
 
In an on-going study, Du et al. (2011) studied patients with chronic heart failure 
from four Sydney hospitals.  These researchers measured physical function and activity, 
self efficacy and self-care behaviour with the SF-36, a Home-Heart-Walk 6 minute test 
and the Minnesota Living with Heart Failure Questionnaire.66  Preen et al. (2005) 
investigated the mental and physical aspects of quality of life for cardiovascular patients 
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in a multidisciplinary intervention using the SF-12 survey to improve discharge care 
planning.  Preen et al. found GP participation, patient satisfaction, and continuity of care 
were enhanced in a study which included length of stay (LOS) as a variable for 
consideration.55 
 
 
3.5  CLINICAL CHARACTERISTICS OF THE PROJECT COHORT 
 
In this chapter the clinical characteristics of the CofCP cohort (n=281 patients) were 
assessed as a prelude to the identification in the following chapters, of any drug related 
problems experienced by the cohort.  In characterising the cohort, LOS and the number 
of drugs the patients were prescribed, were considered as clinical characteristics.   
 
The influence of these two factors on polypharmacy and in particular on the 
patients’ continuity of care, was taken into account.  In addition, for the CofCP cohort 
of chronically ill cardiovascular patients, LOS was the determining factor on which the 
provision or non-provision, and comprehensiveness of a hospital discharge summary, 
was decided.18   
 
 
3.5.1  JUSTIFICATION FOR ASSESSMENT OF  LOS  AS A CLINICAL  
CHARACTERISTIC 
 
In the literature, research into LOS for patients with cardiovascular disease 
predominantly centred around organisational resource management, health insurance or 
the cost of hospital care.  These factors were commonly targeted regardless of whether 
Australian or international healthcare environments were investigated.67-69  For 
example, Australian researchers investigated cost estimation for LOS in the monitoring 
of acute coronary syndromes and cost savings from pharmacist initiated changes to drug 
therapy, medical procedures and LOS prediction.70-71  American researchers 
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investigated safety and LOS with the prescribing of glycoprotein IIb/IIIa inhibitors in 
percutaneous coronary interventions and found an economically driven change in 
medication selection may not have been appropriate.72 
 
3.5.1.1  Australian Perspective: Clinical Aspects of LOS 
However, the literature did reveal Australian research which reported LOS when 
targeting the clinical aspects of care.  This research included a) an evaluation of a 
rehabilitation casemix classification which predicted LOS in stroke care but not in 
spinal cord injury and b) an analysis of the effects of a post discharge CofC intervention 
on discharge  satisfaction.  These latter researchers found no difference between the 
experimental groups in hospital LOS.55,73-74  
 
3.5.1.2  International Perspective: Clinical Aspects of LOS 
International research which reported LOS when targeting clinical aspects of care 
included USA research into a) the impact of cross-clamping time in aortic arch repair 
which showed increased LOS correlated with increased age and b) the effect of 
nesiritide versus dobutamine in heart failure.  These latter researchers concluded there 
was no difference in LOS for treatment with nesiritide however, mortality and 
readmissions were reduced.75-76   
 
Lisby et al. (2010) in Denmark, specifically targeted LOS as a primary endpoint 
when studying the outcomes of medication review on admission of elderly patients to an 
acute care, internal medicine hospital.  Medical physicians were ‘not obliged’ to comply 
with clinical pharmacists’ recommendations to modify or change inappropriately 
prescribed drugs and less than half the involved hospital physicians did.  Lisby et al. 
found there were no significant or clinically relevant differences in LOS or QOL 
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between the control and intervention groups.77  As intended in this study, Swiss research 
included LOS when characterising their study cohort for investigation of the association 
of polypharmacy with high risk, potential drug-drug interactions in cardiovascular 
disease.78 
 
3.5.2  ASSESSMENT OF NUMBER OF PRESCRIBED DRUGS AS A CLINICAL 
CHARACTERISTIC 
 
Drug-drug interactions are one only, of a number of drug related problems (DRP) and 
‘DRP’ is one only, of a number of acronyms applied to drug related situations, burdens, 
events or reactions.79  Further, problems can be drug related or patient related; actual or 
potential and of high or low severity.45-80  Most of these drug problems affect the 
patients’ safety and quality of care and hence, the patients’ continuity of care.55    
Further and in addition to the broad range of factors associated with DRPs, the higher 
the number of drugs routinely consumed by chronically ill patients with cardiovascular 
disease, the more their problems were compounded.78  
 
Several researchers described polypharmacy as the concurrent and active, daily 
consumption of ≥5 prescribed drugs.81-83  An in-depth study of polypharmacy in heart 
failure by Flesch and Erdmann (2006), reported the high consumption levels of 
cardiovascular drugs necessary for treatment and found that American patients (on 
average) were prescribed 7.5 drugs and 11.1 doses daily on hospital discharge.   
 
Fialová et al. (2005) and Müller (2008) found the relative risk of potentially 
inappropriate medication (PIP) use was also positively associated with polypharmacy.81-
83  Regardless of the specific patient characteristics, situation factors or drug 
components, partly unpredictable drug interactions are created or exacerbated by 
polypharmacy.78,83-84  In turn, the larger the number of drugs to be listed on patients’ 
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notes and in discharge summaries the larger was the leeway for inaccuracies and 
incompleteness in transferring patient information across health care sectors.16 
   
In Australia, widespread and comprehensive electronic recording and transfer of 
accurate patient information is still not a reality.16,33,36,85  Richardson and McKie (2008) 
described the transfer of healthcare information in Australia by claiming that patient 
notes were still transferred using ‘19th Century clipboards’ (p.36)16.  Therefore, staff 
were not alerted to the risks of polypharmacy or of inappropriate procedures such as the 
administration of conflicting drugs, the failure to administer a drug or to document pre 
and post discharge requirements.16  These researchers raised some practical suggestions 
to improve the continuity, safety and quality of health care while they acknowledged 
their research was limited and that their survey response rates were low and 
circumspect. 
 
3.6  SURVEY RESPONSE CHARACTERISTICS OF THE CofCP COHORT  
 
 
In this chapter not only the response rates, but the characteristics of the patients in the 
CofCP cohort who did and did not respond to QOL surveys were taken into account.   
Any non-response bias was considered to be a confounder to the validity of outcomes 
generated from survey responses.  Hence, the respondents/non-respondents 
characteristics of 1) age at discharge; 2) LOS and 3) number of discharge prescriptions, 
were assessed to identify any relevant differences between proposed subgroups. 
 
Several research studies on the representativeness of survey/questionnaire 
results, reported that differences between respondents and non-respondents were likely 
to bias estimations from respondents’ data on socio-economic status and health 
profiles.85-89  In 2005, Tolonen et al. studied these differences in 27 populations which 
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included an Australian cohort.  Differences, hence bias, were reported for cohorts which 
included subgroups of patients with cardiovascular disease.89   
 
In addition to the likelihood of survey bias from respondents’ socio-economic 
status and health profile differences within a population, Tolonen et al. (2006) 
researched these differences across populations.  They found that survey bias from 
differences in respondents’/non-respondents’ socio-economic status and health profiles  
tended to be similar even when they had geographical and cultural differences.90  It was 
also found that the larger the difference in response rates between surveys conducted 
over two points in time, the larger the difference in the trend of the survey results.  
However, it should be noted that the Tolonen et al. studies, analysed data from two 
points in time separated by ≥10 years.90   
 
 
 
 
 
3.7  IMPLEMENTATION OF THE CONTINUITY OF CARE PROJECT (CofCP)  
 
OPERATIONAL DEFINITIONS 
 
3.7.1  CONTINUITY OF CARE is a perception of quality health care resulting from the 
ongoing management of issues which cause disruption to optimal patient care. 
 
In the context of the study reported in this chapter: 
 
Continuity of Care is perceived by the researchers as the ongoing support of patients 
recruited into the research project, by provision of a comprehensive discharge protocol 
and a post discharge medication review to identify any drug related problems.  
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3.7.2  POTENTIALLY INAPPROPRIATE PRESCRIBING (PIP) 
In this study the phases ‘potentially inappropriate prescribing or prescriptions’ and 
‘potentially inappropriate medication’ are equal in meaning and represented by the 
abbreviation ‘PIP(s)’.  Prudent et al. (2008) define ‘potentially inappropriate 
medication’ as drugs with an unfavourable risk/benefit ratio when safer or equally 
effective alternatives are available.126 
 
 
3.8  PROJECT  METHOD  
 
3.8.1  PROJECT DESIGN 
The CofCP was a prospective clinical trial in which patients were randomised by GP 
referral or non-referral for a Home Medicines Review (HMR) service post hospital 
discharge.  All patients were recruited into the study on an ‘intention to treat’ basis for 
the provision of an HMR service.  The provision of an HMR report to the researchers, 
which was written by an accredited pharmacist for the patients’ GP, confirmed the 
patients’ continuity of care after discharge and was the end-point of data collection for 
this project.   
 
 
3.8.2  PROJECT SITE 
 
A quarter of the population in the state of NSW, Australia; lived in Western Sydney 
with a regional population estimated at 1.9 million people in 2009.   The area was 
serviced by the healthcare professionals (HCP) in the Western Sydney Division of 
General Practice (WSDGP).92  In Western Sydney, Westmead Hospital is an affiliated 
teaching hospital with the University of Sydney, as well as being a specialised 
quaternary referral hospital for cardiovascular disease.   
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Prior to upgrading and extensions in 2005, the hospital was recorded as having 
975 beds.18  Due to constant change and primarily, seasonal fluctuation in bed numbers, 
Westmead Hospital is currently included in the ‘>500 beds’ classification of hospital 
size by the NSW Government Department of Health.93  The hospital provided 
comprehensive medical and surgical services and is a leading centre for the treatment 
and rehabilitation of patients with cardiovascular impairment.  The cardiology unit of 
Westmead Hospital was the site chosen for recruitment of patients into this study 
between 2004 - 2007. 
 
3.8.3 PROJECT SUBJECT RECRUITMENT 
 
The cardiology Unit at Westmead Hospital was divided into three wards.  One ward 
admitted primarily, ‘Day Only’ or ‘Short Stay’ patients and the second ward 
accommodated critically ill, monitored cardiac patients.  The third, a Coronary Care 
step down ward, included patients transferred directly from the Emergency Department.  
Patients were recruited from all wards.   
 
The project received ethics approval from The University of Sydney and the 
recruitment process required separate patient consent for the Ethics Committees of 1) 
Western Sydney Area Health Service (SWAHS), 2) the Australian Health Insurance 
Commission (HIC), and 3) the Australian Department of Veterans Affairs (DVA).  
Project recruitment consents included the agreement that any patients’ data collected 
prior to a point of mishap (e.g. death or injury) or withdrawal from the project, could be 
included in de-identified group analyses.  The recruited patients were fully consented 
prior to discharge.   
 
There were no incentive payments to either patients or HCP involved in the 
study and no cost to the patients for Home Medicines Review (HMR) service.  After 
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referral by GPs, HMR services were approved items for cost reimbursement to GPs and 
pharmacies in the community, by the HIC through the Australian Medicare Benefits 
Scheme (MBS).94 
 
3.8.3.1 Selection of Patients  
Initially, patients were approached for recruitment on, but not restricted to, their 
utilisation of HCPs practising in Western Sydney.  Secondly, each subject was 
discharged on at least one cardiovascular medication.  Third, it was ascertained that 
patients, or an untrained carer, would administer their daily medications at home.  In 
addition,  patients met one or more of the guidelines for HMR service referral by GPs.95-
98   Subject and carer recruitment criteria are shown in Figures 3.2 and 3.3.   
 
 
 
Figure 3.2 Subject Inclusion Criteria 
 
1. Patients who were currently in Westmead Hospital under the management of the 
cardiovascular team 
2. Patients who were taking 1 or more cardiovascular drugs 
3. Patients who met one or more of the following conditions: 
• Currently taking five or more regular prescribed drugs 
• Taking more than 12 doses of prescribed drugs per day 
• Had significant changes made to drug regimen in the last three months 
• On drugs with narrow therapeutic index or requiring therapeutic   
Monitoring 
• Symptoms suggestive of an adverse drug reaction 
• Sub-therapeutic response to medication treatment 
• Are possibly non-compliant or not managing drug-related therapeutic   
devices 
• Managing their own medications and are at risk due to language 
difficulties, physical impairment, dexterity problems, impaired sight or  
hearing, or cognitive difficulties 
4. Patients who were recently discharged directly to their homes or a private  
Residence 
5. Patients who managed their own prescribed drugs at home 
6. Patients who lived and were treated or serviced through a Health Care  
Professional practicing within the WSDGP boundaries 
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Figure 3.3 Carer Inclusion Criteria 
1. Carers who regularly administered medications to a discharged patient who 
met  
   the inclusion criteria for patients 
 
2. Carers who were not formally trained in medication administration 
 
 
 
 
Recruitment in the Cardiology Unit was limited by 1) the transfer in, of around 10% 
ward capacity from Regional and NSW Country Hospitals; 2) many patients were day 
only patients and were admitted and discharged in one day, and 3) the same chronically 
ill patients were regularly readmitted for short lengths of stay (LOS).18 
 
 Patients recruited into the study were discharged through existing standard 
hospital procedures, prior to receiving HMR service through patient nominated  
community GPs and pharmacies.  The patient’s participation in the study was not 
controlled in any way and all HCPs in the community were nominated by the patient.  
All patients were offered an HMR service post discharge, and a request for referral was 
sent by the project researcher to all patients’ GPs.  The patients were informed before 
discharge, that there was no cost to them for the service and that HMR referral was at 
the discretion of their GP. 
 
 
3.8.3.2  Subjects from a Non-English Speaking Background 
The necessity for interpreters at all stages of recruitment was ascertained.  Every subject 
was sent the Dartmouth COOP Quality of Life survey to assess their activities of daily 
living (ADL) on two occasions.  The COOP charts were made available to patients in 
English, Spanish, Chinese, Slovak, and Arabic (Appendix 10.0).    A few carers were 
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recruited on behalf of participants and, although offered, none of the recruited patients 
or carers requested an interpreter. 
3.8.4  PROJECT DATA SOURCES 
 
3.8.4.1  Medical Records and Discharge Summaries 
After patient consent on recruitment, the patients’ full medical records and current 
treatment files were accessed by researchers.  Research files for each recruited patient 
contained coded copies of demographic details, admission forms, serum biochemistry 
results, drugs prescribed pre admission and prior to discharge.   
 
Routinely, discharge summaries were not provided for ‘Day Only’ patients who 
were not commenced on new pharmacotherapy.  Partially computerised discharge 
summaries were generally written by junior resident medical officers.  On discharge, 
patients were given a sealed copy of their summaries to hand deliver to their GPs at 
consultation within 3 days.  However, patients were not provided with a separate copy 
of their discharge drug regimen, for their own information.   
 
In this project, copies of the discharge summaries were again offered to all 
patients’ GPs by facsimile, when contacted by the researchers, immediately post 
discharge.  At the same time, all patient nominated community pharmacies were 
provided with a discharge summary by facsimile.  In general, these summaries included 
a brief outline of the patients’ treatment while hospitalised, their chronic and acute 
diseases and drugs prescribed on discharge. 
 
3.8.4.2  Home Medicines Review (HMR) Reports 
On the same day as the subjects’ discharge, a request for an HMR referral was sent by 
facsimile to the patients’ GPs by the researchers.  On receipt of GPs’ referrals, the 
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community pharmacies arranged for accredited pharmacists to conduct an HMR in the 
patients’ homes.  Besides the patients’ discharge summaries, current serum 
biochemistry results were provided to the accredited pharmacists by researchers.   
 
The community pharmacy provided the accredited pharmacists with the GPs’ 
referral forms which included the patients’ post discharge pharmacotherapy.  Hence, 
HMR reports were a source of drug regimen prescribed by the GP post discharge, drugs 
currently consumed by the patient at HMR, and patients’ drug related problems.  
Reports written for the referring GPs were copied to the research team, on request, by 
the accredited pharmacists. 
 
3.8.4.3  The Dartmouth COOP Charts 
 
The original version of the Dartmouth Co-Operative ‘Generic Measure of Function, 
Health Status and Quality of Life’ charts (COOP charts) was selected to measure any 
change in the cohort’s quality of life at two points in time (Appendix 10.0).  These self 
administered surveys were explained to the patients prior to discharge and were mailed 
out immediately and 6 months after discharge.   
 
The patients reported on the quality of 9 different aspects of daily living, 
including their physical, emotional and social status during the two weeks preceding 
receipt of the survey.  Patients were followed up with two phone calls if the charts were 
not returned after three weeks from mailing at discharge and post discharge.   
 
Selection of the COOP charts was influenced by the extensive literature 
available on their use in research with components and, or subjects similar to this 
project.61,99-101  The COOP charts were developed and repeatedly tested for reliability 
and validity during the Dartmouth Primary Care Co-operative Information Project.102   
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The charts were also chosen as they were in a form of lifestyle measurement 
suited to the subjects recruited into this study.103  Further, the charts were deemed 
effective and quick to complete because of their broad patient/subject appeal from lack 
of complexity.104  The availability and standardization of measures in different 
languages also added to their practicality. 
 
There have been claims of lack of sensitivity in the COOP charts and this was 
considered, however did not outweigh their practicality for use.105-106  Each COOP chart 
recorded the patients’ responses to illustrated activities of daily living (ADLs), 
emotional and social factors affecting patients’ quality of life.  Responses to each factor 
were recorded on a scale of 1 – 5 and a score of 1 indicated the healthiest or most ideal 
score.  There were nine COOP charts in the sets mailed to the subjects and summation 
of the scores on each chart allowed derivation of changes in the factors assessed, and in 
overall quality of life (QOL) between discharge and 6 months post discharge. 
 
3.8.5  MULTIDISCIPLINARY HEALTH CARE PROFESSIONALS (HCPs)  
Medical, nursing and pharmacy staff in the hospital cardiology unit were invited to 
participate in the research and were consulted prior to implementation of the project.  
Subsequently, formal participation was demonstrated by representation on the project 
steering committee.  This involved a Consultant Cardiologist, Nurse Unit Manager and 
Hospital Patient Advocate.  Pharmacists were represented by the Director of Pharmacy 
WSAHS, the Pharmacy Guild and Pharmaceutical Society of Australia (NSW Branch).  
Informal participation on the wards included the patients’ medical and nursing teams 
who witnessed the three separate consent forms, for each subject. 
 
Primary HCPs were represented by their professional affiliates in Western 
Sydney Division of General Practice (WSDGP).  Besides providing All community 
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GPs, pharmacies and accredited pharmacists with comprehensive patient information, 
these HCPs were provided with information packages and invited to participate in the 
research.   
 
3.8.6  PROJECT DATA ANALYSIS 
Whenever continuous variables resulted from data collection, and were normally 
distributed, relevant paired or independent samples students’ t tests were conducted and 
chi squared approximations were conducted for categorical or dichotomous variables.  It 
was outside the realm of this research to empirically measure the clinical impact of 
changes to patients QOL at discharge or 6 months post discharge.  Instead when 
relevant, an effect size approximation was conducted using an eta squared estimation.  
Where appropriate, this estimation was conducted on results yielding a ‘t’ value for 
students ‘t’ tests showing statistically significant differences between the means of the 
variables tested.  Eta squared estimations (tsq/tsq+(N-1)) for effect size were based on 
Cohen’s values of 0.01~small effect; 0.06~moderate effect and 0.14~large effect.107-108   
 
 
3.9  PROJECT RESULTS  
The 281 subjects in the CofCP were comprised of 194 (69.0%) patients who did not 
receive an HMR, and 87 (31.0%) patients for whom there was an indication they had 
received a GP referral and HMR service.  The latter group included 79 (28.1%) patients 
whose HMR reports, confirming HMR service, were copied to the researchers as data 
sources for post discharge health status and drug related analyses.  As there was no 
confirmation of HMR service or report available for 8 of the 87 patients, they were re-
allocated to the majority subgroup for discharge data assessment only.   
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The project recruitment consents included the agreement that patients’ data 
collected prior to a point of mishap (e.g. death or injury) or withdrawal from the project, 
could be included.  The withdrawal of one patient soon after discharge and the reported 
death of a patient a few days after their HMR report was provided to the research team, 
did not reduce the number of discharge summaries or HMR reports available for data 
analyses (Figure 3.1).  Hence, all patients recruited into the project (n=281) were 
divided into an experimental group called the HMR Report Group (n=79) and non-
experimental group called the non-HMR Report Group (n=202). 
 
3.9.1  CofCP COHORT CHARACTERISTICS 
3.9.1.1  Age and Length of Stay (LOS) 
The median age of a) the CofCP cohort (n=281) was 65 (IQR 19: 55-74) years, b) the 
HMR Report group (n=79) was 69 (IQR 18: 58-76) years and c) the non-HMR Report 
group (n=202) was 65 (IQR 18: 56-74) years at discharge.  The mean LOS for the 
cohort was 13.9 (SD± 11.8) days. 
 
3.9.1.2  Gender Distribution – within groups 
Within group testing for gender was analysed using Chi-square testing with the 
expectation of equal numbers of males and females in each group at discharge.  Table 
3.1 shows the male gender distribution as 162 (57.7%) in the cohort; 121 (59.9%) in 
non-HMR Report group and 41 (51.9%) in HMR Report group.  The cohort (n=281) 
and non-HMR Report group (n=202) showed a statistically significant predominance of  
male patients. 
 
3.9.1.3  Prescriptions for Discharge Drugs 
Table 3.2 shows the distribution of prescriptions written for drugs prescribed at 
discharge for the CofCP cohort and subgroups.  It should be noted that all separately 
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documented prescriptions on discharge summaries were counted, regardless of the 
strength or form of the drug’s active ingredient.  For example, one patient may have 
been concurrently prescribed different strengths of warfarin dependent on ongoing, and 
changing, biochemistry results. 
 
There were 2476 prescriptions written for the cohort on their discharge with a 
mean 8.8 (SD± 6.3) prescriptions.  Comparison of mean number of prescriptions, 
between the non-HMR  Report  group  and  HMR  Report  group  showed  no  
significant difference at  discharge (CI 95% t=-0.61 df=279 p=0.55).    
 
 
Table 3.1 Gender distribution within cohort and subgroups at discharge 
Patient Group Male 
 
Female 
 
Chi-square test 
 Number 
patients 
% 
frequency 
Number 
patients 
% 
frequency 
 
χ2 
 
df 
 
Sig. 
Cohort 
(n=281) 
162 57.7 119 42.3 6.5 1 <0.05 
Non-HMR 
Report group 
(n=202) 
121 59.9   81 40.1 7.8 1 <0.05 
HMR Report 
group (n=79) 
41 51.9   38 48.1 0.1 1 >0.05 
df=degrees of freedom.   Sig=significance 
 
Table 3.2 Distribution of prescriptions for the cohort and subgroups for discharge drugs 
Patient Group Discharge Drugs 
 Number 
prescriptions 
Mean (±SD) Range 
CofC cohort n = 281 2476 8.8 (6.3) 1 - 34 
Non-HMR Report group n = 202 1751 8.6 (6.4) 1 - 34 
HMR Report group n 79   725 9.1 (6.0) 1 - 32 
SD = standard deviation 
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3.9.2  QUALITY OF LIFE (QOL) SURVEY  
 
3.9.2.1  QOL Health status - within the cohort 
Table 3.3 shows paired t tests of the COOP survey results, listing the 9 
contributing health status charts, within the CofCP cohort (n=281) at discharge and 6 
months post discharge.  An assessment of physical fitness showed a statistically 
significant difference between these two points in time with p=0.04.  A decrease in the 
mean score indicated an improvement in the cohort’s physical fitness 6 months after 
discharge.  An estimation of the effect size on the improvement in physical fitness, 
between discharge and post discharge, shows an Eta squared result of 
small<0.03<moderate effect on the cohort.   
 
An assessment of ‘Change in health’ showed a statistically significant difference 
over the same time period with p=0.01.  An increase in the mean score indicated the 
cohort perceived a decline in their overall health status 6 months after discharge.  The 
Eta squared result indicated a moderate<0.10<large effect on the cohort. 
 
3.9.2.2  QOL Health status - between the subgroups 
Table 3.4 shows independent samples t tests of the COOP survey results listing the 9 
contributing health status charts between groups for the HMR Report (n=79) and non-
HMR Report (n=202) groups at discharge.  Table 3.5 shows the same analysis between 
the subgroups at 6 months post discharge.  For all nine charts at both points in time, 
there were no significant differences between the two subgroups.  
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Table 3.3 Comparison of the COOP QOL response and scores within the CofCP cohort 
between discharge and 6 months post discharge surveys 
 
CofCP cohort (n=281) Discharge 6m post 
discharge 
t tests 
 
COOP Charts Number 
patients 
Mean (SD±) Mean (SD±) t 
value 
 
df 
p 
value 
Chart 1 Physical fitness 
 
163 3.6 (1.1) 3.4 (1.2)  2.07 162 0.04* 
Chart 2 Feelings 
 
163 2.4 (1.1) 2.4 (1.2)  0.13 162 0.90 
Chart 3 Daily activities 
 
162 2.6 (1.2) 2.4 (1.2)  1.54 161 0.13 
Chart 4 Social activities 
 
165 2.3 (1.3) 2.1 (1.2)  1.56 164 0.12 
Chart 5 Pain 
 
160 2.8 (1.3) 2.8 (1.3) -0.47 159 0.64 
Chart 6 Change in 
health 
162 2.2 (1.1) 2.7 (1.0) -4.17 161 0.01* 
Chart 7 Overall health 
 
161 3.3 (0.9) 3.2 (1.1)  0.74 160 0.46 
Chart 8 social support 
 
161 2.0 (1.2) 2.1 (1.2) -0.59 160 0.56 
Chart 9 Quality of life 
(patients’ view) 
159 2.5 (0.8) 2.4 (0.9)  0.77 158 0.44 
df=degrees of freedom.   SD=standard deviation.  *significant at p≤0.05
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Table 3.4 Comparison of COOP QOL Survey response and scores between the HMR 
Report and non-HMR Report groups at discharge 
T1: DISCHARGE HMR Report 
Group: n=79  
non-HMR Report 
Group: n=202  
t tests 
 
COOP Charts Number 
patients 
Mean 
(SD±) 
Number 
patients 
Mean 
(SD±) 
t 
value 
 
df 
p 
value 
Chart 1 Physical 
fitness 
 62 3.7 
1(1.2) 
149 3.6 
(1.2) 
 0.37 209 0.72 
Chart 2 Feelings 65 2.6 
4(1.2) 
153 2.5 
(1.2) 
 0.32 216 0.75 
Chart 3 Daily 
activities 
64 2.7 
(1.3) 
149 2.8 
(1.2) 
-0.63 211 0.52 
Chart 4 Social 
activities 
65 2.5 
(1.3) 
154 2.4 
2(1.3) 
 0.75 217 0.46 
Chart 5 Pain 64 2.7 
(1.3) 
153 2.9 
(1.3) 
-1.30 215 0.20 
Chart 6 Change in 
health 
62 2.3 
(1.3) 
150 2.3 
(1.1) 
 0.27 210 0.79 
Chart 7 Overall 
health 
65  3.3 
(1.0) 
152 3.4 
(0.9) 
-0.67 215 0.51 
Chart 8 social 
support 
65 2.1 
(1.3) 
152 2.1 
(1.2) 
 0.30 215 0.76 
Chart 9 Quality of 
life (patients’ view) 
64 2.54 
(0.9) 
150 2.5  
(0.8) 
-0.07 212 0.94 
df=degrees of freedom.   SD=standard deviation.    
 
 
 
Table 3.5 Comparison of COOP QOL Survey response and scores between the HMR 
Report and non-HMR Report groups at 6 months post discharge 
T2: 6 MONTHS HMR Report 
Group: n=79 
Non-HMR Report 
Group: n=202 
t tests 
 
COOP Charts Number 
patients 
Mean 
(SD±) 
Number 
patients 
Mean 
(SD±) 
t 
value 
 
df 
p 
value 
Chart 1 Physical 
fitness 
60 3.30 
(1.3) 
120 3.3 
(1.3) 
-0.32 178 0.75 
Chart 2 Feelings 60 2.2 
(1.2)  
119 2.4 
(1.2) 
-0.87 177 0.33 
Chart 3 Daily 
activities 
59 2.4 
(1.3) 
119 2.4 
(1.2) 
-0.15 176 0.88 
Chart 4 Social 
activities 
60 2.0 
(1.2) 
120 2.1 
(1.3) 
-0.89 178 0.37 
Chart 5 Pain 59 2.6 
(1.3) 
117 2.8 
(1.3) 
-0.78 174 0.43 
Chart 6 Change in 
health 
60 2.7 
(1.0) 
120 2.7 
(1.0) 
000 178 1.00 
Chart 7 Overall 
health 
60 3.1 
(1.2) 
117 3.2 
(1.0) 
-1.27 175 0.21 
Chart 8 Social 
support 
59 1.9 
(1.2) 
118 2.1 
(1.2) 
0.96 175 0.34 
Chart 9 Quality of 
life (patients’ view) 
60 2.4 
(1.0) 
117 2.4 
(0.9) 
0.03 175 0.97 
df=degrees of freedom.   SD=standard deviation.   
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3.9.3  QUALITY OF LIFE (QOL) SURVEY RESPONSE 
3.9.3.1  QOL Survey – within groups 
Table 3.6 shows paired samples t tests of COOP survey response rates within the cohort and 
subgroups at discharge and 6 months post discharge.  The HMR Report group patients 
included in these analyses received their HMR service at any time during implementation of 
the project. 
Response rates for the CofCP cohort (n=281) were 219 (77.9%) at discharge and 
180 (64.1%) post discharge.  Table 3.6 also shows there were no significant differences in 
the mean scores for the overall COOP survey within any of the groups between the two 
points in time.   
 
3.9.3.2  QOL Survey – between groups 
Table 3.7 shows independent samples t tests of the COOP survey response rates, and 
difference in means for overall QOL assessment, between subgroups at discharge and 6 
months post discharge.  This assessment was the overall QOL assessed over 9 charts.  The 
HMR Report group patients included in these analyses received their HMR service at any 
time during implementation of the project. 
Comparison of the means for HMR Report group (n=79) and non-HMR Report 
group (n=202) showed no significant difference when t tested at discharge and post 
discharge. 
 
3.9.3.3  Overall QOL for HMR recipients – within groups 
Table 3.8 shows paired samples t tests COOP survey response rates and QOL scores within 
the CofCP cohort and HMR Report group.  These are the results of patients who were the 
recipients of an HMR service between discharge and 6 months post discharge.  It should be 
noted that the difference between this table and Tables 3.6 and 3.7,  is that only these 
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patients had received their HMR service before responding to the second round of the 
COOP surveys at 6 months post discharge.  Hence, these analyses were conducted to detect 
any differences in survey results bought about by the conduct of an HMR service as an 
intervention. 
 
At discharge 68 (24.4%) and 50 (63.3%) HMR recipients in the CofCP cohort 
(n=281) and HMR report group (n=79) responded, respectively.  At 6 months post 
discharge 62 (22.1%) and 49 (62.0%) HMR recipients in the cohort and HMR Report group 
responded, respectively.  Table 3.8 also shows there were no significant differences in the 
mean scores for the COOP survey for overall QOL assessment between the two time points  
for either group.
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Table 3.6 Comparison of COOP survey response and overall QOL from 9 charts within the CofCP cohort and subgroups at  
discharge and 6 months post discharge. 
 
COOP Survey:  
QOL – 9 charts 
Discharge Post Discharge 
6 months 
t tests 
within groups 
 
GROUP 
Number patients  
(% response) 
QOL 
mean (SD±) 
Number patients 
(% response) 
QOL 
mean (SD±) 
t 
value 
 
df 
p 
value 
CofCP cohort  
n = 281 patients 
219 (77.9) 24.0 (7.1) 180 (64.1) 23.4 (7.4)  0.21 164 0.83 
Non-HMR Report group 
n = 202 
154 (76.2) 24.0 (7.0) 120 (56.4) 23.7 (7.1) -0.17 110 0.87 
HMR Report group  
n = 79 
  65 (82.3) 23.9 (7.5) 60 (75.9) 22.8 (8.1)  0.66   53 0.51 
df=degrees of freedom.   SD=standard deviation. 
 
 
 
 
Table 3.7 Comparison of COOP survey response and overall QOL scores between the CofCP subgroups at discharge and  
6 months post discharge.  
 
COOP Survey: 
QOL- 9 charts 
HMR Report Group n=79  
 
non-HMR Report Group n=202 t tests 
between subgroups 
 
TIME 
Number patients 
(% response) 
QOL 
Mean (SD±) 
Number patients 
(% response) 
QOL 
Mean (SD±) 
 
t value 
 
df 
 
p value 
Discharge  
 
65 (82.3) 23.9 (7.5) 154 (76.2) 24.0 (7.0) -0.41 218 0.68 
Post Discharge  
 
60 (75.9) 22.8 (8.1) 120 (59.4) 23.7 (7.1) -0.72 178 0.47 
df=degrees of freedom.   SD=standard deviation. 
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Table 3.8 Comparison of overall QOL scores within CofCP cohort and HMR Report group 
for recipients of HMR services between discharge and 6 months post discharge.   
 
COOP Survey: 
QOL – 9 charts 
Discharge Post Discharge 
6 months 
t tests 
within groups 
 
HMR service 
recipients  
Number 
patients (% 
response) 
QOL 
mean 
(SD±) 
Number 
patients (% 
response) 
QOL 
mean 
(SD±) 
t 
value 
 
df 
p 
value 
CofCP cohort  
n= 281 patients 
 
68 (24.4) 19.2 
(11.4) 
62 (22.1) 19.5 
(11.4) 
-0.53 55 0.60 
HMR Report group 
n= 79 patients 
 
50 (63.3) 23.5 
( 7.3) 
49 (62.0) 23.2 
( 7.9) 
-0.91 41 0.37 
df=degrees of freedom.   SD=standard deviation 
 
 
3.9.4  QUALITY OF LIFE (QOL) SURVEY RESPONDERS AND NON-RESPONDERS 
The personal and clinical characteristics of patients who did and did not respond to the 
COOP QOL survey were compared at discharge and 6 months after discharge.  The 
characteristics compared were: 1) Age in years at discharge, 2) LOS in days, and 3) 
number of prescriptions at discharge.  These comparisons determined any differences in 
the composition of the response/non-response groups within the cohort and subgroups at 
discharge and post discharge. 
 
3.9.4.1  Survey Responders/non-Responders at discharge – within groups 
Table 3.9 shows independent samples t tests of characteristics of subjects who responded 
to the COOP QOL survey and those who did not, at discharge, within the CofCP cohort 
and subgroups.  Survey responders and non-responders were analysed for age at discharge, 
LOS and the number of drug prescriptions on discharge.   
 
 
For discharge age in the CofCP cohort (n=281), there was a significant difference 
between responders and non-responders at discharge, with responders 4.3 years older than 
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non-responders.  This result was reflected in the non-HMR Report group (n=202) with a 
significant difference in age at discharge with responders 5.2 years older than non-
responders.  In the HMR Report group (n=79) there was no significant difference in age 
between responders and non-responders at discharge. 
 
In the CofCP cohort and non-HMR Report group, Levene’s tests showed 
significance values below 0.05 for variance in LOS.  Hence the t test values tabulated in 
Table 3.9 for LOS, were calculated with equal variances not assumed.  In the cohort, HMR 
Report group and non-HMR Report group there were no significant differences in LOS 
between responders and non-responders at discharge.  
 
For number of prescriptions at discharge in the CofCP cohort, HMR Report group 
and non-HMR Report group there were no significant differences in number between 
responders and non-responders at discharge. 
 
 
3.9.4.2  Survey Responders/non-Responders post discharge – within groups 
Table 3.10 shows independent samples t tests of the differences in the same three 
characteristics of subjects who responded to the COOP QOL survey and those who did not 
at 6 months post discharge, within the CofCP cohort and subgroups. 
 
For discharge age in the CofCP cohort and non-HMR Report group, Levene’s tests 
indicated that t tests were calculated with equal variances not assumed (Table 3.10).  There 
was a significant difference between responders and non-responders.  For discharge age in 
the cohort and non-HMR group, the post discharge survey responders were 3.6 and 4.9 
years older, respectively.  In the HMR Report group there was no significant difference in 
age at discharge, between responders and non-responders to the post discharge survey.   
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For LOS and number of discharge prescriptions in the cohort, non-HMR Report 
group and HMR Report group there were no significant differences between responders 
and non-responders to the 6 months post discharge survey. 
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Table 3.9 Comparison of subject characteristics between COOP survey responders within CofCP cohort and subgroups at discharge. 
 
DISCHARGE  COOP Responders COOP Non-Responders t tests 
  Number 
patients 
Mean 
(SD±) 
Number 
patients 
Mean 
(SD±) 
t 
value 
 
df 
p  
value 
CofC cohort n=281 Age: years 221 65.4 (11.9) 60 61.1 (13.9)  2.33 279 0.02* 
 LOS: days 221 14.7 (12.4) 60 14.7 (25.5) -0.73   67 0.47a 
 Discharge prescriptions 221   8.8 (  6.4) 60   8.6 (  5.8)  0.34 279 0.74 
non-HMR Report group  Age: years 153 64.9 (11.5) 49 59.7 (13.7)  2.61 198 0.01* 
n=202 LOS: days 153 11.7 (12.0) 49 15.0 (28.2) -0.78   51 0.44a 
 Discharge prescriptions 153   8.7 (  6.5) 49   8.7 (  6.3) -0.05 198 0.96 
HMR Report group n=79  Age: years 68 66.2 (12.9) 11 66.2 (13.8) -0.02   78 0.97 
 LOS: days 68 13.4 (13.3) 11 13.6 (12.6) -0.06   78 0.95 
 Discharge prescriptions 68   9.4 (  6.3) 11   8.1 (  3.7)  0.72   78 0.47 
aEqual variances not assumed.   *significant at p ≤ 0.05.       df=degrees of freedom.   LOS=length of stay.   SD=standard deviation 
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Table 3.10 Comparison of subject characteristics between COOP survey responders within CofCP cohort and subgroups post discharge. 
 
POST DISCHARGE 6 months  COOP Responders COOP Non-Responders t tests 
  Number 
patients 
Mean 
(SD±) 
Number 
patients 
Mean 
(SD±) 
t 
value 
 
df 
p  
value 
CofC cohort n=281 Age: years 180 65.7 (11.3) 101 62.1 (14.1)  2.19 173 0.03a* 
 LOS: days 180 12.3 (16.1) 101 13.6 (17.8) -0.63 279 0.53 
 Discharge prescriptions 180   8.5 (  6.2) 101   9.4 (  6.5) -1.06 279 0.29 
non-HMR Report group  Age: years 120 65.7 (10.7)   82 60.8 (13.7)  2.75 145 0.01a* 
n=202 LOS: days 120 12.4 (16.1)   82 13.6 (19.4) -0.63 200 0.53 
 Discharge prescriptions 120   8.2 (  6.4)   82   9.3 (  6.5) -1.14 200 0.26 
HMR Report group n=79 Age: years   60 65.6 (12.6)   19 67.8 (14.7) -0.65   77 0.52 
 LOS: days   60 12.8 (12.9)   19 13.3 (  8.9) -0.14   77 0.89 
 Discharge prescriptions   60   9.1 (  5.9)   19   9.6 (  6.6) -0.33   77 0.74 
aEqual variances not assumed.   *significant at p ≤ 0.05. df=degrees of freedom.   SD=standard deviation 
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3.10 PROJECT DISCUSSION 
 
 
3.10.1  CofCP - IMPLEMENTATION 
This chapter describes the implementation of the CofCP empirical research designed to 
investigate the medication management of chronically ill patients after hospital discharge.  
Recruitment into the project was labour intensive and required a strict consideration of the 
acute on chronic, cardiovascular patients’ disease severity.  The extended timeframe for 
recruitment of a pre-conceived number of subjects (from the WMP17) meant that one to 
one patient contact hours stretched between mid 2004 to early 2007.  Completion of HMR 
services and 6 month QOL survey follow-up was completed by mid 2007. 
 
 Restriction of project implementation to one clinical researcher slowed progress, 
but standardised and controlled all components of hospital protocol, data collection, 
interpretation and analysis.  A total of 281 patients were recruited into the CofCP and 
medical records and discharge data were available for all subjects.   
 
Provision of an HMR report was the end point of data collection and confirmed 
continuity of care in the community.  The CofCP cohort (n=281) was divided into the 
HMR Report group (n=79) and non-HMR Report group (n=202) for further investigations 
into medication management at hospital discharge and post discharge. 
 
3.10.2  CofCP COHORT CHARACTERISTICS 
Subjects were characterised by assessing their age, gender, LOS and number of drug 
prescriptions at discharge and by surveying the HRQL factors affecting the cohort.  Subject 
characteristics were also compared to determine differences in survey responders and non-
responders, and between the HMR Report and non-HMR Report subgroups.   
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Landi et al. (2007) reported that most elderly people are unable to undertake all 
activities of daily living (ADLs); have higher rates of morbidity; and long hospitalizations.  
In addition these patients had multi-drug regimens; have poorer pharmacokinetics and 
pharmacodynamics and hence, have poorer QOL.60  Parra et al.(2011) and Haywood et al. 
(2005) not only included several established HRQL scales and indexes in their research, 
importantly, as research variables and for patient characterisation, they included age, 
gender, number of drugs consumed and LOS.63-64  In their research with cardiovascular 
patients, researchers targeted LOS for cost of care evaluations or clinical research and 
Dixon et al, determined clinical status and prognostic factors which included age, gender 
and LOS.65,70-71,73-75 
 
 These variables were determined to characterise the CofCP patients and were the 
same variables assessed for the same purpose by Straubhaar et al. (2006) and Tolonen et al. 
(2005).78,90  It was found the CofCP cohort and both subgroups had more male than female 
patients.  However, the cohort (n=281) and the non-HMR Report group (n=202) showed a 
significant predominance of males not found in the HMR Report group (n=79).  The 
predominance of male patients was consistent with a large Australian population study 
which showed gender distribution for initial and follow up surveys as 658/1297 (50.7%) 
and 456/891 (51.2%) male cardiovascular patients, respectively.90 
 
The mean number of drugs prescribed for the cohort and subgroups clearly 
indicated polypharmacy in the prescribing of discharge drugs.  For the number of discharge 
prescriptions, there was no significant difference between the two subgroups which 
reinforced the representativeness of the minority HMR Report group for the majority non-
HMR Report group.  The exacerbation of DRPs and PIP by polypharmacy was stressed by 
several researchers including Flesch and Erdmann (2006), Fialová et al. (2005) and Müller 
(2008), particularly at hospital discharge.81-84  For the study cohort of chronically ill 
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cardiovascular patients, polypharmacy was found to further complicate their already 
complex pharmacotherapy. 
 
There is little doubt it is important to quantify the HRQL factors which influence 
the patients’ ADLs and which influence their management of complex drug regimens.56-
57,109  In addition, researchers found an association between impaired physical 
performance; reduced ability in routine ADLs; and inappropriate drug use identified by 
Beers criteria.60  These HRQL factors were measured in the CofCP cohort by application 
of the COOP QOL charts at hospital discharge and 6 months post discharge.    The survey 
ascertained any characteristic QOL differences between subgroups and any change in the 
cohort’s QOL after HMR service. 
 
The COOP QOL survey showed a significant improvement in the CofCP cohort’s 
physical fitness factor, 6 months post discharge.  The improvement was estimated to have a 
small to moderate effect on the cohort.  However, the cohort also showed a significant 
decline in their ‘overall health status’ after 6 months and this had a moderate to large 
effect.  Notably, Schenkeveld et al. (2010) found a perceived decline in the health status of 
cardiovascular patients, was not related to higher 6 year mortality rates.110 
 
In an on-going study, Du et al. (2011) assessed self efficacy and self-care behaviour 
beside QOL factors in patients from the same cardiology unit assessed in this, and the 
following chapters.  In the future, this research might help explain the CofCP cohort’s 
perceived health decline, as no changes were found in the other seven survey factors.66 
Hence in the cohort’s overall QOL assessment, there were no significant differences 
between discharge and 6 months post discharge within or between the cohort and 
subgroups. 
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Although the sensitivity of the COOP charts to detect changes in QOL has been 
questioned by some researchers, their use was recently found to be simple, reliable, valid 
and responsive for group use by international and Australian/NZ researchers.58,61  The high 
COOP response rates reported in this chapter centred around 75.0% and were in agreement 
with the literature.  In  most of the accessed research which involved cardiovascular 
patients, QOL was measured pre and post an HRQL intervention.55-57,59,62-63,66 
 
In this CofC project, COOP charts were also utilised to measure any changes in 
QOL for the recipients of an HMR service.  The number of QOL survey responses 
assessed were limited by the restriction to patients serviced within 6 months of discharge.  
It was of note that there was a high response rate, particularly before HMR service 
(63.3%), by those patients who were subsequently, recipients of the service.   
 
No significant differences were found in QOL for the HMR recipients when 
assessed as part of the cohort or within the HMR Report group after HMR service.  In 
characterising the CofCP patients, all QOL outcomes reinforced the proposition that the 
minority HMR Report group (n=79) was representative of the majority subgroup and 
hence, the cohort (n=281), at discharge and post discharge. 
 
3.10.3  SURVEY RESPONDENTS AND NON-RESPONDENTS 
In the literature, researchers stressed the importance of acknowledging differences in 
response rates and the characteristics of non-responders to avoid bias in establishing 
patients’ health profiles.89-90  Tolonen et al (2005) researched the effect and potential effect 
of the non-response components of surveys on international populations in the 
Multinational monitoring of trends and determinants in Cardiovascular Disease Project 
(WHO MONICA), which included an Australian population.89   
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The Australian population response rate was 136/1161 (11.7%) for the initial 
survey and 127/764 (16.6%) for the 10 year follow up survey.  The QOL survey response 
rate for the CofCP cohort was 219/281 (77.9%) patients at discharge and 180/281 (64.1%) 
patients at 6 months post discharge (Table 3.6).  Although the Diagnosis Related Group 
(DRG), clinical characteristics, gender distribution and mean ages of the two cohorts were 
comparable, the size of the Australian population studied and the expanse of time between 
their initial and follow-up surveys was not. 
 
 In the CofCP, responders to the COOP surveys in the cohort and non-HMR Report 
group were significantly older (mean range 64.9 to 65.7 years) than non-responders for 
both surveys.  In the cohort and both subgroups, there were no significant differences 
between responders and non-responders, in either survey, for LOS (mean range 11.7 to 
15.0 days).   
 
Also, in the cohort and both subgroups there were no significant differences 
between responders and non-responders in either survey, for number of prescriptions at 
discharge (mean range 8.2 to 9.6 prescriptions).  Hence, in LOS and prescriptions at 
discharge, the responders in the HMR Report group (n=79) were representative of the 
CofCP cohort in both surveys. 
 
For follow-up surveys, assessment of the CofCP cohort found the general response 
rate decreased, with increased respondent age.  These findings were consistent with those 
of Tolonen et al. when assessing cardiovascular patients.89-90  However, in characterising 
the Australian population of cardiovascular patients at follow-up, Tolonen et al. showed a 
ratio of 0.56 (14.0%:25.0%) responders to non-responders in 275/764 (36.0%) patients 
assessed for drug-related factors.   
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 Utilising the number of drugs prescribed at discharge as ‘drug-related factors’, the 
CofCP cohort showed a ratio of 1.7 (64.1%:35.9%) responders to non-responders in 281 
patients at follow up.  Compared with the Tolonen et al. research,89-90 and acknowledging 
the disparity in cohort sizes and follow-up periods, it is suggested that the CofCP cohort 
was shown to be characteristically, highly responsive to QOL survey participation.   
 
 
3.11  CONCLUSION 
 
 
Measurement of the cohort and subgroups’ overall QOL from accumulated scores in 
physical fitness, feelings, daily activities, social activities, pain levels, change in health, 
overall health, social support and patients’ perception of their quality of life, showed no 
significant difference between the subgroups.  In addition, there were no significant 
differences in the survey response rates at either discharge or post discharge between the 
subgroups.  There were significantly more male patients in the CofCP cohort (n=281) and 
non-HMR Report group (n=202).   
 
In support of the QOL survey outcomes as characteristic of the cohort’s health 
profiles, it was found that the majority of responders to the follow-up survey were 
significantly older than non-responders.  However, there were no significant differences 
between responders and non-responders in the subgroups in either survey, for LOS or 
importantly, in the number of prescriptions at discharge.  Further, the CofCP cohort was 
shown to be characteristically responsive to QOL survey participation. 
 
It was shown the study cohort was subject to polypharmacy in their discharge 
regimen.  Polypharmacy has been claimed to exacerbate DRPs and PIP and is innately 
associated with complex cardiovascular pharmacotherapy.20,45,78,83-84  Hence, the cohort’s 
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level and nature of DRPs and PIP at both discharge and in the community requires further 
investigation. 
 
 In this chapter study, other than for male gender, it was shown that there was an 
absence of any significant differences in personal, clinical, QOL characteristics or survey 
factors, between the subgroups.  For these variables, assessment showed there were no 
significant confounders which might jeopardise comparison of outcomes in further 
subgroup investigations.   
 
The subdivision of the cohort (n=281) into the HMR Report group (n=79) and the 
non-HMR Report group (n=202) based only on the availability or non-availability of an 
HMR report, was supported.  In the context of this thesis, the availability of the HMR 
report was confirmation and indicative of continuity of patient care in the community. 
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Figure 4.1 Chapter 4.0 Flowchart 
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CHAPTER 4.0  INVESTIGATING EXPOSURE TO DRUG RELATED PROBLEMS 
(DRPs)  
 
4.1  CHAPTER SUMMARY 
Following the identification of the complex nature and polypharmacy associated with the 
discharge regimen of the CofCP cohort, this study investigated any interruption by DRPs 
to the patients’ continuity of care after discharge.  For the Home Medicines Review 
(HMR) Report group (n=79), drugs and diseases were recorded on discharge summaries, 
HMR referral forms and HMR reports.  The documents were analysed for comparison at 
hospital discharge and after GP consultation in the community, at HMR service.  After 
categorisation of drugs and diseases by Anatomical Therapeutic Chemicals (ATC) and 
International Classification of Diseases Version 10, respectively, DRPs identified from 
available HMR reports were classified according to the Westerlund System.   This system 
not only classified potential DRPs but also recognised actual patient related problems 
arising from their complex pharmacotherapy.   
 
4.2  OPERATIONAL DEFINITION 
4.2.1.  CONTINUITY OF CARE is a perception of quality health care resulting from the 
ongoing management of issues which cause disruption to optimal patient care. 
In the context of the study reported in this chapter: 
Continuity of care is perceived by the researchers as the ongoing management of 
patients’ complex drug regimen by identification and resolution of drug related problems 
at post discharge medication review.  
4.3 PUBLICATION NOTE: In the following paper, the empirical study is referred to as 
the Westmead Medicines Project (WMP) (n=281 patients). The paper is cited in 
subsequent chapters as: Ellitt GR, Engblom E, Aslani P, Westerlund T, Chen TF. Drug 
related  problems  after  discharge  from  an  Australian  teaching  hospital. Pharm World  
Sci. 2010;32:622-630. Doi: 10.1007/s11096-010-9406-9
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4.4  Drug related problems (DRPs), Polypharmacy and CofC 
 
In the preceding paper, analyses of data ‘at discharge’ were conducted on lists of drugs 
and diseases in patients’ discharge summaries.  Analysis of data and DRPs ‘at HMR’ 
service were conducted on lists of drugs and diseases in HMR reports written by 
accredited pharmacists.  The comments and recommendations of the accredited 
pharmacists were taken into account for analysis of DRPs. 
 
This study found the most frequently reported drug related problem (DRP) was 
the patients’ uncertainty about the aim of their drugs which was followed by the 
potential for drug-drug interaction (DDI) and adverse drug reactions (ADRs).  
Regardless of the level at which any of the problems were reported, all actual and 
potential DRPs were a barrier to the patients’ continuity of care (CofC) after hospital 
discharge.  However, the HMR Report group benefited by the identification of these 
problems at HMR service.   
 
 Further evidence of the HMR Report group’s exposure to polypharmacy was 
found at both discharge and at HMR service in the community, however it was not 
considered  under the Westerlund System as a DRP.  There was a high level of actual 
DRPs which could receive timely resolution at HMR service, and potential DRPs to be 
reported to the group’s referring GPs.  The representativeness of the HMR Report group 
to the CofCP cohort has been proposed and the potential DRPs identified for the 
subgroup in this chapter, require further investigation.  Hence, it is recommended that 
the risk severity of involved drugs and the extent and source of any potentially 
inappropriate   prescribing   for  the  subgroup,   be  investigated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
at  discharge and  post discharge after GP consultation, at HMR service. 
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Figure 5.1 Chapter 5.0 Flowchart 
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CHAPTER 5.0 LOW and HIGH SEVERITY RISK DRUGS 
 
 
5.1  CHAPTER SUMMARY 
This chapter investigates the effect of prescribing high risk drugs on continuity of 
patient care between discharge from an acute care hospital and Home Medicines 
Review (HMR) service in the community..  The number of patients at risk and high risk 
drugs were investigated at discharge and at HMR for a subgroup (n=79) of patients 
from the Continuity of Care Project (CofCP) (n=281 patients).  Patients’ drugs and 
diseases were analysed by application of an international, well validated method to 
identify predetermined severity ratings allocated to specific drugs, and the source and 
extent of potentially inappropriate prescribing (PIP). 
 
 In this chapter study, analyses of PIP ‘at discharge’ were conducted on lists of 
drugs and diseases in hospital discharge summaries.  Analyses of PIP ‘at HMR’ service 
were conducted on lists of drugs and diseases in HMR reports written by accredited 
pharmacists.  The comments and recommendations made by the pharmacists in HMR 
reports were not taken into account. 
 
5.2 INTRODUCTION 
The period following a patient’s discharge from hospital into the community and to 
primary care is crucial in the management of their prescribed drugs and is heavily 
reliant on an integration of medical and pharmacy-based services.1-2  In turn those 
services are reliant on the accurate transfer of information between the hospital, patient 
and primary healthcare professionals.3-4  Even with the best intentions and accurate 
transfer of patient information, it is the quality and appropriateness of that transferred 
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information which is instrumental in maintaining the safety and continuity of patient 
care.5 
 
Discharge summaries in Australia are the primary mode of transferring the 
patients’ in-hospital history, treatments, diagnoses and pharmacotherapy to their 
primary care, general medical practitioner (GP).6-7  As such, the provision of 
comprehensive and accurate information is of utmost importance regardless of the 
patients’ age.8   It is also essential to transfer accurate information from the patients’ 
GPs to the patients’ nominated pharmacies for organisation of medication reviews.24,149   
 
It then follows that patient focussed reports written after Home Medicines 
Review (HMR) can reveal the accumulated changes to the patients’ pharmacotherapy 
between discharge and HMR.11-12  Timely medication review post discharge from 
hospital, and conducted in the patients’ homes, presents an opportunity to access and 
record the drugs the patient is actually consuming, regardless of the appropriateness or 
source of the prescribing.13   
 
 The literature abounds with advice and tools for determination of appropriate 
prescribing, potentially inappropriate prescribing (PIP) and polypharmacy, medication 
appropriateness, drugs-to-avoid, problematic prescribing and suboptimal prescribing.14-
20   These indicators, indices and criteria are described in many ways by their developers 
and include descriptions such as sensitive, descriptive, disease-dependent/independent, 
explicit and/or implicit.21-24  The outcomes measures include e.g. satisfaction/non-
satisfaction of criteria, allocation of low or high severity ratings, proportions of patients 
receiving appropriate treatment, patient risk and most of the outcomes which describe 
drug related problems including misuse, under and over prescribing.11,23-25 
 
 Chapter 5 Identifying Low and High Severity Risk Drugs                          Page 116 
 
 This study investigated the appropriateness of prescribing immediately post 
discharge from an acute care hospital.  The identification of an PIP at discharge and at 
medication review in the community was to determine the source (when and where), the 
extent, and the severity of risk to the continuity and quality of the patients’ healthcare 
after discharge. 
 
 
5.3  STUDY AIM To determine the extent of potentially inappropriate prescribing to 
which patients were exposed at hospital discharge and at medication review in the 
community. 
 
 
5.3.1  NULL HYPOTHESES 
To achieve the study aim for a cohort of patients (n=79) for whom an HMR report was 
available as shown in Figure 5.1, the following null hypotheses were proposed. 
 
There is no statistically significant difference between discharge and HMR in: 
 
1. the distribution of patients’ drugs and diseases. 
 
 
2. the distribution of allocated severity ratings. 
 
 
3. the distribution of instances of potentially inappropriately prescribed (PIP) drugs 
or drug related situations. 
 
 
4. the distribution of patients at risk and degree of allocated severity ratings.  
 
 
5. the type and distribution of criteria identifying the severity rating of prescribed 
drugs. 
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5.4  OPERATIONAL DEFINITIONS 
5.4.1  CONTINUITY OF CARE is a perception of quality health care resulting from the 
ongoing management of issues which cause disruption to optimal patient care. 
 
In the context of the study reported in this chapter: 
Continuity of Care is perceived by the researchers as the quality use of medicines by 
the ongoing management and timely identification of inappropriately prescribed drugs 
which put the patients’ healthcare and optimal pharmacotherapy at risk.26 
 
5.4.2  POTENTIALLY INAPPROPRIATE PRESCRIBING (PIP) 
In this study, the terms ‘potentially inappropriate prescribing’ ‘potentially inappropriate 
prescriptions’ and ‘potentially inappropriate medication’ are adopted as equivalent 
concepts and are abbreviated as ‘PIP’.  Prudent et al. (2008) define ‘potentially 
inappropriate medication’ as drugs with an unfavourable risk/benefit ratio when safer or 
equally effective alternatives are available.27 
 
 
5.5  METHOD 
 
5.5.1  STUDY DESIGN 
The study reported in this chapter, involved a retrospective analysis of patients’ drugs 
and diseases on discharge from hospital and at medication review in the community.  
The provision of HMR reports to the patients’ GPs by accredited pharmacists was the 
end point of data collection for this study.  Patients’ drugs were examined to identify 
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any predetermined severity ratings allocated by Beers criteria to those drugs, and to 
identify the risk of potentially inappropriate prescribing(PIP)  at two points in time.28   
 
5.5.2  SUBJECTS AND DATA SOURCES 
This study analysed the drugs prescribed for, and diseases of a subgroup of (n=79) 
patients of the Continuity of Care Project (CofCP) (n=281) (Figure 5.1).  All subjects 
recruited to the project were patients under the care of a cardiovascular team and were 
discharged from the Cardiology Unit of Westmead Hospital to their homes, between 
mid 2004 and 2007.  Patients whose median age was 69 (IQR 18: 58-76) years, met the 
suggested Australian Commonwealth Government’s eligibility criteria for HMR referral 
by a GP, and were discharged on at least one cardiovascular drug.29  
 
All research consent forms and protocols were accepted by the ethics 
committees of The University of Sydney, Western Sydney Area Health Service, 
Commonwealth Health Insurance Commission and the Veteran’s Affairs Board.6 From 
the full cohort of patients a subgroup of patients (n=87) received an HMR and 79/87 
HMR reports were received by the research team at Westmead hospital.30-31  In this 
study, the subgroup of patients for whom an HMR report was received by the research 
team, are reported as the HMR Report group (n=79) (Fig. 5.1). 
 
 Data sources analysed, included the patients’ hospital medical records, discharge 
summaries and HMR reports.  Hospital discharge summaries were generated by the 
attending medical teams for the patients’ delivery to their community GP.32  Short stay 
or ‘day only’ patients did not routinely receive a discharge summary hence, a list of the 
patients’ discharge drugs was recorded in lieu of the summary.  All HMR referring GPs 
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and nominated pharmacies received copies of their patient’s discharge summary or 
medication list. 
 
 HMR reports written for the patients’ referring GPs, by accredited pharmacists, 
were copied to the research team by those pharmacists.31  Prior to writing their reports, 
accredited pharmacists received copies of patients’ discharge summaries and GPs 
referral forms.  This allowed a comparison and/or reconciliation of discharge regimen, 
GP’s orders on referral forms, and drugs consumed at time of medication review.  This 
study analysed diseases and drugs recorded on hospital discharge summaries and on 
HMR service reports (Fig. 5.1). 
 
 
5.5.3  DRUG SEVERITY RATING CRITERIA 
The updated Beers criteria, published by Fick et al. (2003), were chosen for 
identification of PIP.  These explicit criteria rate potentially inappropriate drugs as of 
low or high severity.27,33-36  Beers criteria were developed using a modified Delphi 
method for formulating group judgements by an expert panel on the rating of specific 
drugs prescribed for patients ≥65 years of age.28,37  Beers criteria are criticized in the 
literature for inclusion, exclusion and omission of specific drugs in diverse 
circumstances which this study does not replicate.14-15,18,20-21 
 
These criticisms have been taken into account and Beers criteria were used in 
this study as a tool to identify an evidence base.  That is, data relevant to the patient 
population under study, and to quantify any health gains or negative consequences 
relevant to achieving the aim of this study.1  Beers criteria were chosen for this study 
after consideration of literature reviews and research which included:  
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a) Literature reviews assessed the application of Beers criteria in various 
healthcare settings and found that Beers’ identification of inappropriate 
prescribing and prescribing trends, were noteworthy regardless of 
methodological differences.35   
 
 
b) Beers criteria were also compared with other consensus-approved clinical 
indicators which demonstrated important links between patterns of care and 
clinical outcomes.38  
 
 
 
 
c) Systematic review of healthcare outcomes identified by Beers criteria, found 
an association with the detrimental healthcare impact of inappropriate 
medication use.39 
 
d) As an indication of the widespread acceptance of Beers criteria, Blackwell et 
al. (2008) researched and reported on the national uptake of the criteria for 
the assessment of American Medicaid and Medicare enrolees.40   
 
 
Therefore, it was accepted that application of the Beers criteria could provide an 
explicit, validated and international approach to identification of PIP in the Australian 
healthcare environment.21,23 
 
5.5.3.1  Application of Beers Criteria  
Beers Criteria allocate a severity rating for specific drugs independent of diagnoses or 
conditions in 48 criteria (Table 1) 28 and ratings considering diagnoses or conditions in 
20 criteria (Table 2).28  In this study, the Beers criterion targeting blood clotting 
disorders or patients receiving anticoagulant therapy was divided into two criteria for 
ease of analysis (No.54 and No.55) and the two tables of criteria were numbered 
consecutively from 1–69 (Appendix 5.1).   
 
In this study, the 69 criteria were applied to patients’ drugs and diseases to 
determine criteria applicability.41 Criteria were deemed applicable to the group if at 
least one patient was prescribed the drugs and, or met the conditions of the criterion.  
The active ingredients of drugs in the explicit criteria were counted whenever they were 
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targeted by any criterion and as many times as prescribed in a different form or strength 
(e.g. insulin, warfarin).  That is, unless specific conditions were expressed as in criteria 
No. 10: temazepam dose >15mg; No.22: ferrous sulphate >325mg/day. 
 
For the HMR Report group (n=79), purpose designed databases were 
constructed for all drugs prescribed and diseases diagnosed at discharge and HMR.  All 
drugs and diseases were coded numerically for data entry purposes.  Alphabetical and 
numerical lists of the drugs and diseases were then prepared and further databases were 
designed to record patient responses to the applicable Beers criteria. 
 
 In the response databases, dichotomous (yes, no) responses to the criterion were 
recorded in rows, against the patients’ code numbers, with applicable Beers criteria in 
columns.  If a therapeutic category was listed in a criterion, it was necessary to 
repeatedly access the drugs database to capture all drugs within the category being 
assessed e.g. anticoagulants: warfarin, heparin, and low dose aspirin.  The patient was 
scored as being/not being exposed to an instance of PIP, along with the severity risk 
indicated by that criterion. 
 
Identification of PIP by Beers criteria ‘at discharge’ was conducted on lists of 
drugs or diseases in discharge summaries.  Identification of PIP by Beers criteria ‘at 
HMR’ service was conducted on lists of drugs or diseases in HMR reports written by 
accredited pharmacists.  The pharmacists’ comments and recommendations in the 
report, were not taken into account..   
 
The provision of the HMR reports, to the researchers by the accredited 
pharmacists, was the end point of data collection for this study 
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5.5.3.2  Allocation of Severity Ratings 
Application of the Beers criteria allowed analyses that indicated the number of high and 
low severity ratings allocated to the patients’ drugs at discharge and HMR.  In order to 
apply Beers criteria, each of the patients’ drugs and disease states were repeatedly 
assessed by different criteria for allocation of severity ratings.  For example, a patient 
with heart failure, rheumatoid arthritis and a gastric ulcer who was taking piroxicam 
would have recorded 3 high severity ratings allocated for the one drug from the 
application of the following criteria. 
No.28  Independent of diagnoses or conditions: Long-term use of full-dosage, longer  
 half-life, non-COX-selective non-steroidal anti-inflammatory drugs (NSAIDs). 
Concern: Have the potential to produce GI bleeding, renal failure, high blood 
pressure, and heart failure 
No.52  Considering Diagnoses or Conditions: Gastric or duodenal ulcers; taking  
NSAIDs or aspirin (>325mg) (coxibs excluded).  Concern: May exacerbate 
existing ulcers or produce new/additional ulcers. 
No.55  Considering Diagnoses or Conditions: Blood clotting disorders or receiving  
anticoagulant therapy; taking Aspirin, NSAIDs, dipyridamole, ticlopidine or  
clopidogrel.  Concern: May prolong clotting time and elevate INR values or  
inhibit platelet aggregation, resulting in an increased potential for bleeding.  
(Appendix 5.1) 
 
 
5.5.4  DATA ANALYSES 
For data analysis and outcome interpretation, three units of analysis were targeted 
namely: 1) allocation of severity ratings to patients’ prescribed drugs 2) patients’ 
exposure to PIP and 3) the form and utility of Beers criteria.  
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Data on drugs and diseases were extracted from the HMR Report group’s 
discharge summaries and HMR reports.  Drugs and diseases were recorded and coded 
according to the Anatomical Therapeutic Chemical (ATC) classification and 
International Classification of Disease version 10 (ICD-10), respectively.42-43  After 
coding, patients’ drugs and diseases were analysed to determine the nature and 
distribution of severity ratings allocated to their drugs and drug related situations.  This 
was an indication of whether or not those patients were at risk of PIP.44-45 
 
It was outside the realm of this study to empirically measure the clinical impact 
on the patients of identified PIP.  Instead, an effect size approximation was conducted 
using an eta squared estimation.  This calculation was based on the ‘t’ value of students’ 
t-tests (t-tests) conducted to assess the null hypothesis of any differences in the 
allocation of severity ratings between discharge and HMR.   
 
Eta squared estimations (tsq/tsq+(N-1)) for effect size were based on Cohen’s 
values of 0.01~small effect; 0.06~moderate effect and 0.140~large effect.46-48 In 
addition, the percentage difference in severity ratings allocated to patients was estimated 
if the difference was shown to be statistically significant.  Regardless of severity rating 
level, all outcomes between discharge and HMR were included to describe the proposed 
impact of that difference in PIP on the patients.   
 
The form and distribution of the applied criteria were also analysed to assess 
how many criteria were applied, and whether or not they carried a low or high severity 
rating.  These analyses indicated the source and changes in the extent of inappropriate 
prescribing at discharge and/or HMR.  In turn, the outcomes provided an insight into the 
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continuity and appropriateness of patients’ pharmacotherapy at discharge and its 
continuance through follow-up in the community.49-51   
 
Data were analysed at discharge and HMR using the Statistical Package for the 
Social Sciences: Statistics Version 17 and Microsoft Excel 2003 software.  All specific 
tests were conducted at an alpha level of 0.05 and included multiple response 
frequencies; t-tests and chi squared relationships. 
 
 
5.6  RESULTS 
 
 
5.6.1  DRUGS AND DISEASES 
 
A total of 87 patients received an HMR post discharge, and a report was available for 
79/87 (90.8%) of those patients.  Table 5.1 shows the number and distribution of drugs 
and diseases analysed for the HMR Report study group (n=79) and paired samples t-
testing of the null hypothesis of no difference between discharge and HMR.  There was 
a significant increase in number of drugs documented at HMR (p=0.001) and a 
significant decrease in number of diseases documented at HMR (p=0.001) than at 
discharge. 
 
5.6.2  APPLICABILITY OF BEERS CRITERIA 
Beers criteria (n=69) were initially applied to the drugs and diseases of the HMR Report 
group (n=79) to determine which criteria were applicable to ≥1 patient in the group at 
any time (Appendix 5.1).   This resulted in 27 criteria being found applicable to the 
group.  Of the applicable criteria, there were 22 criteria which rated drugs/situations of 
high severity and 5 criteria which rated drugs/situations of low severity.   
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Table 5.1  Distribution of drugs and diseases recorded for the HMR Report group (n=79) at discharge and HMR 
Group 
Characteristic 
DISCHARGE   HMR 
 
   Significance 
 
 Total number 
 
Mean (SD±) Range Total number Mean (SD±) Range t value p value 
Drugs 658 8.2 (3.0) 2 - 19 805 10.1 (4.9) 1- 23 -4.09 0.001 
Diseases 411 5.2 (2.8) 1 - 14 286  3.6 (2.9) 1- 12 3.34 0.001 
(t-test: N=79, df=78)  
 
 
Table 5.2  Distribution of severity ratings allocated to the prescribed drugs for the HMR Report group (n=79) by  
application of the Beers Criteria28 at discharge and HMR. 
 
Severity ratings DISCHARGE HMR  Significance 
     
 Number of ratings 
Mean (SD±) per patient 
Number of ratings 
Mean (SD±) per patient 
t value p value 
 
Low severity ratings 
allocated 
0.2 (0.15) 0.1 (0.3) 1.42 0.16 
High severity ratings 
allocated 
2.8 (1.12) 2.2 (1.2) 2.91 0.01 
Low + High severity 
ratings allocated 
2.9 (1.21) 2.3 (1.3) 3.19  0.02 
(t-test: N=79, df=78)  Beers criteria28 (Appendix 5.1). 
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5.6.3  LOW AND HIGH SEVERITY DRUG RATINGS  
Table 5.2 shows the results of HMR Report group (n=79) assessment for the allocation 
of low or high severity ratings to patients’ drugs/situations. Table 5.2 shows the number 
and distribution of severity ratings allocated by Beers criteria and paired samples t-
testing of the null hypothesis of no difference between discharge and HMR.   There was 
no significant difference between discharge and HMR in the number of low severity 
ratings allocated to patients’ drugs/situations (p=0.159).  From discharge, there was a 
significant decrease at HMR in the high severity ratings allocated to patients’ drugs 
(p=0.005).  The combination of low and high severity ratings allocated to patients’ 
drugs/situations showed a significant decrease at HMR (p=0.002).  
 
5.6.3.1  Proposed Impact of Identified Severity Ratings  
The impact on patients of prescribing low and high severity drugs was approximated 
using an eta squared estimation (tsq/tsq+(N-1)).  As shown in Table 5.2, the paired 
samples t-testing of high severity ratings allocated to patients’ drugs/situations at 
discharge and at HMR showed a significant decrease at HMR (t(78)=2.91; p=0.005). 
The eta squared estimation (0.098) indicated a moderate to large effect size.   
 
When the relatively small number of low severity ratings was combined with the 
high severity ratings, t testing showed a significant decrease at HMR (t(78)=3.19; 
p=0.002).  The eta squared estimation (0.115) indicated an unchanged, moderate to 
large effect size from the combined ratings.  In addition, from Table 5.2 the paired 
samples t-testing of the combined severity ratings showed a significant difference at 
HMR with a percentage decrease of 20.4% in total severity ratings at HMR. 
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5.6.4  INSTANCES OF POTENTIALLY INAPPROPRIATE PRESCRIBING (PIP) 
Table 5.3 shows the paired samples t testing of the total number of instances (high and 
low severity) of PIP relative to the number of routine drugs prescribed and patients 
assessed at discharge and at HMR.  The ratio of PIP instances to the number of routine 
drugs (Table 5.1) prescribed for the study group was 127 (19.3%) at discharge and 115 
(14.3%) at HMR service.  Table 5.3 also shows the mean number of PIP instances for 
the HMR Report group (n=79).  Although there was no significant difference in the 
mean number of instances identified by Beers criteria between discharge and HMR 
(p=0.069), the results are consistent with the marked reduction of high severity ratings 
allocated at HMR service. 
 
5.6.5  PATIENTS AT RISK – SPECIFIC CRITERIA 
 
5.6.5.1  Patients at Risk – High Severity Criteria 
The results in Table 5.4 indicated marked differences in the number of patients 
prescribed drugs, or in drug related situations allocated high severity rating at discharge 
and at HMR service.  The relative frequency analysed at discharge and at HMR across 
the 22 criteria showed 7.2% patients and 6.6% patients were prescribed high risk drugs, 
respectively.  Although paired samples t testing of the decrease in number of patients 
prescribed drugs allocated high severity ratings at HMR was not significant (p=0.064), 
the results reflect the reduction of PIP identified at HMR. 
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Table 5.3 Instances of drugs or drug related situations identified as PIP for the HMR Report group (n=79) by Beers criteria28 at discharge 
and HMR. 
 
PIP situations 
identified by Beers 
DISCHARGE: n = 658 drugs*  
 
HMR: n = 805 drugs* 
 
 Significance 
 
Criteria Total 
Number 
Mean 
(SD±) per 
patient 
Ratio PIP to 
discharge 
drugs* 
Total 
Number 
Mean 
(SD±) per 
patient 
Ratio PIP to 
discharge 
drugs* 
 
t value 
 
p value 
Potentially inappropriate 
prescribing instances 
 
 
127  
 
1.6 ( 1.1) 
 
19.3% 
 
115 
 
1.4 ( 1.1) 
 
14.3% 
 
1.84 
 
0.069 
(t-test: N=79, df=78)  * % PIP frequency relative to total number drugs prescribed.   Beers criteria28 (Appendix 5.1). 
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Table 5.4  Distribution of HMR Report group patients (n=79) identified as at risk from high severity drugs or drug related situations by 
applicable Beers criteria* at discharge and HMR. 
 
  DISCHARGE  HMR  
 
 
No. 
Beers Criteria applied 
 
High Severity (n=22) 
Number Patients 
no riska (% relative 
frequency)b 
Number Patients 
at riska (% relative 
frequency)b 
Number Patients 
no riska (% relative 
frequency)b 
Number Patients 
at riska (% relative 
frequency)b 
 2 Indomethacin (Indocin and Indocin SR) 
 
77 ( 97.5)  2 ( 2.5) 75 ( 94.9)  4 ( 5.1) 
 7 Amitriptyline (Elavil), chlordiazepoxide-
amitriptyline (Limbitrol), and 
perphenazine-amitriptyline (Triavil) 
78 ( 98.7)  1 (1.3) 77 ( 97.5)  2 ( 2.6) 
 8 Doxepin (Sinequan) 
 
78 ( 98.7)  1 ( 1.3) 78 ( 98.7)  1 ( 1.3) 
10 Doses of short-acting benzodiazepines: 
doses greater than temazepam (Restoril) 
15 mg. [no other listed drugs were 
prescribed]  
78 ( 98.7)  1 ( 1.3) 0 0 
11 Long-acting benzodiazepines: diazepam 
(Valium) [no other listed drugs were 
prescribed] 
 
78 ( 98.7) 
 
 1 ( 1.3) 
 
0 
 
0 
27 Amphetamines and anorexic agents 
 
78 ( 98.7)  1 ( 1.3) 77 ( 97.5) 2 ( 2.6) 
29 Daily fluoxetine (Prozac) 
 
78 ( 98.7)  1 ( 1.3) 0 0 
31 Amiodarone 
 
78 ( 98.7)  1 ( 1.3) 74 ( 93.7)  5 ( 6.3) 
42 Short acting nifedipine (Procardia and 
Adalat) 
75 ( 94.9)  4 ( 5.1) 77 ( 97.5)  2 ( 2.6) 
44 Mineral oil 
 
0 0 76 ( 96.2)  3 ( 3.8) 
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Table 5.4  Analysis and distribution of HMR Report group patients (n=79) identified as at risk from high severity drugs or drug related 
situations by applicable Beers criteria* at discharge and HMR, continued 
 
  DISCHARGE  HMR  
 
 
No. 
Beers Criteria applied 
 
High Severity (n=21) 
Number Patients 
no riska (% relative 
frequency)b 
Number Patients 
at riska (% relative 
frequency)b 
Number Patients 
no riska (% relative 
frequency)b 
Number Patients 
at riska (% relative 
frequency)b 
50 Heart Failure 
 
69 ( 87.3) 10 (12.7) 71 ( 89.9)  8 (11.3) 
51 Hypertension 
 
78 ( 98.7)  1 ( 1.3) 77 ( 97.5)  2 ( 2.6) 
53 Seizures or epilepsy 
 
77 ( 97.5)  2 ( 2.6) 0 0 
55 Receiving anticoagulant therapy 
 
 6 (  7.6) 73 (92.4)  8 (10.1) 71 (89.9) 
56 Bladder outflow obstruction 
 
74 ( 93.7)  5 ( 6.3) 76 (96.2)  3 ( 3.8) 
58 Arrhythmias 
 
69 ( 87.3) 10 (12.7) 75 (94.9)  4 ( 5.1) 
59 Insomnia 
 
0 0 78 (98.7)  1 ( 1.3) 
60 Parkinson Disease 
 
78 ( 98.7)  1 ( 1.3) 78 (98.7)  1 ( 1.3) 
62 Depression 
 
76 ( 96.2)  3 ( 3.8) 78 (98.7)  1 ( 1.3) 
64 Syncope or falls 
 
78 ( 98.7)  1 ( 1.3) 0 0 
66 Seizure disorder 
 
77 ( 97.5)  2 ( 2.6) 77 (97.5)  2 ( 2 6) 
68 COPD 
 
78 ( 98.7)  1 ( 1.3) 78 (98.7) 1 ( 1.3) 
COPD, chronic obstructive pulmonary disease.   a0 = none documented..   b % frequency relative to total number of patients (n=79).   * 
Beers criteria (Appendix 5.1). Please Note: Where brand named drugs were specified in criteria, only those drugs were taken into account. 
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In Table 5.4 the highest number of patients prescribed drugs rated as of high 
severity was recorded for criterion No.55.  This criterion explicitly rated aspirin, non-
steroidal anti-inflammatory drugs (NSAIDS), dipyridamole (Persantin), ticlopidine 
(Ticlid), and clopidogrel (Plavix) as drugs of high severity when anticoagulant therapy 
was also prescribed.  For example, patients in the HMR Report group who were 
receiving anticoagulant therapy were also prescribed aspirin, indomethacin, diclofenac, 
ketoprofen, meloxicam, or ibruprofen.  At discharge, 73 (92.4%) patients were 
prescribed one of the listed drugs while receiving anticoagulant therapy.  At HMR, 71 
(89.9%) patients were prescribed one of the listed drugs while receiving anticoagulant 
therapy. 
The second highest number of patients prescribed drugs rated as high severity 
was recorded for criterion No.50.  This criterion explicitly rated disopyramide (Norpace, 
and high sodium content drugs (sodium and sodium salts [alginate, bicarbonate, 
biphosphate, citrate, phosphate, salicylate, and sulphate]) as drugs of high severity when 
patients were diagnosed with heart failure.   For example, patients in the HMR Report 
group who were diagnosed with heart failure were prescribed sodium bicarbonate or 
sodium citrate.  At discharge, 10 (12.7%) patients were prescribed one of the listed 
drugs while diagnosed with heart failure.  At HMR, 8 (11.3%) patients were prescribed 
one of the listed drugs while diagnosed with heart failure. 
 
5.6.5.2  Patients at Risk – Low Severity Criteria 
Table 5.5 shows the insignificant number of patients prescribed drugs, or in drug related 
situations of low severity rating at discharge and HMR.  The relative frequency 
analysed at discharge and HMR across the 5 criteria showed 1.7% patients and 1.2% 
patients were at low risk, respectively.  Paired samples t testing of the decrease in 
number of patients with low severity ratings at HMR was not statistically significant 
(p=0.821).
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Table 5.5  Distribution of HMR Report group patients (n=79) identified as at risk from low severity drugs or drug related situations by 
Beers criteria* at discharge and HMR. 
 
  DISCHARGE  HMR  
 
 
No. 
Beers Criteria applied 
 
Low Severity (n=6) 
Number Patients 
no risk (% relative 
frequency)b 
Number Patients 
at risk (% relative 
frequency)b 
Number Patients 
no risk (% relative 
frequency)b 
Number Patients 
at risk (% relative 
frequency)b 
13 Digoxin (Lanoxin) (should not 
exceed >0.125mg/d except when 
treating atrial arrhythmias) 
76 (96.2) 3 ( 3.8) 76 (96.2) 3 ( 3.9) 
22 Ferrous sulphate >325mg/d 
 
78 (98.7) 1 (1.3) 0 0 
49 Estrogens only (oral) 
 
78 (98.7) 1 ( 1.3) 0 0 
65 SIADH/hyponatremia 
 
77 (97.4) 2 ( 2.5) 78 (98.7) 1 ( 1.3) 
69 Chronic constipation 
 
0 0 78 (98.7) 1 ( 1.3) 
SIADH, syndrome of inappropriate antidiuretic hormone secretion.   .b % frequency relative to total number of patients (n=79).   * Beers 
criteria (Appendix 1) 
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5.6.6 APPLICATION OF CRITERIA 
Application of the Beers criteria also allowed analyses of the number and type of 
criteria that were applied to the HMR Report group at discharge and at HMR service as 
shown in Table 5.6.  It was found during analysis, that one high severity criterion could 
be applied to one patient a number of times for a number of different drugs.  For 
example, a patient with chronic obstructive pulmonary disease (COPD), anxiety and 
hypertension whose pharmacotherapy included taking diazepam and propanolol was 
assessed at least twice by the following high severity criterion. 
 
No.68  Considering Diagnoses or Conditions: COPD; taking long-acting 
benzodiazepines: chloriazepoxide, chlordiazepoxide-amitriptyline, clidinium- 
chloridazepoxide, diazepam, quazepam, halazepam or chlorazepate. Β-blockers:  
propanolol.  Concern: Central nervous system adverse effects. May induce  
respiratory depression. May exacerbate or cause respiratory depression.  
(Appendix 5.1) 
 
5.6.6.1  Application of Low and High Severity Criteria 
Table 5.6 shows results of paired samples t testing of the number and distribution of low 
and high severity criteria applied to the group.  The table shows the t-testing of the null 
hypothesis of no difference between discharge and HMR.  There was no significant 
difference between discharge and HMR in the number of low severity criteria applied 
(p=0.088).  There was a significant decrease between discharge and HMR in the number 
of high severity criteria applied at HMR (p=0.045).  There was no significant difference 
between discharge and HMR when the number of low and high severity criteria were 
combined (p=0.090).  
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Table 5.6 Distribution of applicable Beers criteria* applied to HMR Report group 
(n=79) at discharge and HMR. 
 
Beers Criteria 
(n=27) 
 
DISCHARGE 
 
Number applied 
HMR 
 
Number applied 
 Significance 
 
 Mean (SD±)  Mean (SD±)  t value p value 
Low severity criteria  0.01 ( 0.1) 0.3 ( 0.8) -1.76 0.088 
High severity criteria  6.6 (14.4) 4.7 (13.3) 2.09 0.045 
Low + High severity 
criteria  
 
6.6 (14.4) 5.0 (13.2) 1.76 0.090 
(t-test: N=27, df=26)   * Beers criteria (Appendix 1) 
 
 
5.7 DISCUSSION 
For the HMR group of patients, this study aimed to test several null hypotheses of no 
differences between discharge and HMR in 1) the distribution of patients’ drugs and 
diseases and 2) the distribution of severity ratings allocated by Beers explicit criteria.  
The study tested for differences in 3) the distribution of instances of PIP.  Further the 
study tested for differences in 4) the distribution of patients at risk and degree of 
severity ratings identified by specific criteria and finally in 5) the distribution and type 
of the applied Beers criteria. 
 
 While testing the null hypotheses all analyses ‘at discharge’ were conducted on 
lists of drugs and diseases in discharge summaries.  All analyses ‘at HMR’ service were 
conducted on lists of drugs and diseases in HMR reports written by accredited 
pharmacists.  The pharmacists’ comments and recommendations in the HMR reports 
were not taken into account. 
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From Chapter 4, the distribution of drugs and diseases for the HMR Report 
group unexpectedly showed that cardiovascular drugs constituted only 46.4% of 
discharge drugs and 39.5% drugs in HMR reports.11  This showed that a significant 
proportion of drugs (~60%) were from non-cardiovascular categories and that within the 
markedly high number of drugs prescribed, most were for co-morbidities.   
 
The prescription of ≥ 5 concurrent active drugs is defined in the literature as 
polypharmacy which is at times, independently labelled as inappropriate prescribing.52  
Polypharmacy is also strongly linked to a “presence of drugs included in the Beers 
criteria…..” (p1331 Steinman et al. 2009).18,27,53-54   Fialova et al. (2005) found the 
relative risk of PIP was positively associated with polypharmacy.52  Alternatively, when 
researching functional burden from (specifically) anticholinergic and sedative drugs,  
Hilmer et al. (2007) found that simply counting drugs was insufficient in assessment of 
potentially harmful drug regimens.  Identification of polypharmacy alone,  “provides no 
guidance for identifying the drugs that should be reduced or eliminated to minimise 
drug-related risk” (p782).55 
 
In testing the differences in the distribution of drugs and diseases, it was found 
the study group were prescribed very high numbers of drugs ranging between 1-23drugs 
with a discharge mean 8.2 (±3.0) drugs and HMR mean 10.1 (±4.9) drugs.11 This level 
of prescribing, and the significant increase shown at HMR indicates that polypharmacy 
should not be ignored as a unique or contributing factor in determinations of PIP and as 
a barrier to continuity of care for cardiovascular patients.26,54,56-57 
 
The impact on patients, in a comparable study group, of significant outcomes 
from the allocation of Beers high severity ratings, was not found in the literature.  
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Further, the literature on estimations of the impact of statistically significant outcomes 
calculated from continuous and/ or repeated measures in cardiovascular healthcare 
research was diverse and dissimilar.58-59   
 
As an example of impact estimations and research diversity (with study 
similarities), a Cochrane review calculated standard effect size on continuous measures.  
The review examined shared decision making (SDM) (e.g. appropriate prescribing) by 
healthcare professionals.  In the review, Légaré et al. claimed that SDM was considered 
to be the crux of patient-centred care in cardiovascular risk factor management.60  The 
review selected studies in which primary research outcomes (e.g. drug severity ratings), 
were evaluated using an objective ‘third-observer instrument’ (e.g. Beers criteria).60  
 
In this study, despite a statistically significant reduction in the allocation of high 
severity ratings at HMR, the result gave no indication of the impact of the reduction on 
the study group.  By using eta squared calculations; the beneficial impact of the 
reduction on patients was estimated to have a large effect size at HMR.  In addition, it is 
proposed that an estimated reduction of 20.4% in severity ratings at HMR, is indicative 
of a highly beneficial impact on the study group.  Taken at face value, the reduction 
reflects the improved patient care administered in the community after acute care 
hospital discharge.   
 
Potentially inappropriate medication use in a European cohort of elderly patients 
(n=2707) was studied by Fialová et al. (2005) who combined both versions of Beers 
criteria (1997 and 2003) with criteria developed by McLeod et al.20,52  Overall, Fialová 
found that 536 (19.8%) patients used at least 1 inappropriate medication with substantial 
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relative differences in patient numbers documented in the Czech Republic (41.1%); 
Denmark (5.8%); and Italy (26.5%).   
 
Barry et al. (2006) combined Table 1 and Table 2 of Beers criteria and assessed 
patients in Ireland (n=181) and identified (also) at least 1 inappropriate prescription in 
62 (34.0%) patients.  Cardiovascular drugs were over 75% of medications documented 
for the Irish cohort.38  Research by Steinman et al. found 214 (6.0%) prescribed drugs 
were flagged as potentially inappropriate by application of the Beers criteria.  This 
outcome resulted from a study cohort of elderly patients (n=256) who used 3678 
medications with a mean (SD±) of 14.4 (±5.0) medications indicated by predominantly 
cardiovascular diseases.18    
 
Outcomes from this study, where the allocation of severity ratings to patients’ 
drugs or drug related situations were indicative of PIP instances, were in general 
agreement with the literature.  In this study, patients’ PIP instances showed a mean 
(SD±) of 1.5 (±1.1) at discharge and 1.4 (±1.1) at HMR service.  Comparable outcomes 
from the literature were expressed as ‘greater than 1 inappropriate medication’ which 
was read as a result between 1 and 2 inappropriate drugs per patient.35,40,52,54,61  
 
However in this study, the ratio of PIP drugs to the number of routine drugs 
prescribed for the HMR Report group at discharge (19.3%) and at HMR (14.3%) was 
markedly higher than those reported by Steinman et al. at (6.0%).   Steinman et al. 
compared the application of Beers and Zhan explicit criteria in a cohort of ‘very elderly’ 
geriatric patients.18  They found outcomes were strongly influenced by the limited 
ability of drugs-to-avoid criteria, such as Beers, to distinguish between drugs that were 
problematic for individual patients and those which were not e.g. clopidogrel and 
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aspirin.18  However, Steinman also found that drugs-to-avoid criteria were best used to 
warn physicians of PIP and a simple means to identify PIP for follow up in 
individualised medication review. 
 
Analyses of differences in where or when potentially inappropriate prescribing 
occurred, utilizing Beers criteria and relevant to this study, were not found in the 
literature.  In this study, the location or time of PIP was described as the source of the 
prescribing i.e. at hospital discharge or after GP consultation in the community.  When 
the outcomes from application of Beers criteria were accepted at face value, the 
allocation of high severity rankings to the patients’ prescribed drugs showed a distinct 
and significant decrease from discharge to HMR.  Hence, these outcomes indicated the 
beneficial intervention of the patients’ GP at post discharge follow-up prior to HMR in 
the community.39  In support of such a finding, research has shown that community 
physicians perceive the most influential factor in safe and effective prescribing, relative 
to hospital-based prescribing, was their personal experience and contact with the 
patients.56,62   
 
Use of the Beers criteria to identify PIP has been extensively reported in the 
literature.  Many researchers, including Spinewine et al. (2007), were critical of the 
Beers criteria for ignoring drug availability in countries other than the USA.21,63-65 
Further, in developing alternate quality assessments for prescribing in primary health 
care, Wettermark et al. (2003) and Galagher and O’Mahoney (2008), specifically 
referred to the importance of taking individual patient diagnoses and prescribing 
practices into account.63,66   
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Similarly in this study, differences were found in the availability of drugs and 
prescribing practices in Australia.  In addition, the majority of the Beers criteria were 
found to be inflexible and did not facilitate patient focussed deliberations on the severity 
ratings allocated to prescribed drugs or drug related situations.16,36,67  This study found 
Beers severity ratings were misleading when allocated to drugs which were rated 
‘independent of diagnoses or conditions’. 
 
As an example, this shortcoming was marked in the application of criterion No. 
55 which rated clopidogrel as a high severity drug when prescribed with aspirin.  Beers 
explicit criteria made no allowance for combing low dose aspirin and clopidogrel as a 
first line treatment under any circumstances.  This combination of drugs was dispensed 
on discharge and was an accepted prescribing practice by the medical team treating the 
study cohort of cardiovascular patients at Westmead Hospital.6,68-69   The explicit, high 
severity drug ratings allocated by Beers to clopidogrel and aspirin, were inflated at 
discharge and subsequently exaggerated the apparent ‘significant’ reduction of 
inappropriate prescribing at HMR.  
 
Converse to the criticisms of explicit criteria, or ‘drugs to avoid criteria’ or 
‘disease-independent criteria’ such as Beers, the use of these criteria especially for 
psychotropic agents, is supported in the literature.18,24,55  These criteria were also 
considered a necessity by researchers who found that ‘disease-dependent’ criteria were 
too restrictive.27,65  
 
Beers criteria are generally described as explicit and ‘disease independent’ 
however, Beers criterion No. 58 is a criterion that took into account the patients’ 
diagnoses or conditions (Appendix 5.1).  This study found that application of Beers 
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criterion No. 58 (Table 5.4) identified the largest reduction of patients at risk of PIP.  
This occurred after GP consultation in the community when tricyclic antidepressants 
prescribed at discharge, were beneficially withdrawn from the regimens of patients with 
cardiac arrhythmia.   
5.8  STUDY STRENGTHS AND LIMITATIONS  
 
It is acknowledged that the number of subjects and HMR reports available for analysis, 
limited generalisation from the study.  The assessment of prescribing appropriateness 
was limited by any inaccuracies and or non-completion of documentation in medical 
records, discharge summaries, GP referral forms and medication review reports.  
However, documentation was representative of a real healthcare environment not 
artificially controlled for research purposes.   
 
The explicit nature of Beers criteria was found to constrain analysis of 
potentially inappropriate prescribing (PIP) in Australia.  It is suggested however, that it 
is unrealistic to expect that one set of criteria could accommodate worldwide differences 
in every context requiring identification PIP.  In this study, differences in the healthcare 
system, availability of drugs, individual patient characteristics and local prescribing 
practices were not accommodated by application of Beers criteria.  
 
5.9  CONCLUSION  
A determination of the extent of PIP after discharge from an Australian acute care 
hospital into the community, confirmed the need for increased vigilance and safer 
prescribing.  It is suggested that the conduct of routine medication reviews in patients’ 
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homes would increase vigilance and improve information exchange with patients and 
healthcare professionals across healthcare borders.   
 
The study evidenced elevated levels of polypharmacy and PIP of high risk drugs 
which, although reduced after GP follow-up, remained at an unacceptable level.  This 
problem especially concerned the ratio between identified instances of PIP and drugs 
routinely prescribed at both hospital discharge and after GP follow up in the 
community.   
 
It is recommended that further research be conducted to identify and address PIP 
using an alternate method to compensate for the constraints of the Beers criteria in 
Australia.  Timely and comprehensive identification of PIP in the period immediately 
after hospital discharge is crucial to the patients’ sustained improvement and continuity 
of care. 
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Chapter 5 Appendix 5.1. Copied from “Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults” Fick et 
al.28 
 
Beers Table I  2002 Criteria for Potentially Inappropriate Medication Use in Older Adults: Independent of Diagnoses or Conditions. (Criteria are 
numbered according to the complete list of Beers Criteria) 
 
Drug Concern Severity 
 Rating  
Applicability of indicator in 
this study of the HMR 
Report group (n=79) 
1. Propoxyphene (Darvon) and combination 
products (Darvon with ASA, Darvon-N, and 
Darvocet-N)  
Offers few analgesic advantages over 
acetaminophen, yet has the adverse effects of 
other narcotic drugs. 
Low No: drug/s not prescribed 
 2. Indomethacin (Indocin and Indocin SR) Of all available nonstreroidal anti-inflammatory 
drugs, this drug produces the most CNS adverse 
effects 
High Applicable 
 3.  Pentazocine (Talwin)  Narcotic analgesic that causes more CNS adverse 
effects, including confusion and hallucinations, 
more commonly than other narcotic drugs. 
Additionally, it is a mixed agonist and antagonist.  
High No: drug/s not prescribed 
 4. Trimethobenzamide (Tigan) One of the least effective antiemetic drugs, yet it 
can cause extrapyramidal adverse effects. 
High No: drug/s not prescribed 
 5. Muscle relaxants and antispasmodics: 
methocarbamol (Robaxin), carisoprodol (Soma), 
chlorzoxazone (Paraflex), metaxalone (Skelaxin, 
cyclobenzapeine (Flexeril), and oxybutynin 
(Ditropan). Do not consider the extended-release 
Ditropan XL. 
Most muscle relaxants and antispasmodic drugs 
are poorly tolerated by elderly patients, since 
these cause anticholinergic adverse effects, 
sedation, and weakness. Additionally, their 
effectiveness at doses tolerated by elderly 
patients is questionable. 
High No: drug/s not prescribed 
 6. Flurazepam (Dalmane) This benzodiazepine hypnotic has an extremely 
long half-life in elderly patients (often days), 
producing prolonged sedation and increasing the 
incidence of falls and fracture. Medium- or short-
acting benzodiazepines are preferable. 
High No: drug/s not prescribed 
 
   Chapter 5 Identifying Low and High Severity Risk Drugs                                                                                                                Page 150 
 
Beers Table I  2002 Criteria for Potentially Inappropriate Medication Use in Older Adults: Independent of Diagnoses or Conditions 
continued. 
 
Drug Concern Severity 
 Rating (High 
or Low) 
Applicability of indicator in 
this study  
 7. Amitriptyline (Elavil), chlordiazepoxide-
amitriptyline (Limbitrol), and perphenazine-
amitriptyline (Triavil) 
Because of its strong anticholinergic and sedation 
properties, amitriptyline is rarely the 
antidepressant of choice for elderly patients. 
High Applicable 
 8. Doxepin (Sinequan) Because of its strong anticholinergic and sedating 
properties, Doxepin is rarely the antidepressant 
of choice for elderly patients. 
High Applicable 
 9. Meprobamate (Miltown and Eqanil) This is a highly addictive and sedating anxiolytic. 
Those using meprobamate for prolonged periods 
may become addicted and may need to be 
withdrawn slowly.. 
High No: drug/s not prescribed 
10. Doses of short-acting benzodiazepines: doses 
greater than lorazepam (Ativan), 3mg; oxazepam 
(Serax, 60mg; alprazolam (Xanax), 2mg; 
temazepam (Restoril), 15mg; and triazolam 
(Halcion), 0.25mg 
Because of increased sensitivity to 
benzoadiazepines in elderly patients, smaller 
doses may be effective as well as safer. Total 
daily doses should rarely exceed the suggested 
maximums. 
High Applicable 
11. Long-acting benzodiazepines: 
chlordiazepoxide (Librium), chlordiazepoxide 
-amitriptyline (Limbritol) clidinium-
chlordiazepoxide (Librax), diazepam (Valium), 
quazepam (Doral), halazepam (Paxipam), and 
chlorazepate (Tranxene) 
These drugs have a long half-life in elderly 
patients (often several days), producing 
prolonged sedation and increasing the risk of 
falls and fractures. Short- and intermediate-acting 
benzodiazepines are preferred if a 
benzodiazepine is required 
High Applicable 
12. Disopyramide (Norpace and Norpace CR) Of all antiarrhythmic drugs, this is the most 
potent negative inotrope and therefore may 
induce heart failure in elderly patients. It is also 
strongly anticholinergic. Other antiarrhythmic 
drugs should be used. 
High No: drug/s not prescribed 
13. Digoxin (Lanoxin)(should not exceed 
>0.125mg/d except when treating atrial 
arrhythmias) 
Decreased renal clearance may lead to increased 
risk of toxic effects 
Low Applicable 
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Beers Table I  2002 Criteria for Potentially Inappropriate Medication Use in Older Adults: Independent of Diagnoses or Conditions 
continued. 
 
Drug Concern Severity 
 Rating  
Applicability of indicator in 
this study  
14. Short-acting dipyridamole (Persantine). Do 
not consider the long-acting dipyridamole (which 
has better properties than the short-acting in older 
adults) except with patients with artificial heart 
valves  
May cause orthostatic hypotension Low No: drug/s not prescribed 
15. Methyldopa (Aldomet) and methyldopa-
hydrochlorothiazide (Aldoril) 
May cause bradycardia and exacerbate 
depression in elderly patients 
High No: drug/s not prescribed 
16. Reserpine at doses >0.25mg May induce depression, impotence, sedation, and 
orthostatic hypotension. 
Low No: drug/s not prescribed 
17. Chlorpropamide (Diabinese) It has a prolonged half-life in elderly patients and 
could cause prolonged hypoglycaemia. 
Additionally, it is the only oral hypoglycemic 
agent that causes SIADH. 
High No: drug/s not prescribed 
18. Gastrointestinal antispasmodic drugs: 
dicyclomine (Bentyl), hyoscyamine (KLevsin 
and Levsinex), propantheline (Pro-Banthine), 
belladonna alkaloids (Donnatal and others), and 
clidinium-chlordiazepoxide (Librax) 
GI antispasmodic drugs are highly 
anticholinergic and have uncertain effectiveness. 
These drugs should be avoided (especially for 
long-term use). 
High No: drug/s not prescribed 
19. Anticholinergics and antihistamines: 
chlorpheniramine (Chlor-Trimeton), 
diphenhydramine (Benadryl), hydroxyzine 
(Vistaril and Atarax), cyproheptadine (Periactin), 
promethazine (Phenergan), triplennamine, 
dexchlorpheniramine (Polaramine) 
All non-prescription and many prescription 
antihistamines may have potent anticholinergic 
properties. Nonanticholinergic antihistamines are 
preferred in elderly patients when treating 
allergic reactions 
High No: drug/s not prescribed 
20. Diphenhydramine (Benadryl) May cause confusion and sedation. Should not be 
used as a hypnotic, and when used to treat 
emergency allergic reactions, it should be used in 
the smallest possible dose. 
High No: drug/s not prescribed 
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Beers Table I  2002 Criteria for Potentially Inappropriate Medication Use in Older Adults: Independent of Diagnoses or Conditions 
continued. 
 
Drug Concern Severity 
 Rating (High 
or Low) 
Applicability of indicator in 
this study  
21. Ergot mesyloids (Hydergine) and 
cyclandelate (Cyclospasmol)  
Have not been shown to be effective in the doses 
studied. 
Low No: drug/s not prescribed 
22. Ferrous sulphate >325mg/d Doses >325mg/d do not dramatically increase the 
amount absorbed but greatly increase the 
incidence of constipation. 
Low Applicable 
23. All barbiturates (except phenobarbital) except 
when used to control seizures 
Are highly addictive and cause more adverse 
effects than most sedative or hypnotic drugs in 
elderly patients. 
High No: drug/s not prescribed 
24. Meperidine (Demerol)  Not an effective oral analgesic in doses 
commonly used. May cause confusion and has 
many disadvantages to other narcotic drugs 
High No: drug/s not prescribed 
25. Ticlopidine (Ticlid) Has been shown to be no better than aspirin in 
preventing clotting and may be considerably 
more toxic. Safer, more effective alternatives 
exist. 
High No: drug/s not prescribed 
26. Ketorolac (Toradol) Immediate and long term use should be avoided 
in older persons, since a significant number have 
asymptomatic GI pathologic conditions. 
High No: drug/s not prescribed 
27. Amphetamines and anorexic agents These drugs have potential for causing 
dependence, hypertension, angina, and 
myocardial infarction 
High Applicable 
28. Long-term use of full-dosage, longer half-
life, non-COX-selective NSAIDs: naproxen 
(Naprosyn, Avaprox, and Aleve), oxaprozin 
(Daypro), and piroxicam (Feldene) 
Have the potential to produce GI bleeding, renal 
failure, high blood pressure, and heart failure 
High No: drug/s not prescribed 
29. Daily fluoxetine (Prozac) Long half-life of drug and risk of producing 
excessive CNS stimulation, sleep disturbances, 
and increasing agitation. Safer alternatives exist. 
High Applicable 
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Beers Table I  2002 Criteria for Potentially Inappropriate Medication Use in Older Adults: Independent of Diagnoses or Conditions 
continued. 
 
Drug Concern Severity 
 Rating (High 
or Low) 
Applicability of indicator in 
this study  
30. Long-term use of stimulant laxatives: 
bisacodyl (Dulcolax), cascara sagrada, and 
Neoloid except in the presence of opiate 
analgesic use 
May exacerbate bowel dysfunction High No: drug/s not prescribed 
31. Amiodarone (Cordarone) Associated with QT interval problems and risk of 
provoking torsades de pointes. Lack of efficacy 
in older adults. 
High Applicable 
32. Orphenadrine (Norflex) Causes more sedation and anticholinergic 
adverse effects than safer alternatives 
High No: drug/s not prescribed 
33. Guanethidine (Ismelin) May cause orthostatic hypotension. Safer 
alternatives exist. 
High No: drug/s not prescribed 
34. Guanadrel (Hylorel) May cause orthostatic hypotension. High No: drug/s not prescribed 
35. Cyclandelate (Cyclosdpasmol) Lack of efficacy Low No: drug/s not prescribed 
36. Isoxsurpine (Vasodilan) Lack of efficacy. Low No: drug/s not prescribed 
37. Nitrofurantoin (Macrodantin) Potential for renal impairment. Safer alternatives 
available. 
High No: drug/s not prescribed 
38. oxazosin (Cardura) Potential for hypotension, dry mouth, and urinary 
problems. 
Low No: drug/s not prescribed 
39. Methyltestosterone (Android, Virilon, and 
Testrad) 
Potential for prostatic hypertrophy and cardiac 
problems. 
High No: drug/s not prescribed 
40. Thioriadzine (Mellaril) Greater potential for CNS and extrapyramidal 
adverse effects 
High No: drug/s not prescribed 
41. Mesoriazine (Serentil) CNS and extrapyramidal adverse effects. High No: drug/s not prescribed 
42. Short acting nifedipine (Procardia and 
Adalat) 
Potential for hypotension and constipation. High Applicable 
43. Clonidine (Catapres) Potential for orthostatic hypotension and CNS 
adverse effects. 
Low No: drug/s not prescribed 
44. Mineral oil Potential for aspiration and adverse effects. Safer 
alternatives available 
High Applicable 
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Beers Table I  2002 Criteria for Potentially Inappropriate Medication Use in Older Adults: Independent of Diagnoses or Conditions 
continued. 
 
Drug Concern Severity 
 Rating (High 
or Low) 
Applicability of indicator in 
this study  
45. Cimetidine (Tagamet) CNS adverse effects including confusion Low No: drug/s not prescribed 
46. Ethacrynic acid (Edecrin) Potential for hypertension and fluid imbalances. 
Safer alternatives available 
Low No: drug/s not prescribed 
47. Desiccated thyroid Concerns about cardiac effects. Safer alternatives 
available 
High No: drug/s not prescribed 
48. Amphetamines (excluding methylphenidate 
hydrochloride and anorexics) 
CNS stimulant adverse effects High No: drug/s not prescribed 
49. Estrogens only (oral) Evidence of carcinogenic (breast and endometrial 
cancer) potential of these agents and lack of 
cardioprotective effect in older women. 
Low Applicable 
Abbreviations: CNS, central nervous system; COX, cyclooxygenase; GI, gastrointestinal; NSAIDs, nonsteroidal anti-inflammatory drugs; SIADH, syndrome of inappropriate 
antidiuretic hormone secretion 
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Beers Table 2  2002 Criteria for Potentially Inappropriate Medication Use in Older Adults: Considering Diagnoses or Conditions. (continuous 
numbering from Table 1) 
 
Disease or Condition Drug Concern Severity 
Rating (High 
or Low) 
Applicability of 
indicator in this study 
50. Heart Failure Disopyramide (Norpace, and high sodium 
content drugs (sodium and sodium salts 
[alginate, bicarbonate, biphosphate, citrate, 
phosphate, salicylate, and sulphate]) 
Negative inotropic effect. 
Potential to promote fluid 
retention and exacerbation of 
heart failure. 
High Applicable 
51. Hypertension Phenylpropanolamine hydrochloride (removed 
from the market in 2001), pseudoephedrine; 
diet pills, and amphetamines 
May produce elevation of 
blood pressure secondary to 
sympathomimetic activity. 
High Applicable 
52. Gastric or duodenal 
ulcers 
NSAIDs and aspirin (>325mg) (coxibs 
excluded) 
May exacerbate existing 
ulcers or produce 
new/additional ulcers 
High No: diagnoses/drugs not 
recorded  
 
53. Seizures or epilepsy Clozapine (Clozaril), chlorpromazine 
(Thorazine), thioridazine (Mellaril), and 
thiothixene (Navane) 
May lower seizure thresholds. High Applicable 
54. Blood clotting disorders 
or  
 
55. receiving anticoagulant 
therapy 
Aspirin, NSAIDs, dipyridamole (Persantin), 
ticlopidine (Ticlid), and clopidogrel (Plavix) 
May prolong clotting time 
and elevate INR values or 
inhibit platelet aggregation, 
resulting in an increased 
potential for bleeding 
High No: diagnoses/drugs not 
recorded  
 
Applicable 
56. Bladder outflow 
obstruction 
Anticholinergics and antihistamines, 
gastrointestinal antispasmodics, muscle 
relaxants, oxybutynin (Ditropan), flavoxate 
(Urispas), anticholinergics, antidepressants, 
decongestants, and tolterodine (Detrol) 
May decrease urinary flow, 
leading to urinary retention. 
High Applicable 
57. Stress incontinence α-Blockers (Doxazosin, Prazosin, and 
Terazosin), anticholinergics, tricyclic 
antidepressants (imipramine hydrochloride, 
oxepin hydrochloride and amitriptyline 
hydrochloride), and long-acting 
benzodiazepines 
May produce polyuria and 
worsening of incontinence 
High No: diagnoses/drugs not 
recorded 
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Beers Table 2  2002 Criteria for Potentially Inappropriate Medication Use in Older Adults: Considering Diagnoses or Conditions continued.  
 
Disease or Condition Drug Concern Severity 
Rating (High 
or Low) 
Applicability of 
indicator in this study 
58. Arrhythmias  Tricyclic antidepressants (imipramine 
hydrochloride, Doxepin hydrochloride, and 
amitriptyline hydrochloride) 
Concern due to proarrhythmic 
effects and ability to produce 
QT interval changes 
High Applicable 
59. Insomnia Decongestant, theophylline (Theodur), 
methylphenidate (Ritalin), MAOIs, and 
amphetamines 
Concern dur to CNS 
stimulant effects 
High Applicable 
60. Parkinson disease Metoclopramide (Reglan), conventional 
antipsychotics, and tacrine (Cognex) 
Concern due to their 
antidopaminergic/ cholinergic 
effects. 
High Applicable 
61. Cognitive impairment  Barbitutrates, anticholinergics, antispasmodics, 
and muscle relaxants. CNS stimulants: 
dextroAmphetamine (Adderall), 
methylphenidate (Ritalin), methamphetamine 
(Desoxyn), and pemolin 
Concern due to CNS-altering 
effects 
High No: diagnoses/drugs not 
recorded  
 
62. Depression Long-term benzodiazepine use. Sympatholytic 
agents: methyldopa (Aldomet), reserpine, and 
guanethidine (Ismelin) 
May produce or exacerbate 
depression 
High Applicable 
63. Anorexia and 
malnutrition 
CNS stimulants: DextroAmphetamine 
(Adderall), methylphenidate (Ritalin), 
methamphetamine (Desoxyn), pemolin, and 
fluoxetine (Prozac)   
Concern due to appetite-
suppressing effects. 
High No: diagnoses/drugs not 
recorded 
64. Syncope or falls Short- to intermediate-acting benzodiazepine 
and tricyclic antidepressants (imipramine 
hydrochloride, Doxepin hydrochloride, and 
amitriptyline hydrochloride) 
May produce ataxia, impaired 
psychomotor function, 
syncope and additional falls. 
High Applicable 
65. SIADH/hyponatremia SSRIs: fluoxetine (Prozac), citalopram 
(Celexa), fluvoxamine (Luvox), paroxetine 
(Paxil), and sertraline (Zoloft) 
May exacerbate or cause 
SIADH. 
Low Applicable 
66. Seizure disorder Bupropion (Wellbutrin) May lower seizure threshold High Applicable 
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Beers Table 2  2002 Criteria for Potentially Inappropriate Medication Use in Older Adults: Considering Diagnoses or Conditions continued. 
 
Disease or Condition Drug Concern Severity 
Rating (High 
or Low) 
Applicability of 
indicator in this study 
67. Obesity Olanzapine (Zyprexa) May stimulate appetite and 
increase weight gain 
Low Applicable 
68. COPD Long-acting benzodiazepines: chlordiazepoxide 
(Librium) chlordiazepoxide-amitriptyline 
(Limbritol), clidinium-chlordiazepoxide 
(Librax), diazepam (Valium), quazepam 
(Doral), halazepam (Paxipam), and 
chlorazepate (Tranxene). ß-blockers: 
propanolol 
CNS adverse effects. May 
induce respiratory depression. 
May exacerbate or cause 
respiratory depression 
High Applicable 
69. Chronic constipation Calcium channel blockers, anticholinergics, and 
tricyclic antidepressant (imipramine 
hydrochloride, Doxepin hydrochloride, and 
amitriptyline hydrochloride) 
May exacerbate constipation Low Applicable 
Abbreviations: CNS, central nervous systems; COPD, chronic obstructive pulmonary disease; INR, international normalized ratio; MAOIs, monamine oxidase inhibitors; 
NSAIDs, nonsteroidal anti-inflammatory drugs; SIADH, syndrome of inappropriate antidiuretic hormone secretion; SSRIs, selective serotonin reuptake inhibitor
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Figure 6.1. Chapter 6.0 Flowchart 
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CHAPTER 6.0  QUALITY OF PRESCRIBING 
 
6.1 CHAPTER SUMMARY 
In this chapter discontinuity in appropriate prescribing, identified in Chapter 5, was again 
examined to determine its affect on the continuity of patient care during the period 
immediately post discharge from acute care hospitalisation.  A Home Medicines Review 
(HMR) Report group of patients (n=79) from the Continuity of Care Project (CofCP) 
(n=281), was identified as being exposed to potentially inappropriate prescribing (PIP) at 
discharge and at HMR.  The HMR Report group’s exposure was previously identified by 
application of the Beers criteria, and is further investigated in this chapter, using indicators 
custom-designed for use in an Australian healthcare environment.  The alternate method of 
identification was applied and the subgroups’ results on patterns, sources, extent, and 
patient impact of PIP, were analysed. 
 
 In this chapter study, analyses of PIP ‘at discharge’ were conducted on lists of 
drugs and diseases in hospital discharge summaries.  Analyses of PIP ‘at HMR’ service 
were conducted on lists of drugs and diseases in HMR reports written by accredited 
pharmacists.  The comments and recommendations made by the pharmacists in HMR 
reports were not taken into account. 
 
6.2  INTRODUCTION 
Medication safety and medication problems in acute care are the subjects of several 
published reports for the Australian Commission on Safety and Quality in Health Care 
(2009).1-2  In these reports, methods of developing or sustaining medication safety and 
information transfer were examined, especially during the patient’s transition between 
acute care hospital and the community.3  In 2001, introduction of the HMR service to the 
Australian healthcare system was instigated by the Commonwealth Government to be 
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organised through community pharmacies after referral by the patient’s nominated general 
practitioner (GP).4,5-6  This service, which included pharmacists’ HMR reports to the 
referring GP with the aim of resolving any drug related problems, targeted ‘at risk’ patients 
of all ages transferred to their homes.   
 
At risk patients included those with three or more medical conditions, heart failure, 
polypharmacy and patients with significant changes to their prescribed drug regimen.7-8  
To research and address widespread concerns on patient medication misadventure post 
hospital discharge, the Westmead Medicines Project (WMP) was implemented at 
Westmead Hospital, a large teaching hospital of The University of Sydney, from mid 
2004-2005.9  At the completion of the WMP (n=176 patients), a further 105 additional 
patients were recruited to form the cohort for the Continuity of Care Project (CofCP) 
(n=281) between 2005-2007.  
 
During the recruitment of the 281 patients from the cardiology Unit of Westmead 
Hospital, the discharge process included utilising existing, partially computerised 
discharge summaries.  Throughout the CofCP the recruited patients did not receive a 
written copy, for their own use, of their prescribed discharge drugs nor was there an 
apparent ward mechanism for education of patients about their medicines on discharge.9-11  
 
Hospital discharge summaries were the GPs’ primary, patient focused 
communication link with the hospital after discharge.  Hence, the provision of 
comprehensive and accurate information was of the utmost importance for the patients’ 
transfer into primary care and for subsequent, ongoing healthcare services such as HMR.12-
14  
 
Ellitt et al. (2010) identified the drug related problems (DRPs) experienced by the 
HMR Report group from their available HMR reports.10 These reports revealed the most 
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frequent drug related problem was the patients’ uncertainty about the aim of their 
prescribed drugs.4-10  The complexity of the subgroup’s multiple diagnoses, co-morbidities 
and associated pharmacotherapy was also shown.  In addition, it was found that an 
unacceptable level of polypharmacy resulted from the polymorbidity which characterised 
the HMR Report group.15  
In Chapter 5, discontinuity in patient medication safety at both discharge and at 
HMR was revealed by Beers explicit criteria when applied to HMR Report group data.  
The criteria identified a severely high risk of potentially inappropriate prescribing (PIP) at 
both points in time.16  Published shortcomings in the design of the Beers criteria, when 
applied to international healthcare systems, were found to constrain application of the 
criteria to the Australian healthcare system.17  In particular, this applied to the study group 
of cardiovascular patients in the CofCP who were subject to different, local prescribing 
practices.18-19 
 
In this Chapter 6 study the quality of prescribing, for the HMR Report group of 
acute care cardiovascular patients, was re-examined using prescribing indicators developed 
specifically for use in Australia.  The results were to augment the outcomes from 
application of the Beers criteria in the previous chapter.  Any affect on the subgroups’ 
continuity of care was determined by investigation of the extent and source (where and 
when) of any PIP identified during the patients’ transfer from hospital into the 
community.20-21 
 
6.3  STUDY AIM 
To investigate differences in the quality of prescribing between acute care hospital  
discharge and HMR service in primary healthcare.
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6.3.1 NULL HYPOTHESES 
To achieve the study aim for a cohort of patients (n=79) for whom an HMR report was 
available as shown in Figure 6.1, the following null hypotheses were proposed.  
 
There is no statistically significant difference between discharge and HMR in: 
1. the distribution of patients’ drugs and diseases.   
2. the distribution of prescribing appropriateness for patients  
3. the distribution of potentially inappropriately prescribed (PIP) drugs or drug 
related situations. 
4. the distribution of patients at risk of PIP. 
5. the distribution of indicators identifying appropriate and potentially 
inappropriate prescribing.  
 
6.4  OPERATIONAL DEFINITIONS 
6.4.1 CONTINUITY OF CARE is a perception of quality health care resulting from the 
ongoing management of issues which cause disruption to optimal patient care. 
In the context of the study reported in this chapter: 
Continuity of Care is perceived by the researchers as the quality use of medicines for 
ongoing management of optimal pharmacotherapy through identification of appropriate 
prescribing by customised Australian indicators.22 
 
6.4.2 POTENTIALLY INAPPROPRIATE PRESCRIBING 
In this study, the terms ‘potentially inappropriate medication’, ‘potentially inappropriate 
prescribing’ (PIP) and their derivatives, have been adopted as equivalent concepts.  
Prudent et al. (2008) define ‘potentially inappropriate medication’ as drugs with an 
unfavourable risk/benefit ratio when safer or equally effective alternatives are 
available.23 
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6.5  METHOD 
6.5.1  STUDY DESIGN 
This study involved a retrospective analysis of prescribing quality on discharge from 
hospital and during medication review in the community, in Australia.  Drug regimens on 
patients’ discharge summaries and post discharge on HMR reports, were examined to 
identify any PIP at two points in time.24  Provision of HMR reports, for the patients’ GPs, 
to the researchers was the end point of data collection for this study.  The quality of 
prescribing was determined by the application of Basger indicators which were specifically 
designed for use in the Australian healthcare environment.25    
 
6.5.2  SUBJECTS AND DATA SOURCES 
All subjects were recruited into the CofCP (n=281) as patients under the care of a 
cardiovascular team and were discharged from the Cardiology Unit of Westmead Hospital 
to their homes, between mid 2004 and 2007.  Patients whose median age was 69 (IQR 18: 
58-76) years, met the suggested Australian Commonwealth Government’s eligibility 
criteria for HMR referral by a GP.  In addition, the patients were discharged on at least one 
cardiovascular drug.4  All research consent forms and protocols were accepted by the 
Ethics Committees of the University of Sydney, Western Sydney Area Health Service, 
Australian Health Insurance Commission and Australian Government Veteran’s Affairs 
Board.9 
 
The receipt of an HMR report was confirmation that an HMR service had been 
conducted and the report provided data for analysis of drugs currently consumed by the 
patient post discharge.  The HMR services were conducted in the patients’ homes after 
consultation and referral by their GPs.  Accredited pharmacists copied 79/87 HMR reports 
to the research team at Westmead Hospital (Figure 6.1).5-6  The clinical status, diagnoses 
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and drug regimen of the HMR Report group were examined in detail, at two points in time, 
for identification of PIP.  
 
Data sources included the patients’ hospital medical records, discharge summaries 
and HMR reports.  The attending medical teams at Westmead Hospital generated the 
hospital discharge summaries.  The patients then hand delivered these to their community 
GP at an arranged follow up consultation a few days post separation from the hospital.  
This method of information transfer has been demonstrated to be most reliable and only 
one nominated GP (from 281 patient contacts) requested a repeat copy by facsimile.9   
 
During patient recruitment, short stay or ‘day only’ patients did not routinely 
receive a discharge summary therefore a list of the patients’ drugs  at discharge was 
recorded in lieu of the summary.  All nominated GPs and pharmacies received copies of 
their patient’s discharge summary or medication list and full information regarding the 
research.  General practitioners were requested, and encouraged, to consider referring their 
patients to their nominated pharmacy for an HMR service. 
 
Discharge summaries and HMR reports were analysed for drugs, diseases and 
prescribing patterns at discharge and at HMR service.  Medical records were analysed for 
demographics and Quality of Life (QOL) surveys were analysed for 9 QOL components 
(Appendix 10.0).  The surveys were conducted within 2 weeks of discharge and 6 months 
post discharge.  In this study, the subgroup of patients for whom an HMR report was 
received by the research team, are reported as the HMR Report group (n=79) (Fig. 6.1). 
 
6.5.3 PRESCRIBING INDICATORS 
The tool for identification of appropriate prescribing was chosen for its recent development 
and applicability in the Australian health care system.26-27  Basger et al. (2008) developed a 
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set of indicators after considering the limitations of many other recently developed, or 
updated systems for the international health care environment in which they were 
developed.16,25,28  Furthermore, the Basger indicators appeared to address the shortcomings 
of the explicit Beers criteria which were designed in the USA for international application 
to the prescribed drugs and diseases of patients ≥65 years of age.16,29  
 
Although well validated and extensively applied internationally, the Beers criteria  
utilized in Chapter 5 excluded considerations of polypharmacy, patient characteristics, 
local prescribing practices and the availability of drugs in other countries.17,19,30 These 
exclusions influenced the outcomes of the Chapter 5 study which applied internationally 
developed criteria for the identification of PIP in Australia. 
 
The Basger indicators were developed from sources which showed the ‘most 
common reasons that elderly Australians seek or receive healthcare’ and these reasons 
were cross referenced with the ’50 highest-volume Australian Pharmaceutical Benefits 
Scheme (PBS) medications prescribed in Australia.31-32  Although the Basger indicators 
were not published until 2009, data collection from the Australian healthcare system took 
place in 2006 and is highly relevant to this study.  Along side use as a guide for optimum 
prescribing, Basger et al. proposed that the indicators were suitable for use as an adjunct to 
medication review services such HMR, medical and surgical patients transferring across 
care boundaries, quality assessment and in research.25  
 
Basger et al. describe the developed indicators as predominantly explicit.  
However, when the majority of Basger indicators are applied to a patient’s drug regimen 
because of the inclusion of a specific drug, a deduction on the appropriateness of 
prescribing is still required.25  Conversely, the application of Beers explicit criteria to a 
patient’s drug regimen, immediately labels any of the Beers listed drugs as potentially 
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inappropriate.  The 48 Basger indicators and foot notes are attached in Appendix 6.1, at the 
end of this chapter. 
 
6.5.3.1  Application of the Basger Indicators 
Basger indicators test the appropriateness of prescribing of drugs whilst taking into account 
the disease indicators for the drugs, co-morbidities and patient characteristics e.g. pain and 
activities of daily living.  Purpose designed databases were constructed in SPSS - Statistics 
Version 17 and Microsoft Excel 2007 programmes for all drugs prescribed.  Similar 
databases were constructed for diseases and co-morbidities recorded for the HMR Report 
group at discharge and after GP consultation at HMR service.   
 
Alphabetical and numerical listings of the drugs and diseases, and their codes, were  
recorded for the study group.   Separate SPSS databases recorded the demographics and 
quality of life (QOL) responses required for Basger indicator application.  Additional 
databases were constructed to record patient responses to the 48 Basger indicators at 
discharge and at HMR. 
 
For this study, indicators were considered applicable to the study group if at least 
one patient was prescribed the primary drugs and/or disease state and/or situation in 
question.   Further, it was necessary that all secondary information required for an indicator 
was common to all subjects e.g. QOL responses.  That is, indicators were applied to the 
study group if ≥1 patient was shown to meet the requirements of an indicator.   
 
In the patient response databases, dichotomous (yes, no) responses to each 
component of the criterion were recorded in rows with applicable Basger indicators in 
columns.  To respond to each component of the criteria, it was necessary to repeatedly scan 
the drugs and diseases databases to capture all entries within the category being assessed 
e.g. anticoagulant drug category: warfarin, heparin, low dose aspirin; or cardiovascular 
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disease category: e.g. hypertension, atrial fibrillation, coronary artery disease.  Depending 
on the response to each of the components of the indicator, the indicator was scored as 
satisfied or not satisfied for each patient assessed. 
 
Identification of PIP by Basger indicators ‘at discharge’ was conducted on lists of 
drugs or diseases in discharge summaries.  Identification of PIP by Basger indicators ‘at 
HMR’ service was conducted on lists of drugs or diseases in HMR reports written by 
accredited pharmacists.  The pharmacists’ comments and recommendations in the report, 
were not taken into account.   
 
The provision of the HMR reports, to the researchers by the accredited pharmacists, 
was the end point of data collection for this thesis. 
 
6.5.4 QUALITY OF LIFE CHARTS 
In addition to the primary requirement of the indicator, some indicators required secondary 
data on quality of life (QOL) scores for pain during activities of daily living (ADLs).33-34 
 
For this study, QOL scores for pain level and ADLs were derived from the results 
of a Dartmouth Co-operative (COOP) QOL survey conducted on the CofCP cohort 
(n=281) and reported in Chapter 3 (Appendix 10.0).33-34  Patient reported QOL surveys 
were distributed from, and returned by mail to the researcher.9  Scores for pain level and 
performance of ADLs for the HMR Report group (n=79) were taken from the QOL survey 
collected within two weeks of discharge and then again, 6 months after discharge.  The 
scores for each of the 9 charts in the survey ranged from 1 to 5, with a score of 1 indicating 
no pain or no difficulty managing ADLs.  A score >2 for both these charts informed 
responses to components of Basger indicators at both discharge and HMR for the 
following indicators. 
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No. 21 Patient with osteoarthritis pain interfering with daily activities has been  
   trialled on paracetamol (acetaminophen) 2-4g/day. 
 
 No. 22 Patient taking analgesic(s) does not have pain (j*) that interferes with daily 
  activities.   j* Pain: back complaint, osteo-arthritis, cancer, rheumatoid  
 arthritis.   (Appendix 6.1) 
 
6.5.5.  DATA ANALYSES 
For data analyses and outcome interpretation, three units of analysis were targeted: 
1) the appropriateness of prescribing to which the patients were exposed  
2) the number of patients exposed to potentially inappropriate prescribing (PIP) by 
specific indicators  
3) the number of indicators applied to the study group.   
 
Data from the HMR Report group’s discharge summaries and HMR reports were 
recorded for the analyses of drugs and diseases at discharge and HMR.  Drugs and diseases 
were recorded and coded according to the Anatomical Therapeutic Chemical (ATC) 
classification and International Classification of Disease version 10 (ICD-10), 
respectively.35-36   After coding, the data were analysed to determine whether or not the 
patient was prescribed drugs which did or did not satisfy Basger indicators and this 
signified whether a patient was or was not at risk of PIP.  Basger indicators were expressed 
in an affirmative [xaf] or negative [xne] format or a combinationc of the two.25  For example: 
 
 Indicator No. 5af  Patient with heart failure is taking a β-blocker.  
 Indicator No. 7ne Patient with heart failure is not taking medications that may 
exacerbate heart failure (d*).  
  
(d* Medications that may exacerbate heart failure: antiarrhymthmic drugs (except 
digoxin or amiodarone), carbamazepine, diltiazem, nifedipine, verapamil, NSAIDs 
(excluding low-dose aspirin), sotalol, thiazolidinediones (significant disease), 
tricyclic antidepressants, corticosteroids (oral or inhaled)). 
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Indicator No. 16c Patient with diabetes at high risk of a cardiovascular event (b*) 
is taking an antiplatelet agent unless taking an anticoagulant (c*).  
   
(b*Patients at high risk of a cardiovascular event: Age >75 years,  symptomatic 
cardiovascular disease (angina, myocardial infarction, previous coronary 
revascularization procedure, heart failure, stroke, transient ischaemic attack (TIA), 
peripheral vascular disease) genetic lipid disorder, diabetes and evidence of renal 
disease (micoralbuminuria and/or proteinuria and/or glomerular filtration rate 
<60ml/min)).  (c*Antiplatelet agents: aspirin, clopidogrel. Anticoagulants: 
phenindione, warfarin. Non-haemorrhagic stroke or TIA: aspirin/dipyridamole, 
dipyridamole, ticlopidine) (Appendix 6.1) 
 
            It was outside the realm of this study to directly measure the clinical impact on the 
patients of any identified PIP.  Hence, an effect size approximation was conducted using an 
eta squared estimation.  This calculation was based on the ‘t’ value of students’ t-tests (t 
tests) conducted to assess the null hypothesis of no differences in the distribution of 
prescribing appropriateness between discharge and HMR.  Eta squared estimations 
(tsq/tsq+(N-1)) for effect size were based on Cohen’s values of 0.01~small effect; 
0.06~moderate effect and 0.140~large effect.37-39   
 
           In addition, the percentage difference in severity ratings allocated to patients was 
estimated if the difference was shown to be statistically significant.  All outcomes between 
discharge and HMR were included to describe the proposed impact of that difference in 
PIP on the patients.  
 
The distribution of the prescribing indicators was also analysed to assess how many 
indicators were applied to the study group between discharge and HMR.  In turn, analysis 
of the applied indicators provided an insight into the continuity and appropriateness of 
patients’ pharmacotherapy at discharge and its continuance through follow-up in the 
community.40-41 
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Data were quantitatively analysed at discharge and at HMR.  Tests were conducted 
at an alpha level of 0.05 and included multiple response frequencies; t tests; chi squared 
tests; and eta squared estimations of effect size. 
 
6.6  RESULTS 
 
6.6.1 DRUGS AND DISEASES 
Table 6.1 shows the numbers of drugs and diseases analysed for the HMR Report group 
(n=79) at discharge and at HMR.  It was found that reconciliation and analysis of both 
drugs and diseases showed polypharmacy and polymorbidity were problematic clinical 
characteristics for the study group.  Table 6.1 shows the paired samples t testing of the 
number and distribution of drugs and diseases and testing of the null hypothesis of no 
difference between discharge and HMR.  After discharge, there was a significant increase 
in the number of drugs documented after GP consultation, at HMR (p=0.001) and a 
significant decrease in number of diseases documented at HMR (p=0.001). 
 
6.6.2  APPLICABILITY OF BASGER INDICATORS 
There were 48 Basger indicators initially applied to the drugs and diseases of the HMR 
Report group (n=79) to determine which criteria were applicable to ≥1 patient in the 
subgroup at any time.  Of the 48 Basger indicators published, 32 were found to be 
applicable to the subgroup and the reasons for the non-applicability of 16 indicators appear 
in Appendix 6.1.   
 
6.6.3 ALLOCATION OF PRESCRIBING APPROPRIATENESS 
It was found that application of the Basger indicators required yes/no scoring on each of 
the components of the indicator and a final score on whether or not the components met the 
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overall indicator requirements.  During analysis, it was necessary to repeatedly assess each 
patient’s drugs and disease states to confirm whether or not affirmative or negative 
components of the indicator were met.  As an example:  
 
 
 
Indicator No. 14  Patient with cardiovascular [yes1 or no1], or respiratory disease 
[yes2 or no2] or diabetes mellitus [yes3 or no3] who smokes [yes4] has been offered 
smoking cessation therapy [yes5] (g*).    
 
(g* Smoking cessation therapy: counselling, use of support services, medication; 
for patients smoking >10 cigarettes per day, bupropion, nicotine replacement 
therapy, varenicline (Appendix 6.1). 
 
 
 
 
6.6.4  POTENTIALLY INAPPROPRIATE PRESCRIBING (PIP) INSTANCES 
 
 
Table 6.2 shows the paired sample t testing of HMR Report group assessment for 
identification of appropriate and PIP instances and testing of the null hypothesis of no 
difference between discharge and at HMR service.  After discharge there was a significant 
difference in appropriate prescribing with a decrease of 11.3% at HMR (p=0.009) and a 
concurrent, significant increase of 29.0% in PIP at HMR (p=0.001).  No  significant  
difference   was   found   between   the   two   points    time,   in   the   total   number   of  
assessments  for  each patient  (p=0.173). 
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Table 6.1  Distribution of drugs and diseases recorded for the HMR Report group at discharge and HMR. 
Group 
Characteristic 
DISCHARGE   HMR    
 
Significance 
 
 Total number 
 
Mean (SD±) Range Total number Mean (SD±) Range t value p value 
Drugs 658 8.3 (3.0) 2 - 19 805 10.2 (4.9) 0 - 23 -4.09 0.001 
Diseases 411 5.2 (2.8) 1 - 14 286 3.6 (2.9) 0 - 12  3.34 0.001 
(t-test: N=79, df=78) 
 
 
 
Table 6.2  Distribution of instances of prescribing appropriateness identified by Basger indicators for HMR Report group at  
discharge and HMR.25 
 
Patients (n=79) DISCHARGE HMR  Significance 
 
 Total 
number 
Mean (S.D±) 
per patient 
Range Total 
number  
Mean (S.D±) 
per patient 
Range t value p value 
Appropriate prescribing 
instances identified 
450 5.7 ( 2.2) 2 - 12 399 5.1 ( 2.2) 1 - 12 2.69 0.009 
Potentially inappropriate 
prescribing identified  
255 3.2 ( 1.4) 1 -  8 329 4.2 ( 2.0) 1 - 10 -4.63 0.001 
Assessments 
 
705 8.8 ( 2.8) 3 - 16 728 9.2 ( 3.3) 3 - 17 -1.37 0.173 
(t-test: N=79, df=78) 
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6.6.4.1  Estimated Impact of Potentially Inappropriate Prescribing (PIP) 
The adverse clinical effects on patients of a significant decrease in appropriate 
prescribing and significant increase in PIP were estimated using eta squared (Tsq/tsq + 
[N-1]).  As shown in Table 6.2, the t test of appropriate prescribing at discharge and 
HMR showed a significant decrease at HMR (t(78)=2.69; p=0.009).  The eta squared 
estimation (0.085) indicated a moderate effect size.   
 
From Table 6.2, the t test of PIP at discharge and at HMR service showed a 
significant increase at HMR (t(78)=-4.63; p=0.001).  The eta squared estimation (0.216) 
indicated a large effect size on the patients.  That is, from Table 6.2, the t testing of 
appropriate prescribing showed a significant decrease at HMR of 11.3% and a 
concurrent significant increase in PIP at HMR of 31.6%.  
 
6.6.5  IDENTIFICATION OF POTENTIALLY INAPPROPRIATE PRESCRIBING (PIP) 
Table 6.3 shows the distribution of instances of PIP identified by the Basger indicators 
for the HMR Report group, and its relationship to the number of routine drugs 
prescribed between discharge and HMR.   
 
Table 6.3 shows paired samples t testing of the null hypothesis of no difference 
in the number of instances of PIP identified for the HMR Report group.  The mean and 
(SD±) instances per patient were identified at discharge as 3.1 (±1.4) instances and at 
HMR as 5.1 (±2.2) instances with a significant increase in PIP at HMR (p=0.009). 
 
 The instances of PIP or potentially inappropriate drug related situations relevant 
to the number of routine drugs prescribed for the group were recorded at discharge as 
250 (38.2%) and at HMR as 399 (49.6%).  It should be noted that the satisfaction/non-
 Chapter 6 Quality of Prescribing                                                                     Page 175 
 
satisfaction of Basger indicators did not rely solely on explicit identification of specific 
drugs.  Hence, unlike outcomes from the application of Beers criteria, these results are a 
ratio  of  number  of potentially  inappropriate  prescribing  instances  (e.g. Indicator  
No. 48)  to  the number of routine drugs prescribed.  
 
 
 
6.6.6  SOURCE AND DISTRIBUTION OF INAPPROPRIATE PRESCRIBING BY  
 
SPECIFIC INDICATORS 
 
The results in Table 6.4a-e indicate marked differences in the number and relative 
frequency of patients, identified by separate indicators, at risk of PIP at discharge and at 
HMR.  The relative frequency tabled, represented the proportion of patients identified as 
at risk in relation to those assessed by a specific indicator.  The relative frequency 
analysed across the 32 indicators showed means (SD±) at discharge of 0.3 (±0.1) 
patients and at HMR of 0.4 (±0.1) patients.  This is approximately 1 in 3 patients at 
discharge and 1 in 2 patients at HMR.  The increase in patients at risk at HMR is 
consistent with the significant increase in instances of PIP at HMR, shown in Tables 6.2 
and 6.3. 
.
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Table 6.3 Distribution of PIP situations identified by Basger indicators at discharge and HMR for the HMR Report group (n=79).25 
 
PIP situations  DISCHARGE: n = 658 prescriptions 
 
HMR: n = 805 prescriptions  Significance 
 Total 
Number 
Mean (SD±) 
per patient 
Ratio PIP to 
discharge drugs* 
Total 
Number 
Mean (SD±) 
per patient 
Ratio PIP to 
HMR drugs* 
 
t value 
 
p value 
 
Potentially 
inappropriate 
prescribing 
instances  
 
 
250 
 
3.1 (1.4) 
 
38.2% 
 
399 
 
5.0 ( 2.2) 
 
49.6% 
 
2.69 
 
0.009 
(t test: N=79, df=78)  *% PIP frequency relative to total number drugs prescribed. 
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Table 6.4a Distribution of HMR Report group patients identified as at risk of PIP by Basger indicators at discharge and HMR.25 
 
Basger Indicators applied to HMR 
Report Group (n=79) 
DISCHARGE 
 
HMR 
 
 
Patients Assessed 
(% relative 
frequency)a 
Patients at risk 
(% relative 
frequency)b 
Patients Assessed 
(% relative 
frequency)a 
Patients at risk 
(% relative 
frequency)b 
2. Patient at high risk of a cardiovascular 
event  (b) is taking an HMG-CoA reductase 
inhibitor (statin) 
76 ( 96.2) 22 ( 28.9) 78 ( 98.7) 25 ( 32.1) 
3. Patient with IHD or a history of MI is 
taking a ß-blocker (ß-adrenoceptor 
antagonist) 
32 ( 40.5) 16 ( 50.0) 36 ( 45.6) 12 ( 33.3) 
4. Patient with IHD or a history of MI is 
taking an antiplatelet agent unless taking an 
oral anticoagulant (c) 
31 ( 39.2) 16 ( 51.6) 37 ( 46.8) 35 ( 94.6) 
5. Patient with heart failure is taking a ß-
blocker  
11 ( 13.9) 8 ( 72.7) 10 ( 12.7) 4 ( 40.0) 
6. Patient with heart failure is taking an ACE 
inhibitor or ARB  
11 ( 13.9) 7 (63.6) 10 ( 12.7) 5 ( 50.0) 
7. Patient with heart failure is not taking 
medications that may exacerbate heart failure 
(d) 
11 ( 13.9) 2 ( 18.2) 10 ( 12.7) 3 ( 30.0) 
8. Patient with heart failure or hypertension is 
not taking high sodium-containing 
medications (e) 
29 ( 36.7) 0 45 ( 57.0) 0 
9. Patient with AF is taking an oral 
anticoagulant 
20 ( 25.3) 4 ( 20.0) 12 ( 15.2) 5 ( 41.7) 
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Table 6.4b Distribution of HMR Report group patients identified as at risk of PIP by Basger indicators at discharge and HMR, continued25 
 
Basger Indicators applied to HMR 
Report Group (n=79) 
DISCHARGE 
 
HMR 
 
 
Patients Assessed 
(% relative 
frequency)a 
Patients at risk 
(% relative 
frequency)b 
Patients Assessed 
(% relative 
frequency)a 
Patients at risk 
(% relative 
frequency)b 
11. Patient with a history of non-
haemorrhagic stroke or TIA is taking an 
antiplatelet agent unless taking an 
anticoagulant (c)  
1 (  1.3) 1 (100.0) 4 (  5.1) 3 ( 75.0) 
12. Patient with risk factors for myopathy (f) 
is not taking ≥ 40mg/day of simvastatin or 
atorvastatin  
48 ( 60.8) 0 35 ( 44.3) 2 (  5.7) 
13. Patient with cardiovascular disease is not 
taking an NSAID 
73 ( 92.4) 6 (  8.2) 68 ( 86.1) 8 ( 11.8) 
16. Patient with diabetes at high risk of a 
cardiovascular event (b) is taking an 
antiplatelet agent unless taking an 
anticoagulant (c) 
18 ( 22.8) 10 ( 55.6) 22 ( 27.8) 10 ( 45.5) 
17. Patient with diabetes is not taking a 
medication that may increase or decrease 
blood glucose concentrations (h) 
16 ( 20.3) 0 22 ( 27.8) 4 (18.9) 
20. Patient taking metformin for diabetes is 
not concurrently taking glibenclamide 
6 (  7.6) 0 21 ( 26.6) 0 
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Table 6.4c Distribution of HMR Report group patients identified as at risk of PIP by Basger indicators at discharge and HMR, continued25 
 
Basger Indicators applied to HMR 
Report Group (n=79) 
DISCHARGE 
 
HMR 
 
 
Patients Assessed 
(% relative 
frequency)a 
Patients at risk 
(% relative 
frequency)b 
Patients Assessed 
(% relative 
frequency)a 
Patients at risk 
(% relative 
frequency)b 
21. Patient with OA pain interfering with 
daily activities has been trialled on 
paracetamol (acetaminophen) 2-4 g/day 
6 (  7.6) 1 ( 16.7) 2 (  3.8) 2 (100.0) 
22. Patient taking analgesic(s) does not have 
pain (j) that interferes with daily activities 
45 ( 57.0) 30 ( 66.7) 11 ( 14.1) 7 ( 36.4) 
23. Patient taking an opioid (k) is taking 
prophylactic treatment for constipation 
1 (  1.3) 1 (100.0) 11 ( 13.9) 7 ( 63.6) 
24.Patient with risk factors for impaired renal 
function (l) is not taking an NSAID 
72 ( 91.1) 10 ( 13.9) 73 ( 92.4) 24 ( 32.9) 
25. Patient is not concurrently taking an ACE 
inhibitor or ARB, diuretic and NSAID 
(excluding low-dose aspirin [acetylsalicylic 
acid])  
51 ( 64.6) 3 (  5.9) 47 ( 59.5) 2 ( 4.3) 
27. Patient with depression is not taking 
anticholinergic-type antidepressants (m)  
3 (  3.8) 0 1 (  1.3) 0 
29. Patient taking an SSRI is not concurrently 
taking medications known to increase the risk 
of gastrointestinal bleeding (o) 
2 (  2.5) 2 (100.0) 1 (  1.3) 1 (100.0) 
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Table 6.4d Distribution of HMR Report group patients identified as at risk of PIP by Basger indicators at discharge and HMR, continued25 
 
Basger Indicators applied to HMR 
Report Group (n=79) 
DISCHARGE 
 
HMR 
 
 
Patients Assessed 
(% relative 
frequency)a 
Patients at risk 
(% relative 
frequency)b 
Patients Assessed 
(% relative 
frequency)a 
Patients at risk 
(% relative 
frequency)b 
30. Patient taking an SSRI is not currently 
taking other medications that may contribute 
to serotonin toxicity (p) 
2 (  2.5) 1 ( 50.0) 0 0 
32. Patient is not  taking more than one 
medication with anticholinergic activity (q) 
9 ( 11.4) 1 ( 11.1) 17 ( 21.5) 3 (17.6) 
33. Patient taking a PPI is not taking a 
medication that may cause dyspepsia (r) 
30 ( 38.0) 25 ( 83.3) 26 ( 32.9) 13 (50.0)) 
34. Patient with COPD is not taking 
benzodiazepines 
4 (  5.1) 0 4 (  5.1) 0 
36. Patient using a salbutamol (albuterol) or 
terbutaline inhaler more than three times per 
week for reversible airways disease has been 
prescribed an inhaled corticosteroid 
6 (  7.6) 4 (66.7) 15 ( 19.0) 15 (100.0) 
37. Patient with asthma is not taking a 
medication that may worsen asthma (s) 
5 (  6.3) 2 ( 80.0) 6 (  7.6) 5 ( 83.3) 
41. Patient with an URTI (t) is not receiving 
antibacterials 
1 (  1.3) 0 1 (  1.3) 0 
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Table 6.4e Distribution of HMR Report group patients identified as at risk of PIP by Basger indicators at discharge and HMR, continued25 
 
Basger Indicators applied to HMR 
Report Group (n=79) 
DISCHARGE 
 
HMR 
 
 
Patients Assessed 
(% relative 
frequency)a 
Patients at risk 
(% relative 
frequency)b 
Patients Assessed 
(% relative 
frequency)a 
Patients at risk 
(% relative 
frequency)b 
42. Patient with osteoporosis who is not 
receiving at least 600 IU of vitamin D daily 
from dietary sources is receiving 
supplementation with vitamin D (u) 
2 (  2.5) 2 (100.0) 6 (  7.6) 5 ( 83.3) 
43. Patient with osteoporosis who is not 
receiving at least 1200mg of calcium daily 
from dietary sources is receiving calcium 
supplementation (v) 
2 (  2.5) 1 ( 50.0) 4 (  5.1) 1 ( 25.0) 
44. Patient with osteoporosis is receiving anti-
osteoporotic medication (w) 
2 (  2.5) 1 ( 50.0) 8 ( 10.1) 3 ( 37.5) 
48. Patient has had no significant change in 
medications in the previous 90 days 
79 (100.0) 79 (100.0) 79 (100.0) 79 (100.0) 
aRelative frequency of: patients assessed by the indicator/ patients in the HMR group (n=79). 
bRelative frequency of: patients at risk of potentially inappropriate prescribing/ patients assessed by the indicator. 
(b-w) these letters refer to additional information on requirements of indicators which appear in Appendix 6.1. 
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6.6.6.1  Specific Prescribing Indicators 
From Table 6.4 the highest number of patients to whom any one indicator was applied 
and not satisfied, signifying PIP, was recorded for Indicator No.48.  For optimal 
prescribing, this indicator required that there had been no changes made to the patients’ 
drug regimen in a period of 90 days preceding the assessment.  This indicator was 
applied to 79 (100%) patients and was 100% not satisfied at either discharge or HMR.  
The entire subgroup of patients was exposed to the risk of PIP in the form of changes to 
their established drug regimen while in hospital, and then again following discharge, at 
follow-up with their GP, prior to HMR.   
 
The possibility or occurrence of change in the study group’s drug regimen, was 
not unexpected.  However, the level and source of PIP identified was unexpected.  
Indicator No 48 reinforced the importance of identifying and qualifying any recent 
change in patients’ drug regimen under any circumstances.   
 
 The second highest number of patients in Table 6.4 to whom an indicator was 
applied and not satisfied signifying PIP, at both discharge and at HMR service, was 
recorded for Indicator No.2.  This indicator required that patients at high risk of a 
cardiovascular event were taking a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitor (statin).  The indicator was applied at discharge to 76 (92.2%) 
patients and applied at HMR to 78 (98.7%) patients.  The indicator was not satisfied at 
discharge for 22 (28.9%) patients and at HMR for 25 (32.1%) patients.  The nature of 
all applicable indicators and number of patients assessed and identified as at risk of 
potentially inappropriate prescribing by those indicators, appears in Table 6.4. 
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6.6.7  APPLICATION OF PRESCRIBING INDICATORS 
Table 6.5 shows the results of paired samples t testing  of the number and distribution of 
prescribing indicators applied to the HMR Report group (n=79).  The table shows the 
testing of the null hypothesis of no difference between discharge and HMR.  There was 
no significant difference between discharge and HMR in the number of indicators 
whose requirements were satisfied when applied to the subgroup (p=0.542) or total 
number of indicators applied to the group (p=0.743).  After discharge, the increase in 
mean number of indicators whose requirements were not satisfied when applied to the 
group at HMR, was marked; however was not statistically significant (p=0.092).  This 
result was consistent with: 
a) significant increase in the degree of inappropriateness of prescribing  
for the group at HMR (e.g. decrease in appropriate prescribing) (Table 6.2); 
 
b)  significant increase in instances of PIP or drug related situations at HMR  
(Table 6.3);  and 
 
c)  significant increase in numbers of patients at risk as identified by specific  
indicators at HMR (Table 6.4).   
 
 
Table 6.5  Distribution of Basger indicators across HMR Report group (n=79) at 
discharge and at HMR.25 
 
Basger Indicators 
(n=32) 
 
DISCHARGE: 
Number 
Indicators 
Mean (S.D±) 
HMR: 
Number 
Indicators 
Mean (S.D±) 
 
 
 
t value 
Significance 
 
 
p(value) 
Requirements 
satisfied 
13.9 (20.6) 13.0 (17.3) 0.01 0.542 
Requirements not 
satisfied  
  7.7 (15.2) 
 
10.1 (15.3) 0.99 0.092 
Number applied 
  
22.0 (24.9) 
 
22.6 (23.7) 0.38 0.703 
(t test: N=79, df=78) 
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6.7  DISCUSSION 
 
 
For the HMR Report group of patients, this study tested several null hypotheses of no 
difference between discharge and HMR in 1) the distribution of patients’ drugs and 
diseases and 2) the distribution and appropriateness of prescribing.  The study also 
tested for differences in 3) the instances of potentially inappropriate prescribing (PIP) in 
relation to patients’ overall drug consumption.  Further, differences were determined in 
4) the risks to patients identified by specific criteria and finally in 5) the distribution of 
the applied prescribing indicators.  The aim was achieved utilising the Basger 
indicators.25 
 
 While testing the null hypotheses all analyses ‘at discharge’ were conducted on 
lists of drugs and diseases in discharge summaries.  All analyses ‘at HMR’ service were 
conducted on lists of drugs and diseases in HMR reports written by accredited 
pharmacists.  The pharmacists’ comments and recommendations in the HMR reports 
were not taken into account. 
 
In their diverse range of diseases and high number of prescribed drugs, the HMR 
Report group of patients were shown to need the specialised care recommended by Lim 
et al. for older patients discharged from Australian hospitals to their homes.14  These 
researchers listed 10 guidelines for appropriate care of patients with polypharmacy 
indicated by multiple co-morbidities.  The guidelines included the early organisation of 
post acute care services e.g. HMR, medication awareness and management for 
continuity of patient care.10   
 
In the literature ‘low level’ polypharmacy was defined as the prescription of 5 
concurrent active drugs and in previous chapters, the HMR Report group of patients 
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were shown to experience a ‘high level’ of polypharmacy which was defined in the 
literature as ‘greater than 10 routine drugs’.15,42-44  Several researchers, including 
Steinman et al. (2009) described polypharmacy as the prescription of ≥6 concurrent 
active medications and labelled this level of prescribing, by itself, as potentially 
inappropriate.23,43,45   
 
The health and safety of the HMR Report group, with an average of 8.3 drugs at 
discharge and 10.2 drugs at HMR, were found to be compromised by the patients’ level 
of polypharmacy.  In addition, the high number of drugs prescribed at discharge was 
significantly increased after post discharge, GP follow-up in the community.  Although 
the Basger indicators were designed to be patient focussed, polypharmacy, by itself, was 
not included as a hazard to medication safety.46-50 
 
A review of strategies and activities for improving medication safety in 
Australia and New Zealand, stressed the need for sustaining medication safety and 
information transfer across healthcare boundaries.1-2  Tamblyn et al. (2003) found the 
level of PIP at discharge indicated that inadequate risk screening occurred pre 
discharge.51  These researchers concluded that inadequate screening for drug related 
problems was demonstrated by the communication of inappropriate medication orders 
across healthcare boundaries.51-52  Mansur et al. also found a direct correlation between 
polypharmacy at discharge and the prevalence of inappropriately prescribed drug use, 
and recommended further research.53  
 
It is not unreasonable to assume that tertiary care hospitals, when providing the 
highest level of acute care in Australia, would demonstrate responsibility, accountability 
and accuracy in medication management and in communicating medicines information.  
These principles are a partial requirement of National guidelines for quality and 
 Chapter 6 Quality of Prescribing                                                                      Page 186 
 
medication continuity between hospitals and primary care in Australia.54-55  However, 
the assumption of quality in medication management was not supported by the study 
outcomes. 
 
This study found that there was a significant increase from discharge to HMR, in 
the patients’ exposure to PIP.  Not only was there an increase in PIP, but an 
unacceptable risk to the patients’ medication safety was already evident at discharge 
from an acute care hospital.1-2  As well as the significant increase in PIP at HMR, risks 
to the patients’ medication safety were intensified by a concurrent, significant decrease 
in appropriate prescribing after GP follow up prior to HMR.   
 
When estimated by effect size, the clinical impact of these two significant 
outcomes was found to have a large, adverse effect on the study group at HMR.56-58  As 
a proportion of PIP instances identified, the estimated reduction of 11.3% in appropriate 
prescribing instances and increase of 29.0% in PIP instances is indicative of a highly 
adverse impact on the study group at HMR.  These concurrent adverse impacts on the 
patients, reflect a lack of patient centred care in the community after acute care hospital 
discharge.59 
 
No reports of the Basger indicators applied by other researchers, or of 
comparative research utilising explicit criteria, were found in the literature for a similar 
patient cohort during transfer from tertiary to primary care.25  Hence comparisons, of 
the extent of inappropriate prescribing from the literature, are approximated for the 
outcomes of this study.  Research in similar cohorts, conducted by Fialová et al. (2005 
and 2009) and Barry et al. (2006), using the well validated and explicit criteria 
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developed by Beers, found that patients in Europe and Ireland respectively, also 
consumed ‘at least 1 inappropriate medication’.16-16,43,60  
Steinman et al. (2009) found that the ratio of PIP relative to the number of 
routine drugs prescribed for a similar study cohort in the USA was 6.0%.45  A direct 
comparison of Steinman et al’s. ratio outcomes with Basger’s identification of PIP 
situations was not appropriate.  However, outcomes from the application of Beers 
criteria in Chapter 5 to the HMR report group, showed markedly higher ratios of PIP 
drugs relative to the number of routine drugs prescribed as 19.2% at discharge and 
12.7% at HMR.  
Outcomes from the present study using the Basger indicators, found a mean 
(SD±) number of potentially inappropriate drug related situations per patient at 
discharge of 3.1 (±1.1) instances and at HMR of 5.1 (±2.2) instances.  These high 
patient averages for drug related instances, were found to have resulted from the 
application of more sensitive indicators custom designed for the Australian healthcare 
system.   
When potentially inappropriate drug related instances were substituted for PIP 
drugs, Basger indicators showed high instances of PIP relative to the number of routine 
drugs prescribed for the cohort.  These were over one third of the routine drugs 
prescribed at discharge [250 (38.2%)] and approximately half of the routine drugs 
recorded for the study group at HMR [399 (49.5%)].  The Basger indicators were found 
to be decidedly less explicit in drugs to avoid, than the previously utilised Beers 
criteria.16,45  
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In this study, the application of 32 of the Basger indicators to the HMR Report 
group of 79 patients showed at discharge there were 85 occasions and at HMR there 
were 89 occasions when 100% relative risk of PIP was identified.  It should be noted 
that these results included 5 occasions when an indicator was applied to 1 patient only.  
The arbitrary decision to apply the indicators when found applicable to 1 patient (only), 
ensured that every patient at risk of PIP was identified.   
 
It was found that the indicators readily identified patients at risk and clearly 
indicated the combinations of disease, pharmacotherapy and health status which 
exacerbated that risk.  Application and scoring of the Basger indicators required a 
decision on whether or not the numerous components of each indicator were satisfied.  
Hence, it was found that Basger’s description of the indicators being ‘predominantly 
explicit’ should be open for further discussion.23,25,61 
 
The application of the Basger indicators to data recorded at HMR found the 
availability of the data was an opportunity to identify PIP for subsequent, timely 
resolution.  The early organisation of post acute care discharge services in the 
community are recommended for patients such as the HMR Report group of the CofCP, 
by the Australian and New Zealand Society for Geriatric Medicine.14   
 
Non-referral by GPs in the Australian community, of hospital patients deemed in 
need of an HMR by other healthcare professionals, was also recorded in a small; 
Australian study by Bollella et al (2008).62  The Bollella study is another reflection of 
the barriers to continuity of care in the current Australian healthcare environment.  
Outcomes of this present study have shown that non-referral for HMR was a missed 
opportunity for the chronically ill patients in the CofCP who were not referred for HMR 
after hospital discharge (Fig. 6.1).9   
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Analysis of the distribution of the Basger Indicators showed there were no 
significant differences between the number or type of indicators applied at discharge 
and HMR.  This signified the consistency with which the indicators were applied to the 
same group of patients, in different healthcare environments, at two discrete assessment 
points.   
 
It was an advantage to be able to include the assessment of recent changes to 
patients’ established drug regimen as a risk factor in PIP.  This was shown to be 
particularly relevant to cohorts recently discharged from an acute care hospital and 
moving from one healthcare sector to another.  Use of the Basger indicators took into 
account drug availability and accepted prescribing practices in Australia (e.g. the 
combination of clopidogrel and aspirin); and individual patient characteristics.  These 
factors added a further dimension to the assessment of the HMR Report group’s drug 
regimens and identification of barriers to their continuity of care after hospital 
discharge.  
 
6.8  STUDY STRENGTHS AND LIMITATIONS 
It is acknowledged that the number of subjects and HMR reports available for analysis, 
limited generalisation from the study.  To date, the application of the Basger indicators 
to a research cohort (other than by Basger et al.), has not been reported in the literature 
and hence the scoring and interpretation of results in this study, was not objectively 
supported by the literature.   
 
The assessment of prescribing appropriateness using clinical notes was limited 
by the questionable accuracy and completeness of documentation of medical records, 
discharge summaries and especially, medication review reports.  However, 
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documentation was representative of the real healthcare environment in which the 
patients were transferred from hospital to the community, and which was not artificially 
controlled for research purposes. 
 
 
6.9  CONCLUSION 
 
 
The study found that there was a distinct and unacceptable level of PIP for the study 
group at hospital discharge and notably, during primary care.  The PIP identified was an 
indication of the sub-optimal prescribing and, or inaccurate documentation of drug 
regimens.  Regardless of the type, level or source of discrepancy identified, this 
constituted a barrier to the patients’ health safety and continuity of care.  The 
identification and timely management of these patient or drug-related problems at HMR 
would  be a  great  advantage  to  the  patients  referred for medication review after their  
acute care hospital discharge.  
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Chapter 6.0 Appendix 6.1. Copied from “Inappropriate Medication Use and 
Prescribing Indicators in Elderly Australians” by Basger et al.25 
 
Basger Table II. Suggested Australian prescribing indicators for commonly occurring 
conditions in patients aged >65 yearsa,b 
 
Indicator Reason for non-applicability 
in this study* 
 1. Patient taking an antihypertensive is at their 
target blood pressure (a) 
*Situation not recorded: target 
blood pressure achievement 
 2. Patient at high risk of a cardiovascular event  
(b) is taking an HMG-CoA reductase inhibitor 
(statin) 
Applied 
 3. Patient with IHD or a history of MI is taking a 
ß-blocker (ß-adrenoceptor antagonist) 
Applied 
 4. Patient with IHD or a history of MI is taking 
an antiplatelet agent unless taking an oral 
anticoagulant (c) 
Applied 
 5. Patient with heart failure is taking a ß-blocker  Applied 
 6. Patient with heart failure is taking an ACE 
inhibitor or ARB  
Applied 
 7. Patient with heart failure is not taking 
medications that may exacerbate heart failure (d) 
Applied 
 8. Patient with heart failure or hypertension is 
not taking high sodium-containing medications 
(e) 
Applied 
 9. Patient with AF is taking an oral anticoagulant Applied 
10. Patient with AF taking an anticoagulant has 
an INR between 2 and 3 
*Blood/Biochemistry results not 
available: INR 
11. Patient with a history of non-haemorrhagic 
stroke or TIA is taking an antiplatelet agent 
unless taking an anticoagulant (c)  
Applied 
12. Patient with risk factors for myopathy (f) is 
not taking ≥ 40mg/day of simvastatin or 
atorvastatin  
Applied 
13. Patient with cardiovascular disease is not 
taking an NSAID 
Applied 
14. Patient with cardiovascular, respiratory 
disease or diabetes mellitus who smokes has been 
offered smoking cessation therapy (g) 
*Situation not recorded: 
smoking cessation therapy offer 
15. Patient with type 2 diabetes and hypertension 
and albuminuria is taking an ACE inhibitor or 
ARB 
*Blood/Biochemistry results not 
available: albuminuria results 
16. Patient with diabetes at high risk of a 
cardiovascular event (b) is taking an antiplatelet 
agent unless taking an anticoagulant (c) 
Applied 
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Basger Table II. Suggested Australian prescribing indicators for commonly occurring 
conditions in patients aged >65 yearsa,b continued 
 
Indicator Reason for non-applicability 
in this study 
17. Patient with diabetes is not taking a 
medication that may increase or decrease blood 
glucose concentrations (h) 
Applied 
18. Patient with diabetes has had an HbA1c 
measurement within the previous 6 months 
*Blood/Biochemistry results not 
available: HbA1c results 
19. Patient taking metformin for diabetes has had 
the dose adjusted for creatinine clearance (l) 
*Blood/Biochemistry results not 
available: creatinine levels 
20. Patient taking metformin for diabetes is not 
concurrently taking glibenclamide 
Applied 
21. Patient with OA pain interfering with daily 
activities has been trialled on paracetemol 
(acetaminophen) 2-4 g/day 
Applied 
22. Patient taking analgesic(s) does not have pain 
(j) that interferes with daily activities 
Applied 
23. Patient taking an opioid (k) is taking 
prophylactic treatment for constipation 
Applied 
24.Patient with risk factors for impaired renal 
function (l) is not taking an NSAID 
Applied 
25. Patient is not concurrently taking an ACE 
inhibitor or ARB, diuretic and NSAID (excluding 
low-dose aspirin [acetylsalicylic acid]  
Applied 
26. Patient with sleep disturbance or anxiety has 
not been taking benzodiazepines for >4 weeks 
*Disease state, disease or drug 
not recorded: sleep patterns or 
anxiety 
27. Patient with depression is not taking 
anticholinergic-type antidepressants (m)  
Applied 
28. Patient with a history of falls is not taking 
psychotropic medications (n) 
*Disease state, disease or drug 
not recorded: history of falls 
29. Patient taking an SSRI is not concurrently 
taking medications known to increase the risk of 
gastrointestinal bleeding (o) 
Applied 
30. Patient taking an SSRI is not currently taking 
other medications that may contribute to 
serotonin toxicity (p) 
Applied 
31. Patient with dementia is not receiving 
anticholinergic medications (n)  
*Disease state, disease or drug 
not recorded: dementia 
32. Patient is not  taking more than one 
medication with anticholinergic activity (q) 
Applied 
33. Patient taking a PPI is not taking a medication 
that may cause dyspepsia (r) 
Applied 
34. Patient with COPD is not taking 
benzodiazepines 
Applied 
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Basger Table II. Suggested Australian prescribing indicators for commonly occurring 
conditions in patients aged >65 yearsa,b continued 
 
Indicator Reason for non-applicability 
in this study 
35. Patient with asthma using an inhaled LABA is 
also using an inhaled corticosteroid 
*Disease state, disease or drug 
not recorded: LABA 
36. Patient using a salbutamol (albuterol) or 
terbutaline inhaler more than three times per 
week for reversible airways disease has been 
prescribed an inhaled corticosteroid 
Applied 
37. Patient with asthma is not taking a medication 
that may worsen asthma (s) 
Applied 
38. Female patient with recurrent UTIs has been 
prescribed intravaginal estrogen 
*Disease state, disease or drug 
not recorded: recurrent UTIs 
39. Patient with a creatinine clearance <60 
ml/min is not receiving nitrofurantoin for UTI 
*Blood/Biochemistry results not 
available: creatinine level 
40. Patient with a creatinine clearance <50 
ml/min is not receiving methenamine (hexamine) 
for UTI prophylaxis  
*Blood/Biochemistry results not 
available: creatinine level 
41. Patient with an URTI (t) is not receiving 
antibacterials 
Applied 
42. Patient with osteoporosis who is not receiving 
at least 600 IU of vitamin D daily from dietary 
sources is receiving supplementation with vitamin 
D (u) 
Applied 
43. Patient with osteoporosis who is not receiving 
at least 1200mg of calcium daily from dietary 
sources is receiving calcium supplementation (v) 
Applied 
44. Patient with osteoporosis is receiving anti-
osteoporotic medication (w) 
Applied 
45. Patient using topical corticosteroids does not 
have itch or discomfort that interferes with daily 
activities 
*Disease state, disease or drug 
not recorded: topical 
corticosteroids 
46. Patient has received influenza and 
pneumococcal vaccination (x) 
*Situation not recorded: 
vaccination record 
47. Patient has no significant medications 
interactions (agreement between two medication 
interaction databases) 
*Situation not recorded: specific 
medication interactions 
48. Patient has had no significant change in 
medications in the previous 90 days 
Applied 
*Reason for non-applicability of indicator to HMR group assessment 
a. Blood pressure targets: proteinuria >1g/day, <125/75mmHg; diabetes, renal impairment, 
proteinuria 0.25-1 g/day, <130/85mmhg; age >65 years (unless any of the other targets apply), 
<140/90mmHg 
b. Patients at high risk of a cardiovascular event: age >75 years, symptomatic cardiovascular disease 
(angina, MI, previous coronary revascularization procedure, heart failure, stroke, TIA, PVD). 
genetic lipid disorder, diabetes and evidence of renal disease (micoralbuminuria and/or proteinuria 
and/or GFR <60mL/min) 
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c.  Antiplatelet agents: aspirin, clopidogrel. Anticoagulants: phenindione, warfarin. Non-haemorrhagic 
stroke or TIA: aspirin/dipyridamole, dipyridamole, ticlopidine 
d. Medications that may exacerbate heart failure: antiarrhythmic drugs (except digoxin or 
amiodarone), carbamazepine, dilitiazem, nifedipine, verapamil, NSAIDs (excluding low-dose 
aspirin), sotalol, thiazolidinediones (significant disease), tricyclic antidepressants, corticosterioids 
(oral or inhaled) 
e. High sodium-containing medications: effervescent tablets and powders - Panadol® Soluble, 
Berocca®, Supradyn®, Aspro Clear® Ural®, Alks-Seltzer®, Eno®, vitamin C (sodium ascorbate), 
Gaviscon®, Mylanta® 
f. Risk factors for statin myopathy: drugs inhibiting metabolism by cytochrome P450 3A4 (dilitiazem, 
verapmil, macrolides); medicines inhibiting metabolism by other means (gemfibrozil); disease 
states (diabetes, hypothyroidism, renal and hepatic disease); age ≥70 years; dose ≥40 mg/day 
g. Smoking cessation therapy: counselling, use of support services, medication; for patients smoking 
>10 cigarettes per day, bupropion, nicotine replacement therapy, varenicline 
h. Medications that may increase or decrease blood glucose concentrations: baclofen, 
chlorpromazine, clozapine, cyclosporin, corticosteroid, haloperidol, hormone replacement therapy, 
olanzapine, phenytoin quetiapine, resperidone, tricyclic antidepressants.  The following may 
decrease blood glucose concentrations: alcohol, isopyramide, perhexiline, quinine and 
trimethoprim/sulfamethoxazole 
i. Metformin dose: 2 g/day maximum for creatinine clearance 60-90 ml/min, 1 g/day for creatinine 
clearance 30-60 ml/min 
j. Pain: back complaint, OA cancer, rheumatoid arthritis 
k. Opioids: buprenorphine, codeine, fentanyl, hydromorphone, methadone, morphine, oxycodone 
(dextropropoxyphene and tramadol have minimal gastrointestinal effects) 
l. Risk factors for impaired renal function: creatinine clearance <60mL/min, heart failure, salt-
restricted diet, volume depletion, concurrent use of diuretics, ACE inhibitors or ARBs, ciclosporin 
or aspirin 
m. Anticholinergic-type antidepressants: amitriptyline, dosulepin (dothiepin) doxepin, imipramine, 
mianserin, nortriptyline, trimipramine 
n. Pyschotropic medications: antidepressants (all), antipsychotics, sedatives/hypnotics 
o. Increased risk of bleeding with SSRIs: aspirin, NSAIDs, warfarin. Consider gastroprotective 
medication if SSRI to be continued 
p. Medications that may contribute to serotonin toxicity: tricyclic antidepressants, MAOIs (including 
moclobemide), venlafaxine, St John’s wort (hypericum), tramadol, pethidine (meperidine), 
dextromethorphan, phentermine, sibutramine, selegiline, lithium 
q. Anticholinergic medications: as per Australian Medicines Handbook, page A90 
r. Medications that may cause dyspepsia: aspirin, bisphosphonates, calcium channel antagonists, 
corticosteroids, dopaminergic agents, erythromycin, iron, nitrates, NSAIDS, potassium chloride, 
tetracycline 
s. Medications that may worsen asthma: NSAIDs (including aspirin), ß-blockers (including eye drops, 
royal jelly, Echinacea) 
t. URTI: includes sore throat, acute otitis media, sinusitis, acute bronchitis and the common cold 
u. Sources of vitamin D: skin exposure for at least 5 (summer) to 15 (winter) minutes per day four to 
six times per week between 10am and 2pm (11am and 3pm daylight saving time), fatty fish (e.g. 
salmon), meat, eggs, liver, vitamin D-fortified foods (e.g. margarine) 
v. Sources of calcium: adequate calcium intake can be provided by three serves of dairy food per day 
– one serve + 250 ml milk or 200g of yoghurt or 40g cheddar cheese.  Calcium-rich non-dairy foods 
= almonds, beans, dried figs, tofu, broccoli, bok choy, tinned salmon and sardines 
w. Anti-osteoporotic medication: bisphosphonate, calcitriol, raloxifene, strontium, teriparatide 
x. Vaccination: annual vaccination with influenza vaccine, vaccination every 5 years with 
pneumococcal vaccine 
……………………………………………………………………………………………………………................................................ 
a This  indicator list is intended to be used by appropriately trained and qualified health professionals 
as a tool to assist in making clinical decisions as part of the medication review process. 
b Prior to the commencement of any medication, the contraindications and precautions for that 
medication should be considered (see table III). 
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AF = atrial fibrillation; ARB= angiotensin ll type 1 receptor antagonist (angiotensin receptor blocker); 
COPD=chronic obstructive pulmonary disease; GFR=glomerular filtration rate; HBA1c=glycosylated 
haemoglobin; IHD=ischaemic heart disease; INR=international normalized ratio; IU=international units: 
LABA=long acting ß-adrenoceptor agonist; MAOI=monoamine oxidase inhibitor; MI=myocardial 
infarction; OA=oseteoarthritis; PPI=proton pump inhibitor; PVD=peripheral vascular disease; 
SSRI=selective serotonin reuptake inhibitor; TIA=transient ischaemic attack; URTI=upper respiratory  
tract infection; UTI=urinary tract infection.
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Figure 7.1 Chapter 7.0 Flowchart 
 
PIP(s) = potentilly inappropriate prescribing/prescriptions. HMR = Home Medicines Review
Hospital Discharge 
n = 281 patients 
non-HMR Report Group 
n=202 Discharge regimens 
 
1575 prescriptions 
CHAPTER 7.0 
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Specific drugs and their potential for inappropriate 
prescribing (PIP) at discharge 
CONTINUITY OF CARE PROJECT (CofCP) 
CofCP cohort n=281 patients at Discharge 
Identification of PIP by Beers criteria 
       HMR Report group n = 114 PIPs 
non-HMR Report group n = 461 PIPs 
 
 
HMR Report Group n=79  
Discharge regimens 
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non-HMR Report group = 29.3% 
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CHAPTER 7.0  IDENTIFYING PATIENTS AT RISK 
 
7.1 CHAPTER SUMMARY 
Initially, this chapter determined and analysed the discharge regimens of the full 
Continuity of Care Project (CofCP) cohort (n=281) for specific drug nature (active 
ingredient) and frequency of prescribing.  Discharge regimens for the Home Medicines 
Review (HMR) Report group  (n=79) and the non-HMR Report group (n=202) were 
compared. 
 
Secondly, this chapter identified patients at risk of potentially inappropriate 
prescribing (PIP) by comparing the re-application of Beers criteria and Basger 
indicators to the HMR Report group (n=79).  In this chapter, in comparison with 
chapters 5 and 6, the specific nature of drugs was targeted within therapeutic 
classifications of PIP drugs.  Lists of drugs and diseases on discharge summaries and 
post discharge HMR reports were compared for PIP.  For the minority HMR Report 
group, these analyses ascertained any change in the specific nature of identified PIP 
drugs at discharge and at HMR service.  
 
  Thirdly, Beers criteria were applied to the full cohort’s regimen at discharge to 
determine any PIP, and data were tabulated for comparison between the two subgroups.  
These analyses showed the specific nature of any PIP drugs, their prescribing frequency 
and the ratio of PIP to discharge prescriptions for the cohort.   
 
Throughout this chapter, further clinical characteristics of the cohort were 
investigated and included the nature (active ingredient) of discharge drugs and of any 
identified PIP drugs.   Comparisons of all characteristics of the minority subgroup with 
those of the majority subgroup were made to establish the representativeness of the 
HMR Report group for the non-HMR Report group, hence for the full CofCP cohort.  
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These factors were ascertained to determine the need for medication review for all 
patients, to augment their continuity of care after hospital discharge. 
 
7.2  INTRODUCTION 
 
 
Achieving continuity of care (CofC) in healthcare environments involves the integration 
of all aspects of patient care and most importantly, involves the quality and 
completeness of care necessary during transfer from hospital back into the community.1-
5  In the Australian healthcare system there is still a heavy reliance on the production of 
partially computerised discharge summaries collated by junior members of the patients’ 
hospital medical team.6-10  On patient transfer, these summaries are the only tangible 
record of the ongoing care required for the many patients whose post discharge 
wellbeing is primarily sustained by pharmacotherapy.11  Hence, the opportunity for 
timely reconciliation of medicines and review of appropriateness of drugs prescribed on 
discharge is crucial to the integration of quality care in any healthcare system.12-14 
 
 In the Australian healthcare system, Home Medicines Review (HMR) services 
are organised and conducted by pharmacists after referral at the discretion of the 
patient’s general medical practitioner (GP).15-17  These medication reviews are designed 
to be conducted in the patients’ homes which present real environments for 
comprehensive reconciliation of all medicines actually consumed.1,18-21  The HMR 
service post discharge, updates the patients’ GPs on current regimen adherence and 
facilitates timely information exchange on patient related problems and any potentially 
inappropriate prescribing (PIP) identified.4,22-25 
 
Beers explicit criteria, written for identification of PIP in international healthcare 
systems, are well validated by use in research and practice and were updated in 2003.26-
30  There is however, a dearth of literature reporting the use of Beers criteria in 
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Australian research or practice and in particular, of prescribing in an Australian acute 
healthcare setting.31-32  In the development of Beers criteria, differences in the 
availability of drugs or prescribing practices in all countries and patient related clinical 
characteristics were not taken into account.  Hence, these factors were seen as important 
inclusions in the prescribing indicators developed by Basger et al. (2008) which were 
customised for use in the Australian healthcare system.33-34   
 
The combined application of Beers criteria and Basger indicators, in Chapters 5 
and 6, to the HMR Report group (n=79) comprehensively identified an unjustifiably 
high level of PIP.  The subgroup was exposed to PIP at both discharge and at HMR.34,41  
However unlike the majority of discharged patients in the non-HMR Report group 
(n=202), the HMR Report group were afforded the opportunity of post discharge 
medication review.  It was during this subgroup’s HMR services that the management 
of both discharge regimen and post discharge changes made after GP consultation, were 
reviewed, reconciled and reported back to the patient’s GP.16,37-39 
 
The literature widely supports claims of markedly exacerbated risk from drug 
interactions and polypharmacy, in particular, for patients prescribed drugs for 
cardiovascular disease.16,37-45  When discharged from an Australian hospital back to the 
community, subjects in this CofCP study were predominantly acute on chronically ill 
patients treated with cardiovascular drugs.2,4   
 
Continuity of care research involving the HMR Report group (Chapter 4), 
showed the group was exposed to polypharmacy and increased drug-related problems 
by the nature of their pharmacotherapy when discharged directly to their homes.4   Liu 
and Christensen (2002), Triller et al. (2005), Straubhaar et al. (2006) and Buajordet et 
al. (2011) also found a relationship between polypharmacy, cardiovascular drugs and  
home discharge.12,41,44-45 
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Alternatively, Hayes et al. (2007) and Robles and Anderson (2011) claimed to have 
found little research on the association between polypharmacy, cardiovascular drugs, and 
continuity of care.46-47  However, Robles stressed the importance of establishing post 
discharge continuity of care with a specific provider through organised healthcare services.   
 
In this study, organised healthcare services in the community are represented by the 
provision of HMR services by pharmacists in the patients’ homes.  No further published 
research was found which linked acute care pharmacotherapy, cardiovascular patients and 
their drug related problems after discharge, with the quality of their continuity of care in 
the community.  Hence, the study in this chapter investigated the links between these 
factors. 
 
7.3  STUDY AIM 
To investigate any risk of potentially inappropriate prescribing of specific drugs, for the 
full cohort, which would cause disruption to discharged patients’ continuity of care. 
 
7.3.1 OBJECTIVES 
To achieve the aim of the study for the full cohort of research subjects by determining the 
nature and distribution of any specific drugs:  
1) prescribed on discharge from hospital for the full cohort of patients (n=281) 
2) shown to be potentially inappropriately prescribed (PIP) for a subgroup of patients 
(n=79) by application of Beers criteria and Basger indicators, on and after 
discharge. 
3) identified as PIP on discharge from hospital for the full cohort of patients (n=281) 
by application of Beers criteria.  
4) which explain the representativeness in clinical characteristics of the minority 
subgroup to the majority subgroup, hence to the full cohort.
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7.4  OPERATIONAL DEFINITIONS 
 
7.4.1  CONTINUITY OF CARE is a perception of quality health care resulting from the 
ongoing management of issues which cause disruption to optimal patient care. 
In the context of the study reported in this chapter: 
Continuity of Care is perceived by the researchers as the timely identification of 
potentially inappropriate prescribing (PIP) on, and after hospital discharge to manage 
patients’ drug related problems and enhance their wellbeing.  
 
7.4.2  POTENTIALLY INAPPROPRIATE PRESCRIBING (PIP) 
In this study the phrases ‘potentially inappropriate prescribing or prescriptions’, and 
‘potentially inappropriate medication’ are equal in meaning and represented by the 
abbreviation ‘PIP(s)’.  Prudent et al. (2008) define ‘potentially inappropriate 
medication’ as drugs with an unfavourable risk/benefit ratio when safer or equally 
effective alternatives are available.48 
 
7.5  METHOD 
 
7.5.1  STUDY DESIGN 
The study reported in this chapter was a comparative analysis of the quality of 
prescribing for the subgroups of cardiology patients recruited as a cohort into the 
prospective Continuity of Care Project (CofCP).  The quality of prescribing was 
examined by determining the nature of the cohort’s discharge drugs and investigating 
any exposure of the cohort to potentially inappropriate prescribing (PIP).  In this study, 
the active ingredients of the cohort’s prescribed drugs were determined to describe the 
nature of their drug regimens.  The nature of the drugs prescribed for the subgroups are 
compared to determine any representativeness of the minority subgroup to the majority 
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subgroup in clinical characteristics.  The patients’ hospital discharge summaries and 
HMR reports were the sources of data for analyses.  The provision to the researchers of 
HMR reports for the patients’ GPs, was the end point of data collection for this study.  
 
7.5.2  SUBJECTS AND DATA SOURCES 
This study analysed the prescribing of drugs on discharge for patients (n=281) recruited 
into the Continuity of Care Project (CofCP) (Figure 7.1).2  All subjects recruited into 
the project were patients under the care of a cardiovascular team and were discharged 
from the Cardiology Unit of Westmead Hospital Sydney, to their homes between mid 
2004 and 2007.  The CofCP cohort was comprised of 162 (57.7%) male and 119 
(42.3%) female subjects with median age of 65 (IQR=19:55-74) years.  Subjects met the 
suggested Australian Commonwealth Government’s eligibility criteria for HMR referral 
by a GP, and were discharged from hospital on at least one cardiovascular drug.19   
 
In this chapter data sources analysed included the patients’ hospital medical 
records, discharge summaries and accredited pharmacists’ HMR reports.  Hospital 
discharge summaries were generated by the attending medical teams for the patients’ 
delivery to their community GP.  During the project implementation ‘Day Only’ 
patients were not provided with a discharge summary.  These patients’ drugs and 
diseases were analysed from their medical records or lists of drugs collated in lieu of a 
discharge summary.  The drug regimen in these lists were included for ‘at discharge’ 
data analyses.   
 
 A detailed account of the subjects recruited, and sources utilised for data 
analyses in this chapter appears in Chapter 3, 5 and 6. 
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7.5.3 DETERMINATION OF COHORT DISCHARGE REGIMENS 
 
Data collated from discharge summaries were for comparative analysis of drugs 
prescribed by the hospital medical team for 1) full CofCP cohort, 2) HMR Report group 
and 3) non-HMR Report group.  Data were analysed for a) prescribed drugs common to 
both the HMR and non-HMR Report subgroups and b) prescribed drugs unique to the 
HMR Report group and c) prescribed drugs unique to the non-HMR Report group.   
 
To conduct the above analyses, units of analysis were based on 1) the number of 
patients prescribed specific drugs, 2) the number of prescriptions for specific drugs, 3) 
the nature of the prescribed drugs.  In all analyses, any one patient could be counted 
several times across a range of different drugs however, each drug was counted only 
once for each patient. 
 
In this study, for the collation and analysis of discharge prescribing, all drugs 
were counted according to their active ingredients, only.  That is, prescriptions for the 
same active ingredient ordered in different strengths or at different frequencies were 
counted as the prescription of one drug only.  Hence, the number of prescriptions for the 
cohort or subgroups could vary from numbers reported in previous chapters where all 
separate prescriptions for an active ingredient were counted. 
 
7.5.4  IDENTIFICATION OF POTENTIALLY INAPPROPRIATE PRESCRIBING (PIP)  
 
-POST DISCHARGE IN THE COMMUNITY 
 
 
To ascertain the difference in prescribing quality between discharge and post discharge 
in the community, Beers criteria and Basger Indicators were re-applied to the drug 
regimens of the HMR Report group.  In comparison to Chapters 5 and 6, re-application 
targeted the nature (active ingredient) of identified PIP drugs and any changes made 
after GP consultation. 
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7.5.4.1  Re-application of Beers Criteria – HMR Report Group 
Beers criteria identify drugs as PIP independent of diagnoses or conditions in 48 criteria 
(Table 1 in Appendix 5.1) and identify drugs as PIP after considering diagnoses or 
conditions in 20 criteria (Table 2 in Appendix 5.1).157  In this chapter, the Beers 
criterion targeting blood clotting disorders or patients receiving anticoagulant therapy 
was again divided into two criteria for ease of analysis (No.54 and No.55) and the two 
tables of criteria were combined and numbered consecutively from 1-69.   
 
In this chapter, the method of application for Beers criteria was consistent with 
the application of Beers criteria in Chapter 5.  However, in this chapter the high or low 
severity ratings of the identified PIP drugs were not determined 
 
The re-application of Beers criteria to the HMR Report group at discharge and at 
HMR, was to determine the nature (active ingredient) of specific drugs which were 
assessed as PIP at these two points in time.  Identification of PIP by Beers criteria ‘at 
discharge’ was conducted on lists of drugs or diseases in discharge summaries.  
Identification of PIP by Beers criteria ‘at HMR’ service was conducted on lists of drugs 
or diseases in HMR reports written by accredited pharmacists.  The pharmacists’ 
comments and recommendations in the report, were not taken into account. 
 
A detailed account of the background to development, format, application 
process and Beers criteria appear in Chapter 5 and Appendix 5.1. 
 
7.5.4.2  Re-application of Basger Indicators – HMR Report Group. 
For a comprehensive identification of PIP, besides the re-application of Beers 
international criteria, Basger indicators for appropriate prescribing were also re-applied 
to the HMR Report group (n=79).  Unlike Beers criteria, Basger indicators were 
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customised for application in an Australian healthcare environment to take into account 
patient characteristics, availability of drugs and local prescribing patterns.33  
 
The method adopted for re-application of Basger indicators in this chapter was 
consistent with the application of Basger indicators in Chapter 6.  As in Chapters 5 and 
6 the identification of PIP by two distinctly different applications added to a 
comprehensive analysis of the HMR Report groups’ prescribed drugs.  The Basger 
indicators were re-applied in this chapter at discharge and at HMR service.  This was to 
determine the nature (active ingredient) of specific drugs, within therapeutic 
classifications, which were assessed as PIP at these two points in time.   
 
The identification of PIP by Basger indicators ‘at discharge’ was conducted on 
lists of drugs or diseases in discharge summaries.  Identification of PIP by Basger 
indicators ‘at HMR’ service was conducted on lists of drugs or diseases in HMR reports 
written by accredited pharmacists.  The pharmacists’ comments and recommendations 
in the report were not taken into account. 
 
A detailed account of the background to development, format, application 
process and Basger indicators appears in Chapter 6 and Appendix 6.1. 
 
 
7.5.5 IDENTIFICATION OF POTENTIALLY INAPPROPRIATE PRESCRIBING 
(PIP): 
AT HOSPITAL DISCHARGE – For the CofCP Cohort 
 
Beers criteria were chosen for the straight forward determination of the quality of 
prescribing in the drug regimens of the full CofCP cohort on discharge from hospital.  
The updated Beers criteria, published by Fick et al. (2003), were chosen for 
identification of PIP for the cohort (n=281).29,48-51  Beers criteria were developed using 
a modified Delphi method for formulating group judgements by an expert panel on the 
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rating of specific drugs prescribed for patients ≥65 years of age.27,52  The shortcomings, 
of Beers criteria were discussed in chapter 5, however the criteria have been widely 
utilised and well validated by published research.22.30.49.53-55 
 
In this Chapter, application of Beers criteria facilitates the qualification of the PIP 
drugs’ active ingredients as the ‘nature’ of the drugs prescribed.  In comparison with 
Basger indicators which predominantly assessed drug interactions between classes of 
drugs, most Beers criteria named specific drugs as PIP.  Beers criteria were utilised in 
Chapter 5 and were found to be practical for providing an explicit, validated and 
international approach to identification of PIP in the Australian healthcare environment 
(Appendix 5.1)46  
 
For analyses in this chapter, identified PIP were recorded as ‘an instance of PIP’ 
without regard to the severity level allocated by Beers criteria (low or high severity).56  
The explicit division of drugs into these two categories was found, in Chapter 5, to not 
affect the impact of PIP on the study group.   
 
Hence, as this study adopts a ‘worse case scenario’ in design and method, this 
means all drugs identified as PIP at any level of severity, carry the same level of risk to 
a patients’ health.  This approach also included the full assessment of drugs prescribed 
for one patient only, so that patients were not arbitrarily excluded from the study as was 
apparent in continuity of care (CofC) research systematically reviewed in Chapter 2.3 
 
A detailed account of the background to development, format, application 
process and Beers criteria appears in Chapter 5 and Appendix 5.1. 
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7.5.6  DATA ANALYSES 
 
All data on prescribed drugs and diseases were coded for analysis, according to the 
Anatomical Therapeutic Chemical (ATC) classification and International Classification 
of Disease version 10 (ICD-10), respectively.57-58  Purpose designed databases were 
constructed in SPSS Statistics Version 17 and Microsoft Office Excel 2007 
programmes.  
 
Data collated from the application of Beers and Basger criteria for the 
identification of PIP were analysed for the HMR Report group (n=79) at discharge and 
at HMR service in the community.  Drug regimen recorded on discharge summaries 
were prescribed by the hospital medical team and regimens recorded on HMR reports 
were drugs currently being taken by patients post discharge, after GP consultation.  
These analyses allowed comparison of the number of patients’ PIP drugs at discharge 
and at HMR, the number of PIP instances at these times and importantly, the nature of 
the specific drugs identified as PIP.  
 
All analyses of data ‘at discharge’ were conducted on lists of drugs or diseases 
in discharge summaries.  Analyses of data post discharge ‘at HMR’ service, were 
conducted on lists of drugs or diseases in HMR reports written by accredited 
pharmacists.  The pharmacists’ comments and recommendations in the report were not 
taken into account. 
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7.6  RESULTS 
 
7.6.1  HOSPITAL DISCHARGE REGIMENS FOR STUDY COHORT (n=281) 
Table 7.1, shows the distribution of patients, prescriptions and discharge drugs for the 
full study cohort (n=281), at discharge.  All discharge drug regimens for the cohort are 
shown by division into the HMR Report group (n=79) and non-HMR Report group 
(n=202).  The table shows the number and nature of the discharge drugs in decreasing 
frequency for the non-HMR Report group.  The relativity of the results to the groups’ 
total discharge data and explanations of the analyses are shown as footnotes to the 
tables. 
 
The prescription of one drug (e.g. warfarin, insulin) at more than one strength, or 
in different form, and/or at different daily frequencies was counted as one (only) 
specific drug response for a patient.  That is, in this chapter the active ingredients of 
drugs describe the nature of the drugs, and are included once only for each patient.  
Adoption of this method to clarify the nature of patients’ drugs resulted in slight 
differences in prescription counts between analyses or chapters. 
 
 
7.6.1.2 Discharge Regimens for CofCP Cohort 
In Table 7.1, analyses of the cohorts’ complete discharge regimens showed a pattern of 
relatively steady decrease in number and nature of the drugs which were tabulated from 
the most to least frequently prescribed for the non-HMR Report group.   
 
 Aspirin was the most frequently prescribed discharge drug and was prescribed 
for 54 (68.4%) HMR Report group patients and 128 (63.4%) non-HMR Report group 
patients.  Aspirin prescriptions accounted for 8.1% of total discharge prescriptions, for 
each subgroup.  Clopidogrel followed aspirin in frequency and was prescribed for 40 
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(50.6%) HMR and 95 (47.0%) non-HMR Report group.  Clopidogrel prescriptions 
accounted for 6.0% of total discharge prescriptions for each subgroup.  Atorvastatin was 
prescribed for 30 (38.0%) HMR and 85 (42.1%) non-HMR Report group patients and 
prescriptions accounted for 4.5% and 5.4% of total discharge prescriptions, respectively. 
 
 For the cohort (n=281), and taking into account prescribed drugs common to and 
unique to the subgroups, there were 213 different drugs prescribed on discharge (Table 
7.1).  With the number of discharge prescriptions recorded as prescriptions for active 
ingredients, total discharge prescriptions averaged 8.0 (SD± 6.6) prescriptions per 
patient for the cohort.  At discharge, a total of 2245 prescriptions was comprised of 670 
(29.8%) HMR Report group and 1575 (70.2%) non-HMR Report group prescriptions 
(Table 7.1). 
 
 
7.6.1.3 Discharge Prescribing Common to Subgroups 
 
From Table 7.1, analysis of the cohort’s discharge regimen for drugs common to the 
HMR and non-HMR Report groups showed a pattern of steady decrease in the number 
and nature of the drugs from the most to least frequently prescribed.  Aspirin, 
clopidogrel and atorvastatin were the most frequently prescribed drugs common to both 
groups. 
 
Table 7.1 shows 104 different drugs were common to both groups on discharge.  
Common drug prescriptions averaged 8.3 (SD± 3.0) HMR and 7.8 (SD± 4.0) non-HMR 
Report group prescriptions per patient.  These prescriptions averaged 6.1% HMR and 
3.7% non-HMR Report group patients per drug.  It was found there was little difference 
in the nature of drugs prescribed, or patterns of prescribing between the HMR and non-
HMR Report groups on discharge.  The total discharge prescriptions for ‘common’ 
drugs for the HMR Report group was 632 (94.3%) of the drugs common to both 
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subgroups.  Total discharge prescriptions for ‘common’ drugs for the non-HMR Report 
group were 1389 (88.2%) of drugs common to both subgroups.  These findings 
reinforced the representativeness of the HMR Report group (n=79) in prescribing for 
the non-HMR Report group (n=202) at discharge. 
 
[Data and analyses to support the above (Section 7.6.1.3) results are separately tabulated 
and attached in Table A in Appendix 7.1 at the end of this chapter.] 
 
7.6.1.4  Discharge Prescribing Unique to HMR Report Group  
 
Analysis of Table 7.1 shows the distribution of prescriptions and drugs unique to the 
HMR Report group (n=79), at discharge.  The discharge drugs prescribed for this group, 
showed a constant pattern of prescribing with 1 or 2 prescriptions for all drugs.  
 
It was noted that 1 patient in the HMR Report group was prescribed sibutramine 
(hydrochloride monohydrate) by the hospital medical team at discharge in 2007.  At 
date of these analyses of cohort discharge regimens, the marketing, supply or 
availability of sibutramine (in particular), had been restricted or withdrawn in Australia, 
Europe and the United States of America (USA).  
 
There were 29 drugs unique to the HMR Report group at discharge.  Nine 
different drugs were prescribed for 2 (2.5%) HMR Report group and each drug 
accounted for 0.3% total discharge prescriptions.  Prescriptions numbers ranged 
between 1– 2 prescriptions per drug.  On average, there were 0.4% HMR Report group 
patients prescribed each drug.  These unique drug prescriptions comprised just 38 
(5.7%) total discharge prescriptions and this small proportion further reinforced the 
representativeness of the bulk (94.3%) of the discharge prescriptions common to both 
groups. 
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[Data and analyses to support the above (Section 7.6.1.4) results are separately tabulated 
and attached in Table B in Appendix 7.1 at the end of this chapter.] 
 
7.6.1.5  Discharge Prescribing Unique to non-HMR Report Group  
 
Table 7.1 also shows the distribution of drugs, unique to the non-HMR Report group 
(n=202), which were prescribed at discharge.  Analysis of the discharge drugs 
prescribed for this group, showed a pattern of steady decrease in the number and nature 
of the drugs from the most to least frequently prescribed. 
Tramadol was the most frequently prescribed drug unique to the non-HMR 
Report group at discharge and was prescribed for 12 (5.9%) patients and accounted for 
0.8% total discharge prescriptions.  Codeine with paracetamol was prescribed for 11 
(5.4%) non-HMR Report patients and accounted for 0.7% total discharge prescriptions.  
There were 81 different discharge drugs prescribed for this group only, and numbers 
ranged between 1 – 12 prescriptions per drug.  On average, there were 0.5% non-HMR 
Report group patients prescribed each drug and prescriptions for drugs unique to this 
group comprised 186 (11.8%) total discharge prescriptions.  
 
[Data and analyses to support the above (Section 7.6.1.5) results are separately tabulated 
and attached in Table C in Appendix 7.1 at the end of this chapter.] 
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Table 7.1a Distribution of specific drugs prescribed for the HMR Report group (n=79) and 
non-HMR Report group (n=202) on discharge. 
  
Specific Drugs 
prescribed  
DISCHARGE: 
HMR Report Group n = 79 
DISCHARGE: 
non-HMR Report Group  
n = 202 
   Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Aspirin             54    8.1   68.4 128    8.1   63.4 
Clopidogrel                    40    6.0   50.6   95    6.0   47.0 
Atorvastatin                    30    4.5   38.0   85    5.4   42.1 
Glyceryl 
trinitratea           
  28    4.2 
 
  35.4    76    4.8 
 
  37.6 
Metoprolol                      24    3.6   30.4    65    4.1   32.2 
Frusemide                       32    4.8   40.5    53    3.4   26.2 
Warfarin                         13    2.0   16.5   40    2.5   19.8 
Perindopril 
arginineb          
  16    2.4 
 
  20.3    38    2.4 
 
  18.8 
Digoxin    19    2.8   24.1    34    2.2   16.8 
Isosorbide 
mononitrate 
  13    1.9 
 
  16.5   35    2.2 
 
  17.3 
Pantoprazole         19    2.9   24.1    35    2.2   17.3 
Simvastatin           26    3.9   32.9    30    1.9   14.9 
Potassium 
Chloride             
  12    1.8 
 
  15.2    28    1.8 
 
  13.9 
Carvedilol             10    1.5   12.7   26    1.6   12.9 
Ramipril                          7    1.0    8.9   25    1.6   12.4 
Omeprazole                     10    1.5   12.7    24    1.5   11.9 
Glyceryl trinitrate 
alternate form c 
   9    1.3 
 
  11.4   24    1.5 
 
  11.9 
Spironolactone                 7    1.0    8.9    24    1.5   11.9 
Magnesium 
aspartate 
  10    1.5 
 
  12.7   22    1.4 
 
  10.9 
Gliclazide     8    1.2   10.1   21    1.3   10.4 
Enoxaparin                       4    0.6    5.1   21    1.3   10.4 
Diltiazem                        10    1.5   12.7   18    1.1   8.9 
Salbutamol                       5    0.7    6.3   18    1.1    8.9 
Paracetemol                       4    0.6    5.1   18    1.1    8.9 
Nicorandil                        6    0.9    7.6   17    1.1    8.4 
Amiodarone                     1    0.2    1.3   17    1.1    8.4 
Sotalol                           3    0.4    3.8   16    1.0    7.9 
Cephalexin                       1    0.1    1.3   16    1.0    7.9 
aGlyceryl trinitrate: sublingual tablets only, also see alternate formc       b also see 
Perindopril with indapamided     cGlyceryl trinitrate: includes transidermal patch (8,23), 
spray (1,0) and ointment (0,1) 
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Table 7.1b Distribution of specific drugs prescribed for the HMR Report group (n=79) and 
non-HMR Report group (n=202) on discharge, continued. 
 
Specific Drugs 
prescribed  
DISCHARGE: 
HMR Report Group n = 79 
DISCHARGE: 
non-HMR Report Group  
n = 202 
 Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Irbesartan       12    1.8    15.2   15    1.0    7.4 
Docusate sodium      9    1.3   11.4   14    0.9    6.9 
Allopurinol          8    1.2   10.1   14    0.9   6.9 
Esomeprazole     3    0.4    3.8   14    0.9   6.9 
Pravastatin                       5    0.8    6.3   12    0.8    5.9 
Prednisolone                    4    0.6    5.1   12    0.8    5.9 
Tramadol                          0 0    0   12    0.8    5.9 
Oxycodone                1    0.2    1.3   11    0.7    5.4 
Codeine with 
Paracetamol   
   0 0 
 
   0   11    0.7    5.4 
Metformin     11    1.6   13.9    9    0.6    4.5 
Calcium 
carbonate     
   7    1.0 
 
   8.9    9    0.6    4.5 
Atenolol                 6    0.9    7.6    9    0.6    4.5 
Metoclopramide         0 0 0    9    0.6    4.5 
Thyroxine         10    1.5   11.4   10    0.6    5.0 
Tiotropium 
bromide             
   4    0.6 
 
   5.1   10    0.6    5.0 
Folic acid          3    0.4    3.8    8    0.5    4.0 
Fluticasone with 
salmeterole    
   1    0.1 
 
   1.3    8    0.5 
 
   4.0 
Thiamine                          1    0.1    1.3    8    0.5    4.0 
Fluticasonef         6    0.9    7.6    7    0.4    3.5 
Ferrous sulphate        4    0.6    5.1    7    0.4    3.5 
Insulin     4 0.6    5.1    7    0.4    3.5 
Rabeprazole       1    0.1 0.2    7    0.4    3.5 
Chloramphenicol 
eye drops    
   0 0 0    7    0.4 
 
   3.5 
Polyethylene glycol 
combinations 
   0 0 0    7    0.4 
 
   3.5 
Trimethoprim                   0 0 0    7    0.4    3.5 
Senna glycosides                  0 0 0    6    0.4    3.0 
Candesartan               3    0.4    0.5    5    0.3    2.5 
Prazosin                          3    0.4    3.8    5    0.3    2.5 
Bisoprolol                        2    0.3    2.5    5    0.3    2.5 
esee Fluticasonef       fsee Fluticasone with salmeterole 
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Table 7.1c Distribution of specific drugs prescribed for the HMR Report group (n=79) and 
non-HMR Report group (n=202) on discharge, continued 
 
Specific Drugs 
prescribed  
DISCHARGE: 
HMR Report Group n = 79 
DISCHARGE: 
non-HMR Report Group  
n = 202 
 Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Celecoxib                         2    0.3    2.5    5    0.3    2.5 
Ipratropium 
bromide             
   2    0.3 
 
   2.5    5    0.3    2.5 
Ezetimbe                          2    0.3    2.5    5    0.3    2.5 
Telmisartan                 2    0.3    2.5    5    0.3    2.5 
Amoxicillin with 
clavanulate   
   1    0.1 
 
   1.3    5    0.3    2.5 
Budesonide                       1    0.1    1.3    5    0.3    2.5 
Acetazolamide                  0 0 0    5    0.3    2.5 
Dextran eye drops    0 0 0    5    0.3    2.0 
Ergocalciferol                   0 0 0    5    0.3    2.5 
Gabapentin                       0 0 0    5    0.3    2.5 
Verapamil                5    0.7    6.3    4    0.3    2.0 
Ranitidine                        4    0.6    5.1    4    0.3    2.0 
Enalapril                         3    0.4    3.8    4    0.3    2.0 
Amlopidine                      2    0.3    2.5    4    0.3    2.0 
Aluminium 
combinations         
   2    0.3    2.5    4    0.3    2.0 
Perhexaline             2    0.3    2.5    4    0.3    2.0 
Roxithromycin                  2    0.3    2.5    4    0.3    2.0 
Amitriptyline           1    0.1    1.3    4    0.3    2.0 
Amoxicillin            1    0.1    1.3    4    0.3    2.0 
Colchicine             1    0.1    1.3    4    0.3    2.0 
Lisinopril                 1    0.1    1.3    4    0.3    2.0 
Cinchocaine and 
zinc oxide 
   0 0 0    4    0.3 
 
   2.0 
Citalopram             0 0 0    4    0.3    2.0 
Nicotine 
transdermal           
   0 0 0    4    0.3 
 
   2.0 
Perindopril with 
indapamided  
   8    1.2 
 
  10.1    3    0.2 
 
   1.5 
Nifedipine              4    0.6    5.1    3    0.2    1.5 
Alendronate      3    0.4    3.8    3    0.2    1.5 
Ciprofloxacin         1    0.1    1.3    3    0.2    1.5 
Darbepoetin alfa     1    0.1    1.3    3    0.2    1.5 
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Table 7.1d Distribution of specific drugs prescribed for the HMR Report group (n=79) and 
non-HMR Report group (n=202) on discharge, continued 
 
Specific Drugs 
prescribed  
DISCHARGE: 
HMR Report Group n = 79 
DISCHARGE: 
non-HMR Report Group  
n = 202 
 Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Fluoxetine              1    0.1    1.3    3    0.2    1.5 
Lactulose                1    0.1    1.3    3    0.2    1.5 
Quinine                   1    0.1    1.3    3    0.2    1.5 
Acetylcysteine         0 0 0    3    0.2    1.5 
Cephazolin     0 0 0    3    0.2    1.5 
Clindamycin           0 0 0    3    0.2    1.5 
Diclofenac               0 0 0    3    0.2    1.5 
Felodipine               0 0 0    3    0.2    1.5 
Flecainide               0 0 0    3    0.2    1.5 
Morphine              0 0 0    3    0.2    1.5 
Sodium chloride      0 0 0    3    0.2    1.5 
Trandolapril          0 0 0    3    0.2    1.5 
Captopril                 2    0.3    2.5    2    0.1    1.0 
Fosinopril               2    0.3    2.5    2    0.1    1.0 
Indomethacin          2    0.3    2.5    2    0.1    1.0 
Amphoteracin          1    0.1    1.3    2    0.1    1.0 
Cadexomer iodine    1    0.1    1.3    2    0.1    1.0 
Indapamide           1    0.1    1.3    2    0.1    1.0 
Risedronate          1    0.1    1.3    2    0.1    1.0 
Sodium Citrate 
/tartrate 
   1    0.1 
 
   1.3    2    0.1    1.0 
Ascorbic acid          0 0 0    2    0.1    1.0 
Baclofen                   0 0 0    2    0.1    1.0 
Dexamethasone 
eye drops        
   0 0 0    2    0.1    1.0 
Domperidone          0 0 0    2    0.1    1.0 
Dothiepin               0 0 0    2    0.1    1.0 
Haloperidol            0 0 0    2    0.1    1.0 
Ispaghula                0 0 0    2    0.1   1.0 
Metronidazole         0 0 0    2    0.1    1.0 
Mirtazapine          0 0 0    2    0.1    1.0 
Quinapril             0 0 0    2    0.1    1.0 
Vitamin 
compounds 
   0 0 0    2    0.1    1.0 
dsee Perindopril arginineb 
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Table 7.1e Distribution of specific drugs prescribed for the HMR Report group (n=79) and 
non-HMR Report group (n=202) on discharge, continued. 
 
Specific Drugs 
prescribed  
DISCHARGE: 
HMR Report Group n = 79 
DISCHARGE: 
non-HMR Report Group  
n = 202 
 Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Clotrimazole          5    0.7    6.3    1    0.1    0.5 
Sodium 
bicarbonate             
   4    0.6 
 
   5.1    1    0.1    0.5 
Carbamazepine       3    0.5    3.8    1    0.1    0.5 
Glimepiride            3    0.4    3.8    1    0.1    0.5 
Rosiglitazone         3    0.4    3.8    1    0.1    0.5 
Famotidine             2    0.3    2.5    1    0.1    0.5 
Flucloxacillin         2    0.3    2.5    1    0.1    0.5 
Methotrexate          2    0.3    2.5    1    0.1    0.5 
Temazepam           2    0.3    2.5    1    0.1    0.5 
Calcitriol                 1    0.1    1.3    1    0.1    0.5 
Cetamacrogol 
cream             
   1 
   0.1 
   1.3    1    0.1    0.5 
Diazepam                1    0.1    1.3    1    0.1    0.5 
Glipizide                1    0.1    1.3    1    0.1    0.5 
Hypromellose 
combinations  
   1 
   0.1 
   1.3    1    0.1    0.5 
Ibruprofen              1    0.1    1.3    1    0.1    0.5 
Imipramine            1    0.1    1.3    1    0.1    0.5 
Latanoprost           1    0.1    1.3    1    0.1    0.5 
Oestrogens             1    0.1    1.3    1    0.1    0.5 
Paraffin and wool 
fat           
   1 
   0.1 
   1.3    1    0.1    0.5 
Phenytoin               1    0.1    1.3    1    0.1    0.5 
Valproate                  1    0.1    1.3    1    0.1    0.5 
Aluminium 
hydroxide            
   0 0 0    1    0.1    0.5 
Betamethasone        0 0 0    1    0.1    0.5 
Biperiden               0 0 0    1    0.1    0.5 
Calcium with 
vitamin D comb.g 
   0 0 0    1    0.1    0.5 
Carbimazole           0 0 0    1    0.1    0.5 
Chlorhexidine 
gluconate       
   0 0 0    1    0.1    0.5 
Clodronate             0 0 0    1    0.1    0.5 
Cyclizine               0 0 0    1    0.1    0.5 
gcomb=combinations 
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Table 7.1f Distribution of specific drugs prescribed for the HMR Report group (n=79) and 
non-HMR Report group (n=202) on discharge, continued. 
 
Specific Drugs 
prescribed  
DISCHARGE: 
HMR Report Group n = 79 
DISCHARGE: 
non-HMR Report Group  
n = 202 
 Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Cyclosporine oral      0 0 0    1    0.1    0.5 
Diphenoxylate 
atropine         
   0 0 0    1    0.1    0.5 
Eplerenone              0 0 0    1    0.1    0.5 
Fluconazole            0 0 0    1    0.1    0.5 
Fluorouracil           0 0 0    1    0.1    0.5 
Gentamycin            0 0 0    1    0.1    0.5 
Hydro-
chlorothiazide            
   0 0 0    1    0.1    0.5 
Hydroxy-
chloroquine             
   0 0 0    1    0.1    0.5 
Hyoscine N-butyl 
bromide        
   0 0 0    1    0.1    0.5 
Lansprazole             0 0 0    1    0.1    0.5 
Lignocaine Oral      0 0 0    1    0.1    0.5 
Lithium carbonate    0 0 0    1    0.1    0.5 
Loperamide                 0 0 0    1    0.1    0.5 
Mesalazine             0 0 0    1    0.1    0.5 
Mometasone           0 0 0    1    0.1    0.5 
Nystatin                 0 0 0    1    0.1    0.5 
Oxazepam              0 0 0    1    0.1    0.5 
Paraffin emulsion     0 0 0    1    0.1    0.5 
Paroxetine 
hydrochloride       
   0 0 0    1    0.1    0.5 
Phenindione           0 0 0    1    0.1    0.5 
Polyvinyl alcohol 
with providone 
   0 0 0    1    0.1    0.5 
Prednisolone eye 
drops         
   0 0 0    1    0.1    0.5 
Prochlorperazine               0 0 0    1    0.1    0.5 
Propanolol                        0 0 0    1    0.1    0.5 
Rofecoxib                         0 0 0    1    0.1    0.5 
Silver 
sulfadiazine 
   0 0 0    1    0.1    0.5 
Sodium 
picosulphate with 
magnesium 
   0 0 0    1    0.1    0.5 
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Table 7.1g Distribution of specific drugs prescribed for the HMR Report group (n=79) and 
non-HMR Report group (n=202) on discharge, continued. 
 
Specific Drugs 
prescribed  
DISCHARGE: 
HMR Report Group n = 79 
DISCHARGE: 
non-HMR Report Group  
n = 202 
 Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Sorbitol & 
Sodium comb.g    
   0 0 0    1    0.1    0.5 
Sucralfate                       0 0 0    1    0.1    0.5 
Sulindac                          0 0 0    1    0.1    0.5 
Terbinafine                       0 0 0    1    0.1    0.5 
Testosterone             0 0 0    1    0.1    0.5 
Theophylline SR                 0 0 0    1    0.1    0.5 
Timolol                           0 0 0    1    0.1    0.5 
Triamcinolone- 
Orabase          
   0 0 0    1    0.1    0.5 
Tribolone                         0 0 0    1    0.1    0.5 
Urea                              0 0 0    1    0.1    0.5 
Voriconazole                  0 0 0    1    0.1    0.5 
Xylometazoline               0 0 0    1    0.1    0.5 
Erythropoietin                  2    0.3    2.5    0 0 0 
Lercandipine                     2    0.3    2.5    0 0 0 
Nofloxacin                        2    0.3    2.5    0 0 0 
Omega-3-
triglycerides          
   2    0.3    2.5    0 0 0 
Raloxifene                        2    0.3 2.5    0 0 0 
Venlafaxine                      2    0.3 2.5    0 0 0 
Zolpidem                          2    0.3 2.5    0 0 0 
Bupropion                        1    0.2    1.3    0 0 0 
Cephalexin                       1    0.1    1.3    0 0 0 
Codeine linctus                  1    0.1    1.3    0 0 0 
Cyanocabalamin                      1    0.1    1.3    0 0 0 
Cyproterone                       1    0.1    1.3    0 0 0 
Doxepin    1    0.1    1.3    0 0 0 
Eformoterol                      1    0.1    1.3    0 0 0 
Eprosartan                        1    0.1    1.3    0 0 0 
Framycetin               1    0.1    1.3    0 0 0 
Hydroxyethyl-
rutosides     
   1    0.1 
 
   1.3    0 0 0 
Medoxy-
progesterone with 
oestrogen 
   1    0.1 
 
 
1.3    0 0 0 
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Table 7.1h Distribution of specific drugs prescribed for the HMR Report group (n=79) and 
non-HMR Report group (n=202) on discharge, continued. 
 
Specific Drugs 
prescribed  
DISCHARGE: 
HMR Report Group n = 79 
DISCHARGE: 
non-HMR Report Group  
n = 202 
 Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Number 
pre-
scriptions 
% total 
pre-
scriptions 
% 
Patients 
Meloxicam                       1    0.1 1.3    0 0 0 
Pholcodine                       1    0.1 1.3    0 0 0 
Pioglitazone                     1    0.1 1.3    0 0 0 
Quinapril                         1    0.1 1.3    0 0 0 
Sertraline                        1    0.1 1.3    0 0 0 
Sibutramine    1    0.1 1.3    0 0 0 
Tamoxifen                         1    0.1 1.3    0 0 0 
Thalidomide                     1    0.1 1.3    0 0 0 
Ticarcillin with 
clavulanic acid 
   1 
   0.1 
1.3    0 0 0 
Discharge drugs 
for HMR group 
n=132, non-HMR 
group n=184 
 
670 
 
  100.0% 
 
 *6.4% 
 
1575 
 
  100.0% 
 
 *4.2% 
*Final averages for ‘% patients’ took into account the total number of discharge drugs for  
each subgroup.  Slight differences in % totals result from rounding errors.
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7.6.2  IDENTIFICATION OF POTENTIALLY INAPPROPRIATE PRESCRIBING (PIP)  
 
FOR THE  HMR REPORT GROUP 
 
 
7.6.2.1. Re-application of Beers criteria 
Table 7.2 shows the re-application of Beers criteria to the HMR Report group (n=79) to 
determine patient distribution, number of PIP instances and in particular, the nature of PIP 
drugs.  Patients’ drug regimen were analysed at discharge and at HMR.  Two drugs 
accounted for a high proportion of the PIP instances identified by Beers criteria and these 
are tabled in decreasing order of prescribing frequency at HMR service in Table 7.2. 
 
Clopidogrel was prescribed for 40 (50.6%) patients at discharge and prescribed for 
31 (39.2%) patients at HMR.  Clopidogrel accounted for 35.7% PIPs at discharge and 
31.0% PIPs at HMR.  At HMR, this was a reduction of 9 (11.4%) patients who were 
potentially inappropriately prescribed clopidogrel. 
 
Aspirin was prescribed for 31 (39.2%) patients at discharge and 29 (36.7%) 
patients at HMR.  Aspirin accounted for 27.7% PIPs at discharge and 29.0% PIPs at HMR.  
At HMR, this was a reduction of 2 (2.5%) patients who were potentially inappropriately 
prescribed aspirin.   
 
Amiodarone was prescribed for 1 (1.3%) patient at discharge and prescribed for 5 
(6.3%) patients at HMR.  Amiodarone accounted for 0.9% PIPs at discharge and 5.0% 
PIPs at HMR.  At HMR, this was an increase of 4 (5.1%) patients who were potentially 
inappropriately prescribed amiodarone. 
 
Table 7.2 shows there were 28 different PIP drugs identified at discharge and 23 at 
HMR.  Analysis showed 12 (5.2%) patients experienced a reduction of 10.7% PIPs 
between discharge and HMR.  After two opportunities for regimen reconciliation, at 
discharge and GP consultation, Beers criteria still identified 100 PIP instances recorded on 
HMR reports.  That is, an average of 1.3 PIP instances per patient. 
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7.6.2.2  Re-application of Basger Indicators  
Table 7.3 shows application of Basger indicators to the HMR Report group (n=79) to 
determine patient distribution, number of PIP instances and in particular, the nature of 
drugs associated with PIP instances.  Patients’ data were analysed from the same 
documents analysed for the application of Beers criteria.  When tabled in decreasing order 
of prescribing frequency at HMR service, there were four predominant PIP situations 
identified by Basger indicators. 
 
The most frequent PIP situation at discharge and HMR service was identified by 
Indicator No. 48 which required no change in medications within 90 days of assessment at 
discharge and HMR service.  Medication change affected 79 (100.0%) patients and 
accounted for 31.0% and 27.9% PIP instances at discharge and HMR, respectively. 
 
The second most frequent PIP situation at HMR service was identified by Indicator 
No. 4 which required patients with ischaemic heart disease (IHD); a history of myocardial 
infarction (MI); non-haemorrhagic stroke or transient ischaemic attack (TIA) to be taking 
an antiplatelet agent unless taking an oral anticoagulant.  The PIP omission of essential 
antiplatelet or oral anti-coagulant drugs was identified for 16 (20.3%) patients at discharge 
and 35 (44.3%) patients at HMR.  Antiplatelet agents and oral anticoagulants routinely 
prescribed for other patients in the group included clopidogrel, aspirin (<325mg/day), 
phenindione and warfarin.  The omissions accounted for 6.5% PIP instances at discharge 
and 12.4% PIP instances at HMR.  At HMR, an increase of 19 (24.1%) patients in the 
specified diagnoses related group (DRG) were not prescribed antiplatelet or anti-coagulant 
drugs. 
 
The third most frequent PIP situation at HMR service was identified by Indicator 
No. 2 which required patients with at high risk of a cardiovascular event to be taking a 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin).  The PIP 
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omission of these statins for patients in this DRG was identified for 22 (27.8%) patients at 
discharge and 25 (31.6%) patients at HMR.  Statins routinely prescribed for other patients 
in the group included atorvastatin, simvastatin and pravastatin.  At HMR, a slight increase 
of 3 (3.8%) patients in the specified DRG were not prescribed a statin.  
 
The fourth most frequent PIP situation at HMR was identified by Indicator No. 24 
which required that patients with risk factors for impaired renal function were not taking a 
non-steroidal anti-inflammatory drug (NSAID).  The PIP addition of NSAIDs for patients 
with these risk factors was identified for 10 (12.7%) and 24 (30.4%) patients at discharge 
and HMR, respectively.  The NSAIDs prescribed for these patients included celecoxib, 
ibuprofen, indomethacin, and meloxicam.  At HMR an increase of 14 (17.7%) patients 
with these risk factors were prescribed an NSAID.   
 
The drug related situations listed in Table 7.3, illustrate the complexity of reporting 
the PIP of specific drugs within a therapeutic classification or drug-related situation named 
by Basger indicators.  Analyses of PIP drug-related situations ‘at HMR’ service were 
conducted on lists of drugs and diseases in the HMR reports written by accredited 
pharmacists.  Their comments and recommendations were not taken into account.  
However, the predominant PIP situations reported above show the inclusion or omission of 
acetylsalicylic acid/aspirin and clopidogrel as the active ingredients with the most frequent 
potential for inappropriate prescribing. 
 
Table 7.3 shows there were 25 different PIP situations identified at discharge and 
24 at HMR, and an increase of 11.0% PIP instances at HMR.  After two opportunities for 
medication reconciliation at discharge and GP consultation, Basger indicators identified as 
many as 283 PIP instances in the 79 HMR reports assessed.  
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Table 7.2 Drugs identified as PIP by Beers criteria, for patients in the HMR Report group (n=79) at discharge and at HMR.36 
 
Specific drugs or dose identified as PIP by 
Beers criteria 
DISCHARGE: patients n = 79  HMR: patients n = 79 
 
 Number 
PIPs  
% total 
PIPs  
% 
Patients 
Number 
PIPs  
% total 
PIPs  
% 
Patients 
Clopidogrel  40   35.7 50.6  31   31.0 39.2 
Aspirin  31   27.7 39.2  29   29.0. 36.7 
Amiodarone   1     0.9   1.3    5    5.0   6.3 
Digoxin exceeding >0.125 µg daily 
 (except atrial arrhythmias) 
  3     2.7   3.8    3    3.0   3.8 
Indomethacin   2     1.8   2.5    3    3.0   3.8 
Mineral oil   0   0   0    3    3.0   3.8 
Nifedipine (Short acting)    4     3.6   5.1    2    2.0   2.5 
Sodium bicarbonate   2     1.8   2.5    2    2.0   2.5 
Amitriptyline   1    0.9   1.3    2    2.0   2.5 
Bupropion   1    0.9   1.3    2    2.0   2.5 
Phentermine    0   0   0    2    2.0   2.5 
Diclofenac   0   0   0    2    2.0   2.5 
Ketoprofen   0   0   0    2    2.0   2.5 
Sodium citrate/ tartrate   1     0.9   1.3    2    2.0   2.5 
Sodium picosulphate   0   0   0    2    2.0   2.5 
Valproate   2     1.8   2.5    1    1.0   1.3 
Diazepam   1     0.9   1.3    1    1.0   1.3 
Doxepin   1     0.9   1.3    1    1.0   1.3 
Imipramine   1    0.9   1.3    1    1.0   1.3 
Meloxicam   1    0.9   1.3    1    1.0   1.3 
Sertraline    1     0.9   1.3    1    1.0   1.3 
Paracetamol   0   0   0    1    1.0   1.3 
 
 Chapter 7 Identifying Patients at Risk       Page 233 
 
Table 7.2 Drugs identified as PIP by Beers criteria, for patients in the HMR Report group (n=79) at discharge and at HMR, continued.36  
 
Specific drugs or dose identified as PIP by 
Beers criteria 
DISCHARGE: n = 79 patients HMR: n = 79 patients 
 
 Number 
PIPs  
% total 
PIPs  
%  
patients 
Number 
PIPs  
% total 
PIPs  
% 
Patients 
Theophylline   0   0   0    1    1.0   1.3 
Docusate sodium combinations   5    4.5   6.3    0   0 0 
Ipratropium   2     1.8   2.5    0   0 0 
Magnesium aspartate   2     1.8   2.5    0   0 0 
Metoprolol   2     1.8   2.5    0   0 0 
Carbamazepine   1     0.9   1.3    0   0 0 
Ferrous sulphate >325 mg/day   1     0.9   1.3    0   0 0 
Fluoxetine   1     0.9   1.3    0   0 0 
Ibuprofen   1     0.9   1.3    0   0 0 
Oestrogens   1     0.9   1.3    0   0 0 
Perindopril   1     0.9   1.3    0   0 0 
Sibutramine   1     0.9   1.3    0   0 0 
Temazepam >15mg dose   1     0.9   1.3    0   0 0 
 
PIP drugs at discharge n=28 and at HMR n=23  
 
 
112 
 
100.0% 
 
    *5.3% 
 
   100 
 
100.0% 
 
    *5.5% 
PIPs = potentially inappropriate prescriptions.  *Final averages for ‘% patients’ took into account the total number of PIP drugs  
identified at discharge and HMR.  Slight differences in % totals result from rounding errors. 
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Table 7.3a Drug related situations identified as PIP by Basger indicators, for patients in the HMR Report group (n=79) at discharge and at 
HMR.35 
 
Drug related situation identified as appropriate 
prescribing by Basger Indicators.   
DISCHARGE: n = 79 patients 
Indicators not satisfied 
HMR: n = 79 patients 
Indicators not satisfied 
 
(All drug examples have been prescribed for ≥1 
patient) 
Number 
PIP 
instances  
% total 
PIP 
instances  
 
% 
patients 
Number 
PIP 
instances 
% total 
PIP 
instances 
 
% 
patients 
No. 48 Patient has not had significant change in 
medications in the previous 90 days. 
  79  31.0 100.0  79  27.9 
 
100.0 
 
No. 4 Patient with IHD or a history of MI is taking an 
antiplatelet agent unless taking an oral anticoagulant (c). 
 16    6.3   20.3  35 12.4 
 
44.3 
 
No. 2 Patient at high risk of a cardiovascular event (b) is 
taking an HMG-CoA reductase inhibitor (statin)  
 22    8.6   28.9  25 8.8 
 
32.1 
 
No 24 Patient with risk factors for impaired renal 
function (l) is not taking an NSAID 
 10    3.9   0  24 8.5 
 
30.4 
 
No. 36 Patient using a salbutamol (albuterol) or 
terbutaline inhaler more than three times per week for 
reversible airways disease has been prescribed an 
inhaled corticosteroid.   
  4    1.6     5.1  15 5.3 
 
 
 
19.0 
 
 
 
No. 33 Patient taking a PPI is not taking a medication 
that may cause dyspepsia (r) [e.g. betamethasone, 
fluticasone, perindopril, ramipril, diltiazem, ferrous 
sulphate >325 mg daily, alendronic acid, amlopidine, 
budesonide, verapamil] 
 25    9.8   31.6   13 27.9 
 
 
 
 
16.5 
 
 
 
 
No. 3 Patient with IHD or a history of MI is taking a β-
blocker (β-adrenoceptor antagonist)  
 16    6.3   20.3 12 12.4 
 
15.2 
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Table 7.3b Drug related situations identified as PIP by Basger indicators, for patients in the HMR Report group (n=79) at discharge and at 
HMR, continued.35 
 
Drug related situation identified as appropriate 
prescribing by Basger Indicators.   
DISCHARGE: n = 79 patients 
Indicators not satisfied 
HMR: n = 79 patients 
Indicators not satisfied 
 
(All drug examples have been prescribed for  
≥1 patient) 
Number 
PIP 
instances  
% total 
PIP 
instances  
 
% 
patients 
Number 
PIP 
instances  
% total 
PIP 
instances  
 
% 
patients 
No 16 Patient with diabetes at high risk of a 
cardiovascular event is taking an antiplatelet agent 
unless taking an anticoagulant (c) 
 10    3.9   12.7  10 3.5 
 
 
12.7 
 
 
No. 13 Patient with cardiovascular disease is not taking 
an NSAID [e.g. aspirin, celecoxib, ibuprofen, 
indomethacin, meloxicam] 
  6    2.4     7.6   8 2.8 
 
 
10.1 
 
 
No 22 Patient taking analgesics(s) does not have pain (j) 
that interferes with daily activities 
 30  11.8   38.0    7 2.5 
 
8.9 
 
No. 23 Patient taking an opioid (k) is taking 
prophylactic treatment for constipation.  
  1    0.4     1.3    7 2.5 
 
8.9 
 
No. 6 Patient with heart failure is taking an ACE 
inhibitor or ARB. 
  7    2.7     8.9 5 1.8 
 
6.3 
 
No. 9 Patient with AF is taking an oral anticoagulant. 
 
   4    1.6     5.1    5 1.8 
 
6.3 
 
No 37 Patient with asthma is not taking a medication 
that may worsen asthma (s) 
   2    0.8     2.5    5 1.8 
 
6.3 
 
No. 42 Patient with osteoporosis who is not receiving at 
least 600IU vitamin D daily from dietary sources is 
receiving supplementation with vitamin D (u)  
  2    0.8     2.5    5 1.8 
 
 
6.3 
 
No. 5 Patient with heart failure is taking a β-blocker  
 
  8    3.1   10.1   4 1.4 
 
5.1 
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Table 7.3c Drug related situations identified as PIP by Basger indicators, for patients in the HMR Report group (n=79) at discharge and at 
HMR, continued.35 
 
Drug related situation identified as appropriate 
prescribing by Basger Indicators.   
DISCHARGE: n = 79 patients 
Indicators not satisfied 
HMR: n = 79 patients 
Indicators not satisfied 
 
(All drug examples have been prescribed for  
≥1 patient) 
Number 
PIP 
instances  
% total 
PIP 
instances  
 
% 
patients 
Number 
PIP 
instances  
% total 
PIP 
instances  
 
% 
patients 
No. 17 Patient with diabetes is not taking a medication 
that may increase or decrease blood glucose 
concentration [e.g. prednisolone] 
  0   0   0    4 1.4 
 
 
1.4 
 
 
No. 7 Patient with heart failure is not taking medications 
that may exacerbate heart failure (d) [e.g. sotalol, 
carbamazepine, quinine, nifedipine, verapamil, 
rosiglitazone] 
   2    0.8     2.5    3 1.1 
 
 
 
1.1 
 
 
 
No 11 Patient with a history of non-haemorrhagic stroke 
or TIA is taking an antiplatelet agent unless taking an 
anticoagulant (c) 
   1    0.4     1.3    3 1.1 
 
 
1.1 
 
 
No. 32 Patient is not taking more than one medication 
with anticholinergic activity (q) [e.g. amitriptyline + 
prochlorperazine; imipramine + tiotropium bromide + 
doxepin; imipramine +tiotropium bromide] 
  1    0.4     1.3    3 1.1 
 
 
 
1.1 
 
 
 
No. 44 Patient with osteoporosis is receiving anti-
osteoporotic medication (w)  
  1    0.4     1.3    3 1.1 
 
1.1 
 
No. 12 Patient with risk factors for myopathy (f) is not 
taking ≥40mg/day of simvastatin or atorvastatin.  
  0   0   0   2 0.7 
 
0.7 
 
No. 21 Patient with OA pain interfering with daily 
activities has been trialled on paracetamol 
(acetaminophen) 2-4g/day. 
  1    0.4     1.3    2 0.7 
 
 
0.7 
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Table 7.3d Drug related situations identified as PIP by Basger indicators, for patients in the HMR Report group (n=79) at discharge and at 
HMR, continued.35 
 
Drug related situation identified as appropriate 
prescribing by Basger Indicators.   
DISCHARGE: n = 79 patients 
Indicators not satisfied 
HMR: n = 79 patients 
Indicators not satisfied 
 
(All drug examples have been prescribed for ≥1 
patient) 
Number 
PIP 
instances  
% total 
PIP 
instances  
 
% 
patients 
Number 
PIP 
instances 
% total 
PIP 
instances 
 
% 
patients 
No. 25 Patient is not concurrently taking an ACE 
inhibitor or ARB, diuretic and NSAID (excluding low-
dose aspirin (acetylsalicylic acid)) [e.g. perindopril, 
ramipril, telmisartan, irbesartan with frusemide or 
spironolactone and indomethacin] 
  3    1.2     3.8 2 0.7 
 
 
 
 
2.5 
 
 
 
 
No 29 Patient taking an SSRI is not concurrently taking 
medications known to increase the risk of 
gastrointestinal bleeding (o) [e.g. fluoxetine + warfarin]  
   2    0.8     2.5 1 0.4 
 
 
1.3 
 
 
No. 43 Patient with osteoporosis who is not receiving at 
least 1200mg calcium daily from dietary sources is 
receiving calcium supplementation. 
  1    0.4     1.3 1 0.4 
 
 
1.3 
 
 
No 30 Patient taking an SSRI is not currently taking 
other medications that may contribute to serotonin 
toxicity (p). 
1    0.4     1.3 0 0 
 
 
0 
 
 
PIP situations at discharge n=25 and HMR  
n= 24 
 
255 
 
 100.0% 
 
  *12.9% 
 
283 
 
  100.0% 
 
*14.9% 
PIPs = potentially inappropriate prescriptions.  *Final averages for ‘% patients’ took into account the total number of PIP situations at 
discharge and HMR.  Slight differences in % totals result from rounding errors.  (a)-(w) = see appendix 7.2   
ACE = angiotensin converting enzyme.   ARB = angiotensin receptor blocker.   AF = atrial fibrillation.  CV = cardiovascular.   IHD = 
ischaemic heart disease.   MI = myocardial infarction.   NSAIDs = non-steroidal anti-inflammatory drugs.   PPI = proton pump inhibitor.   
SSRI = selective serotonin reuptake inhibitor. TIA = transient ischaemic attack.   
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7.6.3  IDENTIFICATION OF POTENTIALLY INAPPROPRIATE PRESCRIBING (PIP) 
FOR CofCP COHORT 
 
Tables 7.4, 7.5, and 7.6 show the results of application of Beers criteria, for the 
identification of PIP, to the regimens of the full study cohort (n=281) at discharge.  These 
tables show the distribution of patients, PIP drugs, and the nature of those drugs by their 
division into the HMR Report group (n=79) and non-HMR Report group (n=202).   
 
The identified PIP drugs are tabulated to show drugs common to both groups, and 
drugs prescribed for the HMR or non-HMR Report groups only.  For comparison, the 
tables show the number and nature of the PIP drugs in decreasing prescription frequency 
for the non-HMR Report group.  These three tables show the relativity of results to the 
groups’ total PIP data and to the  total number of drugs prescribed at discharge.  
Explanations of the analyses are shown as footnotes to the tables. 
 
7.6.3.1  Potentially Inappropriate Prescriptions (PIPs) for Drugs Common to  
 
Subgroups 
 
 
In Table 7.4, analysis of the cohort’s discharge regimen identified the predominance of 
three PIP drugs common to both the HMR and non-HMR Report groups. 
Aspirin was the most frequently prescribed PIP drug common to both groups and 
was prescribed for 31 (39.2%) HMR Report group patients and 128 (63.4%) non-HMR 
Report group patients.  Aspirin prescriptions accounted for 27.2% and 27.8% of total PIPs, 
respectively.  The ratio of aspirin prescriptions to total discharge prescriptions was 4.6% 
HMR and 8.1% non-HMR Report group discharge prescriptions.   
 
Clopidogrel followed aspirin in frequency as a common PIP drug and was 
prescribed for 40 (50.6%) HMR and 95 (47.0%) non-HMR Report group patients.  
Clopidogrel accounted for 35.1% and 20.6% of total PIPs, respectively.  The ratio of 
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clopidogrel prescriptions to total discharge prescriptions was 6.0% discharge prescriptions 
for both subgroups.   
Metoprolol as a common PIP drug, was prescribed for 2 (2.5%) HMR and 65 
(32.2%) non-HMR Report group patients.  Metoprolol prescriptions accounted for 1.8% 
and 14.1% of total PIPs, respectively.  The ratio of metoprolol prescriptions to total 
discharge prescriptions was 0.3% HMR and 4.1% non-HMR Report group discharge 
prescriptions.  This result showed a markedly higher prescribing rate for the non-HMR 
Report group.  
 
In Table 7.4 the HMR Report group showed a total of 108 PIPs for drugs common 
to both subgroups and the non-HMR Report group showed 411 PIPs for drugs common to 
both subgroups at discharge.  There were 24 different PIP drugs identified as common to 
both groups.  On average, 4.7% HMR and 4.8% non-HMR Report patients were exposed 
to these common PIP drugs.   
 
Of the PIPs for drugs common to both subgroups, and although imprecise, the 
HMR Report group averaged between 1.0 and 2.0 PIPs per patient and the non-HMR 
Report group averaged 2.0 PIPs per patient.  Prescriptions for PIP drugs common the both 
subgroups accounted for 94.7% and 89.2% total PIPs, respectively.  The ratio, of PIPs for 
drugs common to both groups to total discharge prescriptions for each group, was 16.1% 
HMR Report group and 26.1% non-HMR Report group.  
 
7.6.3.2  Potentially Inappropriate Prescriptions (PIPs) for Drugs Unique to  
 
the HMR Report Group 
 
 
In Table 7.5 analysis of the cohort’s discharge regimen identified very few PIP drugs 
unique to the HMR Report group only.  Venlafaxine was prescribed for 2 (2.5%) HMR 
Report group patients and was 1.8% of total PIPs with a ratio of 0.3% PIPs to total 
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discharge prescriptions.  The remainder of the drugs were prescribed for 1 (1.3%) HMR 
Report Group patient and each drug accounted for just 0.9% total PIPs.  The ratio, of each 
of these PIPs to total discharge prescriptions, was 0.1%.   
Table 7.5 shows a total of 6 prescriptions and 5 different PIP drugs unique to the 
HMR Report group.  On average, 0.3% HMR Report group patients were exposed to these 
drugs and prescriptions accounted for 5.3% total PIPs.  The ratio, of PIPs for drugs unique 
to the HMR Report group to their total discharge prescriptions, was 0.9%.  
 
7.6.3.3  Potentially Inappropriate Prescriptions (PIPs) for Drugs Unique to  
 
the non-HMR Report Group 
 
In Table 7.6 analysis of the cohort’s discharge regimen identified one PIP drug which was 
predominant and unique to the non-HMR Report group.  Tramadol was the most 
frequently identified PIP drug prescribed for the non-HMR Report group only, at 
discharge.  Tramadol was prescribed for 12 (5.9%) non-HMR patients and accounted for 
2.6% total PIPs.  The ratio of tramadol prescriptions to total discharge prescriptions was 
0.8%.   
 
Table 7.6 shows a total of 50 prescriptions and 18 different PIP drugs unique to the 
non-HMR Report group.  On average, 0.6% non-HMR Report group patients were 
exposed to these drugs and prescriptions accounted for 10.8% total PIPs. The ratio, of PIPs 
for drugs unique to the non-HMR Report group to the group’s total discharge 
prescriptions, was 3.2%.  
 
7.6.3.4  Potentially Inappropriate Prescriptions (PIPs) for the CofCP Cohort  
 
The results in Tables 7.4, 5 and 6 for PIP drugs common to the subgroups and unique to 
each subgroup, give an overview of the potentially inappropriate prescribing for the CofCP 
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cohort.  Application of Beers criteria to the discharge regimen of the full study cohort 
(n=281) revealed the predominance of aspirin and clopidogrel for both subgroups followed 
by metoprolol for the non-HMR Report group as the most frequent PIP drugs for the 
CofCP cohort.  Taking into account the PIP drugs which were common and unique to the 
subgroups, there were 47 different PIP drugs identified on discharge for the cohort. 
 
As shown in Figure 7.1, the HMR Report group ratio of 114 PIPs to 670 discharge 
prescriptions was 17.0%.  For the non-HMR Report group, the ratio of 461 PIPs to 1575 
discharge prescriptions was 29.3%.  Total PIPs for the cohort averaged 2.0 PIPs per 
patient.  For the CofCP cohort, the ratio of total 575 PIPs to total 2245 discharge 
prescriptions was 25.6%. 
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Table 7.4. Distribution of patients and PIPs for specific drugs identified by Beers criteria and common to both the HMR Report group 
(n=79) and non-HMR Report group (n=202) on discharge.36  
 
Specific drug or dose 
identified by Beers criteria 
as PIP 
DISCHARGE: HMR Report Group 
n = 79 patients 
 n= 670 discharge prescriptions  
DISCHARGE: non-HMR Report Group 
n = 202 patients 
 n = 1575 discharge prescriptions  
 Number 
PIPs  
% total 
PIPs* 
% 
Patients 
% ratio PIPs 
to discharge 
prescriptions 
Number 
PIPs 
% total 
PIPs* 
% 
Patients 
% ratio PIPs 
to discharge 
prescriptions 
Aspirin  31 27.2  39.2 4.6 128  27.8  63.4 8.1 
Clopidogrel  40 35.1  50.6 6.0  95  20.6  47.0 6.0 
Metoprolol    2    1.8    2.5 0.3  65  14.1  32.2 4.1 
Perindopril    1    0.9    1.3 0.1  30    6.5  14.9 1.9 
Magnesium aspartate    2    1.8    2.5 0.3  22    4.8  10.9 1.4 
Docusate sodium     5    4.4    6.3 0.9  17    3.7    8.4 1.1 
Amiodarone    1    0.9    1.3 0.2  17    3.7    8.4 1.1 
Digoxin >0.125mg daily 
except in atrial arrhythmias 
   3 
 
   2.6 
 
   3.8 
 
0.4 
 
   7 
 
   1.5 
 
   3.5 
 
0.4 
 
Amitriptyline     1    0.9    1.3 0.1    4    0.9    2.0 0.3 
Ipratropium bromide     2    1.8    2.5 0.3    5    1.1    2.5 0.3 
Ferrous sulphate>325mg/d    1    0.9    1.3 0.1    3    0.7    1.5 0.2 
Fluoxetine    1    0.9    1.3 0.1     3    0.7    1.5 0.2 
Nifedepine (short acting)    4    3.5    5.1 0.6    3    0.7    1.5 0.2 
Indomethacin    2    1.8    2.5 0.3    2    0.4   1.0 0.1 
Sodium bicarbonate    2    1.8    2.5 0.3    1    0.2    0.5 0.1 
Valproate    2    1.8    2.5 0.3    1    0.2    0.5 0.1 
Bupropion    1    0.9    1.3 0.1    1    0.2    0.5 0.1 
Carbamazepine    1    0.9    1.3 0.1    1    0.2    0.5 0.1 
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Table 7.4. Distribution of patients and PIPs for specific drugs identified by Beers criteria and common to both the HMR Report group 
(n=79) and non-HMR Report group (n=202) on discharge, continued.36  
 
Specific drug or dose 
identified by Beers criteria 
as PIP  
DISCHARGE: HMR Report Group 
n = 79 patients 
 n= 670 discharge prescriptions  
DISCHARGE: non-HMR Report Group 
n = 202 patients 
 n = 1575 discharge prescriptions  
 Number 
PIPs  
% total 
PIPs* 
% 
Patients 
% ratio PIPs 
to discharge 
prescriptions 
Number 
PIPs 
% total 
PIPs* 
% 
Patients 
% ratio PIPs 
to discharge 
prescriptions 
Diazepam    1    0.9    1.3 0.1    1    0.2    0.5 0.1 
Ibuprofen    1    0.9    1.3 0.1    1    0.2    0.5 0.1 
Imipramine    1    0.9    1.3 0.1    1    0.2    0.5 0.1 
Oestrogens    1    0.9    1.3 0.1    1    0.2    0.5 0.1 
Sodium citrate/tartrate    1    0.9    1.3 0.1    1    0.2    0.5 0.1 
Temazepam >15mg dose    1    0.9    1.3 0.1    1    0.2    0.5 0.1 
PIP drugs common to 
HMR and non-HMR 
group n=24 
 
108 
 
 
94.7% 
 
 
 
  **4.7%   16.1% 
 
 
 411  
 
 
 89.2% 
 
 
  **4.8% 
 
 
 
    26.1% 
*% PIPs are relative to total PIPs for the subgroup at discharge i.e. HMR group n=114 or non-HMR group n=461.  **Final averages  
for ‘% patients’ took into account the total number of PIP drugs identified for each subgroup i.e. HMR group n=29 or non-HMR  
group n=42.   Slight differences in % totals result from rounding errors. 
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Table 7.5. Distribution of patients and PIPs for specific drugs identified by Beers criteria 
and unique to the HMR Report group (n=79), on discharge.36  
 
Specific drug or dose 
identified by Beers criteria 
as PIP 
DISCHARGE: HMR Report Group 
n = 79 patients 
 n = 670 discharge prescriptions 
 Number 
PIPs  
% total 
PIPs* 
% 
Patients 
% ratio PIPs 
to discharge 
prescriptions 
Venlafaxine  2    1.8 2.5 0.3 
Doxepin  1    0.9 1.3 0.2 
Meloxicam 1    0.9 1.3 0.2 
Sertraline  1    0.9 1.3 0.2 
Sibutramine  1    0.9 1.3 0.2 
PIP drugs for HMR group 
only n=5 
 
6 
 
      5.3% 
 
 
**0.3%    0.9% 
 
*% PIPs are relative to total PIPs for the subgroup at discharge i.e. HMR Report group 
n=114.    **Final averages for ‘% patients’ took into account the total number of PIP drugs 
for the subgroup i.e. HMR Report group n=29.  Slight differences in % totals result from 
rounding errors. 
 
 
 
 
Table 7.6 Distribution of patients and PIPs for specific drugs identified by Beers criteria 
and unique to the non-HMR Report group (n=202), on discharge.36 
 
Specific drug or dose 
identified by Beers criteria 
as PIP 
DISCHARGE: non-HMR Report Group 
n = 202 patients 
 n = 1575 discharge prescriptions 
 Number 
PIPs  
% total 
PIPs* 
% 
Patients 
% ratio PIPs 
to discharge 
prescriptions 
Tramadol  12    2.6    5.9 0.8 
Diltiazem    6    1.3    3.0 0.4 
Celecoxib     5    1.1    2.5 0.3 
Citalopram    3    0.6    1.5 0.2 
Diclofenac    3    0.6    1.5 0.2 
Ezetimbe    3    0.6    1.5 0.2 
Prazosin    3    0.6    1.5 0.2 
Amlodipine    2    0.4    1.0 0.1 
Dothiepin    2    0.4    1.0 0.1 
Felodipine    2    0.4    1.0 0.1 
Metoclopramide    2    0.4    1.0 0.1 
Hyoscine N-butyl bromide    1    0.2    0.5 0.1 
Mirtazapine    1    0.2    0.5 0.1 
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Table 7.6 Distribution of patients and PIPs for specific drugs identified by Beers criteria 
and unique to the non-HMR Report group (n=202), on discharge, continued36 
 
Specific drug or dose 
identified by Beers criteria 
as PIP 
DISCHARGE: non-HMR Report Group 
n = 202 patients 
 n = 1577 discharge prescriptions 
 Number 
PIPs  
% total 
PIPs* 
% 
Patients 
% ratio PIPs 
to discharge 
prescriptions 
Oxazepam >60mg    1    0.2    0.5 0.1 
Paroxetine    1    0.2    0.5 0.1 
Prochlorperazine    1    0.2    0.5 0.1 
Sulindac    1    0.2    0.5 0.1 
Theophylline SR    1    0.2    0.5 0.1 
PIP drugs for non-HMR 
group only n=18 
 
50 
 
     10.8% 
 
 
   **0.6%    3.2% 
 
*% PIPs are relative to total PIPs for the subgroup at discharge i.e. non-HMR Report 
group n=461.    **Final averages for ‘% patients’ took into account the total number of PIP 
drugs for the subgroup i.e. non-HMR group n=42.  Slight differences in % totals result 
from rounding errors. 
   
 
 
 
7.7  DISCUSSION      
 
The aim of this study was achieved by determining the nature and appropriateness of drug 
regimen prescribed for patients in the CofCP cohort (n=281) who were discharged from an 
acute care cardiology unit.  The CofC cohort was comprised of the HMR Report group 
(n=79) and non-HMR Report group (n=202).  The concept underlying the aim of research 
in this chapter, centred around revealing any risks to patients wellbeing and any 
discontinuity in their care on and after hospital discharge.3,59  
 
After assessment of the discharge regimen prescribed for the full CofCP cohort 
(n=281), this study found that aspirin and clopidogrel were the drugs of first choice for 
treatment of many patients in the cardiology unit at Westmead hospital.  The HMR and 
non-HMR Report subgroups were both prescribed aspirin at 8.0%; clopidogrel at 6.0%;  
and atorvastatin at 5.0% total discharge prescriptions.  
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The subgroups showed a highly comparable, gradual reduction from the most to 
least frequent prescription of the same drugs.  These results suggest the majority non-
HMR Report group’s drug regimens follow the same general patterns of prescribing 
established for the minority HMR Report group (Ellitt et al. 2010) and reported in 
Chapter 3.8,215  That research showed the larger proportion (53.4%) of drugs for the 
subgroup were prescribed for chronic co-morbidities, and markedly increased the 
cardiovascular patients’ exposure to polypharmacy and their potential for drug related 
problems.4,41   
 
During research on drug-drug interactions (DDIs) Buajordet et al (2001) 
specifically named antithrombotic drugs such as aspirin, warfarin, heparins and drugs 
for treating coronary heart disease and heart failure, as problematic.  Problematic drugs 
also included e.g. diuretics, nitrates, ACE inhibitors and calcium channel blockers, 
which were reported as responsible for 50.4% of identified drug related, fatal adverse 
events.41  A clear correlation between multiple comorbidity and polypharmacy was 
apparent and Buajordet et al. suggested fatalities resulted from inappropriate drug 
prescribing, especially at hospital discharge.41-42 
 
In the literature, polypharmacy is claimed to exacerbate the high risk of adverse 
reaction to cardiovascular drugs and is reported as the prescribing of ≥5 drugs which 
increases the number of potential drug interaction combinations per patient.40,44-45   
Hence in this study, the discharge prescribing of 8.0 prescriptions per patient evidenced 
the level of polypharmacy and risk experienced by the full cohort of cardiovascular 
patients.43,60-61  
 
This level of prescribing in a similar cardiovascular cohort was evidenced by 
Straubhaar et al.44  Analysis of drugs prescribed on discharge and common to the 
subgroups showed the prescribing representativeness of the minority subgroup in 
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discharge prescription frequency and drug nature.  In addition to the minimal number of 
unique drugs identified, 94.3% HMR Report group’s discharge prescriptions were for 
identical drugs prescribed for the non-HMR Report group at discharge. 
 
 In this study, a comprehensive assessment of drug regimen for the HMR Report 
subgroup by re-application of Beers criteria identified unacceptable levels of PIP.26,33,36  
These were identified on the group’s discharge from hospital and again, after 
consultation with their GP, at an arranged HMR service.26,33,45   
 
Analysis of data ‘at discharge’ was conducted on lists of drugs or diseases in 
discharge summaries and ‘at HMR’ service on lists of drugs or diseases in HMR reports 
written by accredited pharmacists.  The pharmacists’ comments and recommendations 
in the report, were not taken into account.  Beers criteria revealed the inclusion of 
clopidogrel and aspirin in the subgroup’s drug regimen was by far the most frequent PIP 
drugs identified by international prescribing criteria.26,48,46 
 
It was noted that re-application of Beers criteria, with emphasis on analysis of 
the nature of identified PIP drugs, revealed prescription of sibutramine which was 
withdrawn from the Australian market in October 2010.227  Also in 2010, sibutramine 
was no longer available in the USA and was suspended by the European Medicines 
Agency. 62-64   
 
When prescribed for a patient in the HMR Report group at hospital discharge, 
sibutramine as an appetite suppressant for weight loss,64 was grouped within ‘anorexic 
agents’ in Beers criteria No 27 in Chapter 5.  It was only apparent that this drug had 
been prescribed at discharge and discontinued at HMR service when the nature (active 
ingredients) of specific drugs within therapeutic classifications were targeted in this 
chapter. 
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 Basger indicators were re-applied ‘at discharge’ and ‘at HMR’ service to lists of 
drugs or diseases in discharge summaries or HMR reports written by accredited 
pharmacists, respectively.  The pharmacists’ comments and recommendations in the 
report, were not taken into account.   
 
Re-application of Basger indicators, developed for the Australian healthcare 
system, re-identified recent changes in medicines as the most frequently encountered 
PIP.  This outcome was consistent with research by Straubhaar et al. (2006).  These 
researchers found 739 (63.1%) potential drug-drug interactions (DDIs) resulted from 
medication change in a Swiss cohort of cardiovascular patients.44  These potential DDIs 
were 190 (16.2%) total DDIs at discharge.   
 
In this chapter, the re-application of Basger indicators showed medication 
change was only marginally more frequent than the omission of antiplatelet or oral anti-
coagulant drugs.  These were reported as essential to the treatment of cardiovascular 
disease in Australia and, in the study cohort, were identified as low dose aspirin and 
clopidogrel.33,65-66  
 
The re-application of Basger indicators to determine the nature of identified PIP 
did not reveal the prescription of sibutramine which was detected by re-application of 
Beers criteria in this chapter.  Although sibutramine was listed as a drug to avoid in 
Basger Indicator No. 30, sibutramine was not identified as being PIP at discharge.  
Indicator No 30 required that patients taking a selective serotonin reuptake inhibitor 
(SSRI) were not currently taking other medications that may contribute to serotonin 
toxicity.  Sibutramine was included in the list of other medications (Appendix 6.1).33  
On checking the regimen of the patient prescribed sibutramine it was found the patient 
was not prescribed an SSRI and attracted no further assessment by this indicator.   
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 In this study it was found, that regardless of whether aspirin and clopidogrel 
were potentially inappropriately included or omitted, analyses clearly indicated the need 
for patient focussed vigilance in considering their prescription.41,44  That is, at both 
hospital discharge and GP consultation.  After discharge, application of Beers criteria to 
HMR reports revealed a 10.7% decrease from 112 PIP instances and Basger showed a 
15.5% increase from 245 PIP instances, after GP consultation.  Notably within those 
differences, aspirin and clopidogrel still dominated the high level of PIP drugs 
requiring, at least, the opportunity for identification of potential risk by pharmacists 
during medication review in the community.16,67  
 
After re-application of Beers criteria and Basger indicators to the subgroup, the 
application of Beers criteria to the CofCP cohort (n=281) identified the PIP drugs that 
were common and unique to the HMR and non-HMR Report subgroups.31-32,68  Analysis 
of drugs prescribed on discharge and PIP drugs common to both subgroups showed the 
marked dominance of prescriptions for aspirin 159 (56.6%) patients and clopidogrel 137 
(48.8%) patients.  These drugs were shown to expose the full cohort to the potential risk 
of inappropriate prescribing at discharge from an Australian teaching hospital when 
analysed by explicit international criteria.   
 
In Switzerland, Straubhaar et al. (2006) conducted potential DDI research using 
a ‘sensitive’ computerized drug interaction program which like Beers criteria, was 
predominantly drug, not class specific.44  Straubhaar et al. found aspirin and clopidogrel 
were prescribed for 193 (48.3%) of 400 cardiovascular patients discharged from a Swiss 
University hospital.   
 
Although the combination of these two drugs was identified by Straubhaar et al. 
in the ten most prevalent potential DDI combinations, out of 739 identified DDIs, it was 
rated as of minor severity.  In the Swiss cohort, the prescription of ACE inhibitors with 
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potassium sparing diuretics was found to be the most frequently prescribed combination 
with potential for inappropriate prescribing for 64 (16.0%) patients. 44 
Identification of PIP for the CofCP cohort, reinforced the representativeness of 
the smaller HMR Report group (n=79) to the larger non-HMR Report group (n=202) in 
PIP frequency and drug nature.  This was evidenced by the minimal number of PIP 
prescriptions and drugs identified as unique to the subgroup on discharge.  
Representativeness of the HMR Report group was further evidenced by results showing 
94.7% PIPs at discharge were for identical PIP drugs prescribed for the non-HMR 
Report group.   
The full study cohort of 281 patients was written 670 prescriptions for drugs 
with the potential for inappropriate prescription which was 25.6% of their total 
discharge prescriptions.  Aspirin and clopidogrel were the two most frequently, and 
predominantly prescribed discharge drugs and were identified as the most frequent PIP 
drugs identified for both subgroups.  At discharge, the majority non-HMR Report group 
of patients were shown to be exposed to 60.3% more instances of PIP than the minority 
HMR Report group.  Importantly and in addition to this increased risk, the non-HMR 
Report group lacked the opportunity for medication reconciliation at HMR.16,24,39,69   
 
7.8 STUDY STRENGTHS AND LIMITATIONS 
Many of the specific drug related findings of this study, for a recently discharged 
Australian cohort of cardiovascular patients, cannot be generalised to elderly subjects in 
different DRGs or countries.  These findings on the prescribing appropriateness of 
specific drugs were influenced by the availability of drugs and prescribing practices in 
Australia and were, in part, assessed by international criteria.  In this research, the 
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problem was addressed by the parallel application of prescribing criteria developed for 
the Australian healthcare system.   
 
 However, the general findings applicable to the accuracy and completeness of 
hospital discharge protocols and the need for integrated, interdisciplinary transfer of 
patients from hospital to community care, apply to all healthcare systems.  It was not 
possible to check the accuracy and completeness of all documentation in medical 
records, discharge summaries and HMR reports used as data sources.  Hence, these data 
were accepted at face value as a reflection of the documentation in the current 
Australian healthcare environment. 
 
7.9  CONCLUSION 
The study in this chapter showed how cardiovascular patients were exposed to the risks 
associated with PIP and, in detail, the nature of specific drugs prescribed for them at 
discharge by the hospital medical team.  It was found the outcomes of PIP investigation 
was markedly influenced by the design of the tool chosen for its identification.  
However both Beers criteria and Basger indicators revealed unacceptable levels of PIP 
at both discharge and at HMR service.  Further, both methods identified clopidogrel and 
aspirin, either prescribed or omitted, as potentially inappropriate prescribing.  
 
The first objective of this chapter study was to determine the nature and 
distribution of drugs prescribed at discharge from hospital, for the full CofCP cohort.  
The extent of polypharmacy (≥8.0 drugs), the number of prescriptions, and specific 
nature and pattern of discharge prescribing was shown to be a clinical characteristic 
replicated in the subgroups.  The prescription of clopidogrel and aspirin was shown to 
dominate the cohort’s discharge regimens.   
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It was found that 94.3% of the drugs prescribed for the HMR Report group were 
also prescribed for the non-HMR Report group at discharge.  The prescription of drugs 
unique to the minority subgroup only, was negligible.  Hence, the HMR Report group 
was shown as representative of the cohort for discharge prescribing.  The level of 
polypharmacy compromised the ongoing wellbeing of the 281 patients at discharge.  
 
The second objective of this study was to identify the extent and, in particular,  
the active ingredient as the nature of any PIP for the HMR Report group on and after 
discharge.  The re-application of Beers criteria and Basger indicators re-identified the 
subgroups’ high number of PIP instances at both discharge and at HMR in terms of the 
specific drugs prescribed.   
 
It was found the clear potential for inappropriate prescribing of clopidogrel and 
aspirin undermined the safe management of the HMR Report group’s drug regimens, 
even after GP consultation in the community.  It was opportune that this subgroup had 
the benefit of post discharge HMR service for their potential drug-related problems to 
be managed and reported to the patients’ GPs. 
 
The third objective was to identify any PIP on discharge from the hospital for 
the CofCP cohort.  It was shown that 25.6% of the cohorts’ discharge prescriptions were 
for drugs identified by Beers criteria as being potentially inappropriately prescribed.  It 
was also shown that the safe management of the full cohorts’ drug regimens was 
undermined by the identified PIP of clopidogrel and aspirin.     
 
To satisfy the fourth objective of the study, the representativeness of PIP for the 
minority HMR Report group to the majority non-HMR Report group was also shown.  
It was evident in the extent of polypharmacy, and the nature and pattern of prescribing 
of PIP drugs at discharge.  The evidenced representativeness of the HMR Report group 
at discharge reinforced a proposal that all patients in the cohort would also experience 
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the subgroup’s drug-related problems as barriers to their continuity of care post 
discharge, in the community.  
 
Data analyses in this chapter has evidenced the levels of potentially 
inappropriate prescribing in a quaternary care, cardiology unit within the Australian 
healthcare system.  The levels were identified by both international and Australian 
criteria in both tertiary and primary care.  There is concern for the health and safety of 
the patients involved and for the lack of opportunity for risk reduction, especially post 
discharge.   
 
This study has evidenced polypharmacy and potential prescribing problems 
which is preferable to an anecdotal awareness of them.  The ready acceptance of 
primary care services for relevant and constructive medication review after hospital 
discharge would greatly enhance the safety and continuity of integrated care for all 
discharged patients.  
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CHAPTER 7.0 
 
Appendix 7.1 
 
Analysis of data in Table 7.1 
 
Distribution of drugs prescribed for the HMR Report group and non-HMR Report 
group, on discharge: 
 
Table A Discharge drugs common to both subgroups 
Table B Discharge drugs unique to the HMR Report group (n=79) 
Table C Discharge drugs unique to the non-HMR Report group (n=202)
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Table Aa Distribution of specific drugs common to both the HMR Report group (n=79) and non-HMR Report group (n=202) on discharge.  
 
Specific discharge drugs common to both 
groups   
DISCHARGE: 
HMR Report Group n = 79 
DISCHARGE: 
non-HMR Report Group n = 202 
 Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Aspirin            54    8.1  68.4 128    8.1  63.4 
Clopidogrel                     40    6.1  50.6  95    6.0  47.0 
Atorvastatin                    30    4.5  38.0  85    5.4  42.1 
Glyceryl trinitratea             28    4.2  35.4  76     4.8  37.6 
Metoprolol                      24    3.6  30.4  65    4.1  32.2 
Frusemide                      32    4.8  40.5  53    3.4  26.2 
Warfarin                        13    1.9  16.5  40    2.5  19.8 
Perindopril arginineb                     16    2.4  20.3  38    2.4  18.8 
Isosorbide mononitrate          13    1.9  16.5  35    2.2  17.3 
Pantoprazole                    19    2.8  24.1  35    2.2  17.3 
Digoxin                         19    2.8  24.1  34    2.2  16.8 
Simvastatin                     26    3.9  32.9  30    1.9  14.9 
Potassium Chloride              12    1.8  15.2  28    1.8  13.9 
Carvedilol                      10    1.5  12.7  26    1.6  12.9 
Ramipril                          7    1.0    8.9  25    1.6  12.4 
Glyceryl trinitrate alternate formc    9    1.3  11.4  24    1.5  11.9 
Omeprazole                      10    1.5  12.7  24    1.5  11.9 
Spironolactone                    7    1.1    8.9  24    1.5  11.9 
Magnesium aspartate             10    1.5  12.7  22    1.4  10.9 
aGlyceryl trinitrate: sublingual tablets only, see alternate formc       bsee Perindopril with indapamided     cGlyceryl trinitrate: includes 
transiderm patch (8,23), spray (1,0) and ointment (0,1); see sublingual tabletsa 
 
 
 Chapter 7 Identifying Patients at Risk                                                                                                  Page 264 
 
Table Ab Distribution of specific drugs common to both the HMR Report group (n=79) and non-HMR Report group (n=202) on discharge, 
continued.  
 
Specific discharge drugs common to both 
groups   
DISCHARGE: 
HMR Report Group n = 79 
DISCHARGE: 
non-HMR Report Group n = 202 
 Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Enoxaparin                       4    0.6    5.1  21    1.3  10.4 
Gliclazide                        8    1.2  10.1  21    1.3  10.4 
Diltiazem                       10    1.5  12.7  18    1.1    8.9 
Paracetamol                       4    0.6    5.1  18    1.1    8.9 
Salbutamol                        5    0.7    6.3  18    1.1    8.9 
Amiodarone                        1    0.1    1.3  17    1.1    8.4 
Nicorandil                        6    0.9    7.6  17    1.1    8.4 
Cephalexin                       1    0.2    1.3  16    1.0    7.9 
Sotolol                           3    0.5    3.8  16    1.0    7.9 
Irbesartan      12    1.8  15.2  15    1.0    7.4 
Allopurinol                       8    1.2  10.1  14    0.9    6.9 
Esomeprazole                      3    0.5    3.8  14    0.9    6.9 
Pravastatin                       5    0.8    6.3  12    0.8    5.9 
Prednisolone                      4    0.6    5.1  12    0.8    5.9 
Docusate sodium                   9    1.3  11.4  14    0.9    6.9 
Oxycodone                         1    0.2    1.3  11    0.7    5.4 
Thyroxine                       10    1.5  12.7  10    0.6    5.0 
Tiotropium bromide                4    0.6    5.1  10    0.6    5.0 
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Table Ac Distribution of specific drugs common to both the HMR Report group (n=79) and non-HMR Report group (n=202) on discharge, 
continued.  
 
Specific discharge drugs common to both 
groups   
DISCHARGE: 
HMR Report Group n = 79 
DISCHARGE: 
non-HMR Report Group n = 202 
 Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Number 
prescriptions 
% total 
prescription*s 
% 
Patients 
Atenolol                          6    0.9    7.6    9    0.6    4.5 
Calcium carbonate                 7    1.1    8.9    9    0.6    4.5 
Metformin                       11    1.6  13.9    9    0.6    4.5 
Fluticasone with salmeterol       1    0.1    1.3    8    0.5    4.0 
Folic acid                        3    0.5    3.8    8    0.5    4.0 
Thiamine                          1    0.1    1.3    8    0.5    4.0 
Ferrous sulphate                  4    0.6    5.1    7    0.4    3.5 
Fluticasone                      6    0.9    7.6    7    0.4    3.5 
Insulin                4    0.6    5.1    7    0.4    3.5 
Rabeprazole                       1    0.1    1.3    7    0.4    3.5 
Amoxicillin with clavanulate      1    0.1    1.3    5    0.3    2.5 
Bisoprolol                        2    0.3    2.5    5    0.3    2.5 
Budesonide                        1    0.1    1.3    5    0.3    2.5 
Candesartan                       3    0.4    3.8    5    0.3    2.5 
Celecoxib                          2    0.3    2.5    5    0.3    2.5 
Ezetimbe                          2    0.3    2.5    5    0.3    2.5 
Ipratropium bromide                2    0.3    2.5    5    0.3    2.5 
Prazosin                          3    0.4    3.8    5    0.3    2.5 
Telmisartan                       2    0.3    2.5    5    0.3    2.5 
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Table Ad Distribution of specific drugs common to both the HMR Report group (n=79) and non-HMR Report group (n=202) on discharge, 
continued.  
 
Specific discharge drugs common to both 
groups   
DISCHARGE: 
HMR Report Group n = 79 
DISCHARGE: 
non-HMR Report Group n = 202 
 Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Amitriptyline                     1    0.1    1.3    4    0.3    2.0 
Amlopidine                        2    0.3    2.5    4    0.3    2.0 
Amoxicillin                       1    0.1    1.3    4    0.3    2.0 
Aluminium combinations    2    0.3    2.5    4    0.3    2.0 
Colchicine                          1    0.1    1.3    4    0.3    2.0 
Enalapril                         3    0.4    3.8    4    0.3    2.0 
Lisinopril                        1    0.1    1.3    4    0.3    2.0 
Perhexaline                       2    0.3    2.5    4    0.3    2.0 
Ranitidine                        4    0.6    5.1    4    0.3    2.0 
Roxithromycin                     2    0.3    2.5    4    0.3    2.0 
Verapamil                         5    0.7    6.3    4    0.3    2.0 
Alendronate                   3    0.4    3.8    3    0.2    1.5 
Captopril                         2    0.3    2.5    2    0.1    1.0 
Ciprofloxacin                     1    0.1    1.3    3    0.2    1.5 
Darbepoetin alfa                  1    0.1    1.3    3    0.2    1.5 
Fluoxetine                        1    0.1    1.3    3    0.2    1.5 
Lactulose                         1    0.1    1.3    3    0.2    1.5 
Nifedipine                        4    0.6    5.1    3    0.2    1.5 
Perindopril with indapamide      8    1.2  10.1    3    0.2    1.5 
Quinine                           1    0.2    1.3    3    0.2    1.5 
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Table Ae Distribution of specific drugs common to both the HMR Report group (n=79) and non-HMR Report group (n=202) on discharge, 
continued.  
 
Specific discharge drugs common to both 
groups   
DISCHARGE: 
HMR Report Group n = 79 
DISCHARGE: 
non-HMR Report Group n = 202 
 Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Amphoteracin                      1    0.1    1.3    2    0.1    1.0 
Cadexomer iodine                  1    0.1    1.3    2    0.1    1.0 
Fosinopril                        2    0.3    2.5    2    0.1    1.0 
Indapamide                        1    0.1    1.3    2    0.1    1.0 
Indomethacin                      2    0.3    2.5    2    0.1    1.0 
Risedronate                      1    0.1    1.3    2    0.1    1.0 
Sodium citrate/ tartrate    1    0.1    1.3    2    0.1    1.0 
Calcitriol                         1    0.1    1.3    1    0.1    0.5 
Cetamacrogol cream                2    0.3    2.5    1    0.1    0.5 
Carbamazepine                     3    0.4    3.8    1    0.1    0.5 
Clotrimazole                      5    0.7    6.3    1    0.1    0.5 
Diazepam                          2    0.3    2.5    1    0.1    0.5 
Famotidine                        2    0.3    2.5    1    0.1    0.5 
Flucloxacillin                    2    0.3    2.5    1    0.1    0.5 
Glimepiride                       3    0.4    3.8    1    0.1    0.5 
Glipizide                         1    0.1    1.3    1    0.1    0.5 
Hypromellose combinations    1    0.1    1.3    1    0.1    0.5 
Ibruprofen                        1    0.1    1.3    1    0.1    0.5 
Imipramine                        1    0.1    1.3    1    0.1    0.5 
Latanoprost                       1    0.1    1.3    1    0.1    0.5 
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Table Af Distribution of specific drugs common to both the HMR Report group (n=79) and non-HMR Report group (n=202) on discharge, 
continued.  
 
Specific discharge drugs common to both 
groups   
DISCHARGE: 
HMR Report Group n = 79 
DISCHARGE: 
non-HMR Report Group n = 202 
 Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Methotrexate                      2    0.3    2.5    1    0.1    0.5 
Oestrogens                        1    0.1    1.3    1    0.1    0.5 
Paraffin and wool fat              1    0.1    1.3    1    0.1    0.5 
Phenytoin                         1    0.1    1.3    1    0.1    0.5 
Sodium bicarbonate    4    0.6    5.1    1    0.1    0.5 
Rosiglitazone                     3    0.4    3.8    1    0.1    0.5 
Temazepam                         2    0.3    2.5    1    0.1    0.5 
Valproate    1    0.1    1.3    1    0.1    0.5 
Discharge drugs common to HMR and 
non-HMR groups n=103 
 
       632 
 
     94.3% 
 
 
**6.1%       1389 
 
 
     88.2% 
 
**3.7% 
*% prescriptions are relative to total subgroup prescriptions at discharge i.e. HMR Report group n=670 or non-HMR Report group  
n=1575 (Table 7.3h).   **Final averages for ‘% patients’ took into account the total number of subgroup discharge drugs i.e. HMR group 
n=132 or non-HMR group n=184.   Slight differences in % totals result from rounding errors. 
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Table B Distribution of drugs prescribed for patients in the HMR Report group (n=79) 
only, on discharge.  
 
Specific discharge drugs 
prescribed  
DISCHARGE: 
 HMR Report Group n = 79 
 Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Erythropoietin                     2    0.3    2.5 
Insulin protamine                 2    0.3    2.5 
Lercandipine                      2    0.3    2.5 
Nofloxacin                        2    0.3    2.5 
Omega-3-triglycerides             2    0.3    2.5 
Raloxifene                        2    0.3    2.5 
Sodium bicarbonate    2    0.3    2.5 
Venlafaxine                       2    0.3    2.5 
Zolpidem                          2    0.3    2.5 
Bupropion                         1    0.1    1.3 
Cephalexin                        1    0.1    1.3 
Codeine linctus                   1    0.1    1.3 
Cyanocobalamin                      1    0.1    1.3 
Cyproterone                       1    0.1    1.3 
Doxepin    1    0.1    1.3 
Eformoterol                       1    0.1    1.3 
Eprosartan                        1    0.1    1.3 
Framycetin                        1    0.1    1.3 
Hydroxyethyl rutosides            1    0.1    1.3 
Medoxyprogesterone with oestrogen    1    0.1    1.3 
Meloxicam                         1    0.1    1.3 
Pholcodine                       1    0.1    1.3 
Pioglitazone                      1    0.1    1.3 
Quinapril                         1    0.1    1.3 
Sertraline                        1    0.1    1.3 
Sibutramine    1    0.1    1.3 
Tamoxifen                         1    0.1    1.3 
Thalidomide                       1    0.1    1.3 
Ticarcillin with clavulanic acid    1    0.1    1.3 
Discharge drugs for HMR group 
only n=29 
 
           38 
 
    *5.7% 
 
  **0.4% 
*% prescriptions are relative to total subgroup prescriptions at discharge i.e. HMR 
Report group n=670 (Table 7.3h).  **Final averages for ‘% patients’ took into account 
the total number of subgroup discharge drugs i.e.  HMR Report group (n=132).  Slight 
differences in % totals result from rounding errors. 
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Table Ca Distribution of drugs prescribed for patients in the non-HMR Report group 
(n=202) only; on discharge.  
 
Specific discharge drugs 
prescribed  
DISCHARGE: 
 non-HMR Report Group n = 202 
 Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Tramadol                        12    0.8    5.9 
Codeine with paracetemol        11   0.7    5.4 
Metoclopramide                    9    0.6    4.5 
Chloramphenicol eye drops         7    0.4    3.5 
Polyethylene glycol combinations    7    0.1    0.5 
Trimethoprim                      7    0.4    3.5 
Senna glycosides                  6    0.4    3.0 
Acetazolamide                     5    0.3    2.5 
Ergocalciferol                    5    0.3    2.5 
Dextran eye drops    5    0.3    2.0 
Gabapentin                        5    0.3    2.5 
Cinchocaine & Zinc oxide                          4    0.2    1.5 
Citalopram                        4    0.3    2.0 
Nicotine transdermal              4    0.3    2.0 
Acetylcysteine                    3    0.2    1.5 
Cephazolin Infusion               3    0.2    1.5 
Clindamycin                       3    0.2    1.5 
Diclofenac                        3    0.2    1.5 
Felodipine                        3    0.2    1.5 
Flecainide                        3    0.2    1.5 
Morphine                          3    0.2    1.5 
Sodium chloride                   3    0.2    1.5 
Trandolapril                      3    0.2    1.5 
Ascorbic acid                     2    0.1    1.0 
Baclofen                          2    0.1    1.0 
Dexamethasone eye drops           2    0.1    1.0 
Domperidone                       2    0.1    1.0 
Dothiepin                         2    0.1    1.0 
Haloperidol                       2    0.1    1.0 
Metronidazole                     2    0.1    1.0 
Mirtazapine                       2    0.1    1.0 
Quinapril                         2    0.1    1.0 
Aluminium hydroxide               1    0.1    0.5 
Testosterone                         1    0.1    0.5 
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Table Cb Distribution of drugs prescribed for patients in the non-HMR Report group 
(n=202) only; on discharge, continued. 
 
Specific discharge drugs 
prescribed  
DISCHARGE:  
non-HMR Report Group n = 202 
 Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Betamethasone                     1    0.1    0.5 
Biperiden                         1    0.1    0.5 
Calcium with vitamin D 
combinations 
   1    0.1    0.5 
Carbimazole                       1    0.1    0.5 
Chlorhexadine gluconate           1    0.1    0.5 
Clodronate                    1    0.1    0.5 
Cyclizine                         1    0.1    0.5 
Cyclosporine oral                  1    0.1    0.5 
Diphenoxylate atropine            1    0.1    0.5 
Eplerenone                        1    0.1    0.5 
Fluconazole                       1    0.1    0.5 
Fluorouracil                      1    0.1    0.5 
Gentamycin                        1    0.1    0.5 
Hydrochlorothiazide               1    0.1    0.5 
Hydroxychloroquine                1    0.1    0.5 
Hyoscine N-butyl bromide           1    0.1    0.5 
Ispaghula                         2    0.1    0.5 
Lansoprazole                       1    0.1    0.5 
Lignocaine Oral                   1    0.1    0.5 
Lithium carbonate                 1    0.1    0.5 
Loperamide                        1    0.1    0.5 
Mesalazine                        1    0.1    0.5 
Mometasone               1    0.1    0.5 
Nystatin                          1    0.1    0.5 
Oxazepam                          1    0.1    0.5 
Paraffin emulsion                  1    0.1    0.5 
Paroxetine hydrochloride          1    0.1    0.5 
Phenindione                       1    0.1    0.5 
Polyvinyl alcohol with providone    1    0.1    0.5 
Prednisolone eye drops            1    0.1    0.5 
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Table Cc Distribution of drugs prescribed for patients in the non-HMR Report group 
(n=202) only; on discharge, continued. 
 
Specific discharge drugs 
prescribed  
DISCHARGE: 
 non-HMR Report Group n = 202) 
 Number 
prescriptions 
% total 
prescriptions* 
% 
Patients 
Prochlorperazine                  1    0.1    0.5 
Propranolol                        1    0.1    0.5 
Rofecoxib                         1    0.1    0.5 
Silver sulfadiazine    1    0.1    0.5 
Sodium picosulphate with 
magnesium 
   1    0.1    0.5 
Sucralfate                           1    0.1    0.5 
Sulindac                          1    0.1    0.5 
Terbinafine                       1    0.1    0.5 
Theophylline SR                    1    0.1    0.5 
Timolol                           1    0.1    0.5 
Triamcinolone-Orabase             1    0.1    0.5 
Tribolone                         1    0.1    0.5 
Urea                              1    0.1    0.5 
Vitamin compounds                  1    0.1    0.5 
Vitamins with minerals            1    0.1    0.5 
Voriconazole                      1    0.1    0.5 
Xylometazoline                  1    0.1    0.5 
Discharge drugs for non-HMR 
group only n=81 
 
         186  
 
          11.8% 
 
  **0.5% 
*% prescriptions are relative to total subgroup discharge prescriptions i.e. non-HMR 
Report group n=1575 (Table 7.3h).    **Final averages for ‘% patients’ took into 
account the total number of subgroup discharge drugs i.e. non-HMR Report group drugs 
n=184. Slight differences in % totals result from rounding errors. 
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CHAPTER 8.0  HOW INTEGRATED CARE ENHANCES CONTINUITY OF  
 
CARE (CofC) 
 
 
Synthesis Of Concepts, Empirical Research and  
Data Analyses 
 
8.1  CHAPTER SUMMARY 
In the outline of this thesis in Chapter 1, overtly simple questions shaped the objectives to 
be addressed in achieving the primary research aim.  In this chapter, those questions are 
answered and the objectives are addressed.  The questions and objectives are qualified by 
showing how the concept of continuity of care (CofC) was explained and operationalised 
in the context of each chapter study (Figure 8.1).  The analyses of primary data followed 
its collection by the in-hospital recruitment of 281 chronically ill cardiovascular patients 
into the Continuity of Care Project (CofCP).   
 
The end point of data collection for this research was the provision to the 
researcher, of HMR reports written by accredited pharmacists for the patients’ GPs.  
Across all chapters, analyses of data ‘at discharge’ was conducted on lists of drugs and 
diseases in discharge summaries.  Analyses of data ‘at HMR’ service was conducted on 
lists of drugs and diseases in HMR reports written by accredited pharmacists.  The 
pharmacists comments and recommendations were taken into account for identification of 
drug-related problems (DRPs) but were not taken into account for identification of 
potentially inappropriate prescribing (PIP).    
 
All outcomes from group comparisons and analyses confirmed the 
representativeness of the minority HMR Report group (n=79) to the majority non-HMR 
Report group (n=202), hence for the CofCP cohort (n=281).  These outcomes also 
evidenced the full cohort’s need for integrated CofC on, and after discharge.   
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8.2  CONTINUITY OF CARE 
 
 
 
 
 
8.2.1  RESEARCH OBJECTIVE 1) Developing an approach to defining the phrase 
‘Continuity of Care’ so its use in any context, was meaningful and transparent. 
 
8.2.1.1 Defining Continuity of Care (CofC) 
 
Chapter 2 included a systematic literature review on CofC and a commentary on the 
meaning of CofC.  In the literature review the lack of consensus in the literature on how to 
define CofC, was addressed by the development of a working definition.  The working 
definition was used as a baseline for assessment of how the phrase was used in articles on 
pharmacists’ roles in CofC research.  The review of 21 articles found patients who were 
disadvantaged by cultural, personal or cognitive impairments were further disadvantaged 
by exclusion from CofC research.  The opportunity to identify, assess and manage their 
drug related problems was overlooked.  
 
Further to the review, the literature showed a lack of consensus across time and 
healthcare profession in defining the concept of CofC.  Use of the working definition in 
the review showed flexibility and practicality for assessment of its four important 
components.  The commentary on CofC and the use of the working definition as a 
template suggested it should be followed by a description of the concept in the context of 
its use.  This format was followed throughout the thesis and it provided clarity and 
meaning of CofC in each chapter study.  Explanation of the phrase in a particular context 
was found to be essential. 
 
What is the meaning of ‘Continuity of Care’? 
 
 
C O N C E P T S 
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Application of the developed template for CofC to the (overall) research in this thesis :  
 
CONTINUITY OF CARE is a perception of quality health care resulting from the ongoing 
management of issues which cause disruption to optimal patient care. 
 
In the context of the research in this thesis: 
 
Continuity of care was perceived by the researcher as quality health care which resulted 
in support and benefits to patients, especially on transfer between tertiary and primary 
care.  Also, the ongoing nature of the care necessary for chronically ill cardiovascular 
patients required a sustained effort by interdisciplinary caregivers in management of 
patients’ drug-related issues. Further, that optimal care included focussed care which 
identified patients at risk of these issues. 
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8.3  CONTINUITY OF CARE PROJECT 
 
 
 
 
8.3.1 RESEARCH OBJECTIVE 2) Conducting a ‘real’ world, empirical research project 
in a large, acute care teaching hospital 
 
8.3.1.1 Implementation of the CofC Project (CofCP) 
Chapter 3 reported the implementation of the CofCP, in a quaternary care hospital for 
cardiovascular disease in Australia.  Recruitment resulted in a research cohort of 281 
patients.  The discretionary referral by patients’ GPs for post discharge HMR service, 
resulted in 87/281 patients receiving the service.  The availability of HMR reports, as 
confirmation of the conduct of the service, resulted in the randomised division of the 
cohort into an HMR Report group (n=79 patients) and non-HMR Report group (n=202 
patients).   
 
8.3.2 RESEARCH OBJECTIVE 3) Identifying and taking into account the patients’ 
personal, clinical and drug-related characteristics, and their responses to quality of life 
surveys 
 
8.3.2.1  CofCP cohort Characteristics and CofC needs 
Assessment of the personal, clinical and health-related quality of life (HRQL) 
characteristics of these acute on chronically ill patients showed a significant predominance 
 
Did patients need CofC after hospital discharge? 
 
 
EMPIRICAL RESEARCH 
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of male patients in a cohort with a median age of 65 years and a mean of 13.9 days length 
of stay (LOS).   
 
Validation of the responses to a comprehensive HRQL survey of the full cohort 
showed, apart from increased age, there were no significant differences between 
responders and non-responders.  Also, there were there no significant differences in the 
high response rates between the two identified subgroups.  Further, the comparisons 
established the absence of any significant confounders to subsequent investigations of any 
differences in drug-related problems between the subgroups.   
 
The CofCP cohort was shown to experience extensive polypharmacy at discharge 
which would exacerbate their potential for DRPs and it was a clear indication of the full 
cohort’s need for CofC. 
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8.4  ACTUAL and POTENTIAL DRUG RELATED PROBLEMS (DRPs) 
 
 
 
 
8.4.1  RESEARCH OBJECTIVE 4) Analysing any identified drug related problems 
(DRPs), polypharmacy or exposure to potentially inappropriate prescribing (PIP) at 
discharge and in the community 
 
8.4.1.1. Identification of Drug Related Problems (DRPs) Post  
 
Discharge 
 
In Chapter 4, following the identification of the cohort’s potential for DRPs,  instances of 
post discharge DRPs were investigated in the HMR Report group (n=76).  The HMR 
service reports written for the patients’ GPs were the primary source of DRP data.  The 
comments and recommendations made by the accredited pharmacists interviewing the 
patient at HMR service, not only the listed diseases and drugs, were taken into account.   
 
A total of 398 DRPs were recorded for 71/76 (93.3%) of the group showing a mean 
of 5.6 problems per patient.  It was shown the most frequent problem (32.0%) to be actual, 
patient related uncertainty about the aims of specific drugs, followed by potential drug-
drug interactions and adverse drug reactions..  Polypharmacy and a broad range of 
comorbidities requiring non-cardiovascular drugs exacerbated the group’s DRPs.  
Polypharmacy was confirmed by means of 8.7, 8.9 and 10.8 drugs in regimen recorded in 
discharge summaries; GP referrals and HMR reports, respectively. 
 
 
 
Why did patients need CofC after hospital discharge? 
 
 
 
DATA ANALYSES 
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It was found the hospital’s practice of not issuing discharge summaries to short 
stay patients, was a barrier to their CofC.  From the  HMR Report group’s reports they 
were shown to average over 5 DRPs per patient and it was opportune that the most 
frequent of these problems could receive timely resolution.   
 
Polypharmacy and the high level of DRPs still existent at the time of HMR service 
was an indication of the HMR Report group’s need for CofC after hospital discharge. 
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8.5  PATIENT TRANSFER FROM TERTIARY TO PRIMARY CARE 
 
 
 
 
8.5.1  RESEARCH OBJECTIVE 4 cont.) Analysing any identified drug related problems 
(DRPs), polypharmacy or exposure to potentially inappropriate prescribing (PIP) at 
discharge and in the community 
 
 
8.5.1.1  When Did Patients need CofC – Determined by International  
 
Criteria 
 
Chapter 5 reports how the high levels of DRPs and polypharmacy identified in the HMR 
Report group (n=79) post discharge, prompted further investigation.  International criteria 
were utilised to determine the severity of drugs potentially inappropriately prescribed (PIP) 
between discharge and HMR service.  All data analysed ‘at discharge’ were collated from 
discharge summaries and data analysed ‘at HMR’ service were collated from drugs and 
diseases listed in HMR Reports.  The pharmacists’ comments and recommendations were 
not taken into account.   
 
Application of Beers explicit criteria to drug regimen showed there was a highly 
beneficial and significant decrease of 20.4% in the severity rating of drugs prescribed 
between discharge and HMR service.  Instances of PIP relative to routine drug prescription 
decreased, but were not significantly different with 127 (19.3%) at discharge and 115 
(14.3%) at HMR.   
 
 
 
When did the need for CofC arise? 
 
 
DATA ANALYSES continued  
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When assessed, 127 PIP instances at discharge and 115 PIP instances at HMR 
service showed means of 1.6 instances and 1.4 instances per patient, respectively.   
 
In the HMR Report group the most frequently prescribed high severity drugs 
included aspirin, clopidogrel, NSAIDS, dipyridamole and ticlopidine in combination with 
an anticoagulant for 73 (92.4%) patients at discharge and 71 (89.9%) patients at HMR. 
Polypharmacy was confirmed as a contributing barrier to the HMR Report group’s CofC.   
 
Reductions in drug severity, and instances of PIP indicated by Beers criteria at 
HMR service, inferred a positive intervention by GPs post discharge.  The criteria 
allocated an explicit ‘high severity’ rating for the prescription of aspirin and clopidogrel 
regardless of patient diagnoses.  Hence, the frequent prescription of this combination for 
patients discharged from the cardiology unit of Westmead Hospital resulted in a high PIP 
count.   
 
Beers criteria identified unacceptable levels of PIP at both discharge and after GP 
consultation, at HMR service.  As determined by international criteria for potentially 
inappropriate prescribing, the need for CofC in medication management arose at discharge. 
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DATA ANALYSES CONTINUED 
 
 
 
 
 
8.5.1.2  When Did Patients need CofC – Determined by Australian  
 
Indicators 
 
Chapter 6 reports  further identification of PIP utilising customised Australian indicators. 
Further identification was conducted to augment the assessment by Beers criteria in the 
HMR Report group’s (n=79) drug regimens.  Basger indicators were applied to listed 
drugs and diseases in discharge summaries and HMR Reports and the accredited 
pharmacists’ recommendations were not taken into account.   
 
Confirmation of high numbers of drugs prescribed for the subgroup at discharge 
and at HMR service again indicated exposure to polypharmacy.  Basger indicators showed 
the HMR Report group was exposed to a concurrent, significant 11.3% decrease in 
appropriate prescribing instances at HMR and a significant 29.0% increase in PIP 
instances at HMR.  \ 
When assessed, 250 PIP instances at discharge and 399 PIP instances at HMR 
showed means of 3.1 instances and 5.1 instances per patient.  The ratio of PIP to 
prescribed drugs was 38.2% and 49.6% at discharge and HMR, respectively.   
 
The Basger indicator most frequently not satisfied and indicating PIP, showed 
100% HMR Report group had changes to their drug regimen within 90 days prior to both 
discharge and HMR service.  The second indicator showing frequent PIP at both discharge 
and HMR, required patients at high risk of a cardiovascular event to be taking a statin and 
22 (28.9%) patients at discharge and 25 (32.1%) patients at HMR were not.   
 
 
 
When did the need for CofC arise? continued 
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Application of the Basger indicators indentified a strong, adverse impact of 
increased PIP at HMR which reflected reduced patient centred care after GP consultation 
in the community.  However, the HMR Report group were advantaged by the opportunity 
for identification of their PIP instances at HMR service.   
 
Basger indicators identified unacceptable levels of PIP at both discharge and after 
GP consultation, at HMR service.  When determined by customised Australian indicators 
for appropriate prescribing, the need for CofC in medication management arose at 
discharge.   
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8.6  THE EXTENT OF NEED FOR CONTINUITY OF CARE (CofC) 
 
 
 
 
8.6.1 RESEARCH OBJECTIVE 5) Determining, analysing and comparing any specific 
drugs identified as PIP in the full cohort’s drug regimens.  
 
In Chapter 7 analysis of the CofCP cohort’s drug regimens targeted identification of the 
nature (active ingredients) of the drugs and of any PIP drugs.  All results were presented in 
decreasing order of prescribing frequency.  In all analyses, the active ingredients of drugs 
were counted once only for each patient which produced a slight variation in prescription 
numbers, from previous chapter outcomes. 
 
8.6.2 DRUG REGIMENS AT DISCHARGE – Subgroups and Cohort  
 
HMR Report Group (n=79):  At discharge, this subgroup averaged 8.3 prescriptions per 
patient.  Prescriptions for the 103 drugs common to both subgroups numbered 632 (94.3%) 
total subgroup prescriptions.  Prescriptions for the 29 drugs unique to this subgroup 
numbered 38 (5.7%) total subgroup prescriptions with 1 or 2 prescriptions per drug.  The 
small proportion of drugs unique to this minority subgroup further strengthened its 
representativeness in prescribing at discharge. 
 
non-HMR Report Group (n=202):  At discharge, this subgroup averaged 7.8 
prescriptions per patient.  Prescriptions for the 103 drugs common to both subgroups 
numbered 1389 (88.2%) total subgroup prescriptions.  Prescriptions for the 81 drugs 
 
Were all patients in need of CofC? 
 
 
DATA ANALYSES continued  
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unique to this subgroup numbered 186 (11.8%) total subgroup prescriptions with tramadol 
and codeine with paracetemol the most frequently prescribed drugs. 
 
CofCP Cohort (n=281):  At discharge, the cohort averaged 8.0 prescriptions per patient 
from a total of 2245 prescriptions for 213 different drugs.  Aspirin was the most frequently 
prescribed drug for 182 (64.8%) patients, clopidogrel was prescribed for 135 (48.0%) 
patients and atorvastatin was prescribed for 115 (40.9%) patients.  These three drugs 
accounted for 8.1%, 6.0% and ~5.0% of total discharge prescriptions respectively, for both 
the subgroups at discharge.  The corresponding percentages between the subgroups further 
reinforced the representativeness of the minority HMR Report group in discharge 
prescribing. 
 
 
 
8.6.3  PIP AT DISCHARGE AND HMR SERVICE – HMR Report group  
 
HMR Report Group (n=79):  Beers criteria and Basger indicators were re-applied to 
target the nature (active ingredients) of the specific PIP drugs identified at discharge and at 
HMR service.  Also the re-application at two points in time, clarified any changes to the 
nature of identified PIP drugs after GP consultation in the community.   
 
 
Beers Criteria:  Re-application showed Clopidogrel at discharge was PIP for 40 (50.6%) 
patients and was reduced at HMR service by 9 (11.4%) patients.  Aspirin at discharge was 
PIP for 31 (39.2%) patients and was reduced at HMR by 2 (2.5%) patients.  Reduced PIPs 
after GP consultation post discharge benefited 11 patients.  However, there still remained 
31 (39.2%) patients prescribed clopidogrel and 29 (36.7%) patients prescribed aspirin, at 
risk of PIP after GP consultation post discharge. 
 
 
Basger Indicators:  Re-application re-affirmed repeated changes in medications to be 
the most frequent PIP situation identified at both discharge and HMR service.  The second 
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most frequent PIP situation at HMR service, identified 16 (20.3%) patients at discharge; 
and 35 (44.3%) patients at HMR service, had not been prescribed essential antiplatelet or 
anticoagulant drugs.  There was an increase of 19 (24.1%) ‘at risk’ patients not prescribed 
essential clopidogrel or aspirin (<325mg/day) after GP consultation post discharge 
 
 
The outcomes from the two very different assessment tools, were in agreement that 
clopidogrel and aspirin were the most frequently identified or omitted PIP drugs, in 
particular, at HMR service.   
 
 
8.6.4  PIP AT DISCHARGE – Subgroups and Cohort  
 
 
HMR Report Group (n=79):  At discharge, this subgroup averaged between 1 and 2.0 
PIPs per patient.  Prescriptions for the 24 PIP drugs common to both subgroups numbered 
108 (94.7%) total subgroup PIPs. Aspirin was PIP for 31 (39.2%); clopidogrel for 40 
(50.6%); and metoprolol for 2 (2.5) patients.  Prescriptions for the 5 drugs unique to this 
subgroup numbered 6 (5.3%) total subgroup PIPs.  Venlafaxine was prescribed for 2 
patients.  
 
 
non-HMR Report Group (n=202):  At discharge, this subgroup averaged 2.0 PIPs per 
patient.  Prescriptions for the 24 PIP drugs common to both subgroups numbered 411 
(89.2%) total subgroup PIPs.  Aspirin was PIP for 128 (63.4%); clopidogrel for 95 
(47.0%); and metoprolol for 65 (32.2%) patients.  Prescriptions for the 18 drugs unique to 
this subgroup numbered 50 (10.8%) total subgroup PIPs.  Tramadol was prescribed for 12 
(5.9%) patients. 
 
 
 
CofCP Cohort (n=281):  At discharge, the cohort averaged 2.0 PIPs identified from their 
8.0 discharge prescriptions per patient.  There was a total of 575 PIPs for the 47 different 
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PIP drugs identified..  Aspirin and clopidogrel were most frequently PIP for both 
subgroups and accounted for 51.1% total PIPs.  The ratio of total PIPs to total discharge 
prescriptions was 25.6%.  
 
The high ratio of PIP to discharge drugs showed the full CofCP cohort were in 
need of patient focussed CofC at discharge.   
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8.7  STRENGTH IN EXTRAPOLATION OF DATA OUTCOMES 
 
 
 
8.7.1  RESEARCH OBJECTIVE 6) Investigating whether minority subgroup outcomes 
can be extrapolated to predict the medication management necessary for safe, continuous 
patient care. 
 
8.7.1.1  ANALYSIS OF HMR REPORT GROUP DATA 
In the chapter studies, the extrapolation of post discharge outcomes for the minority 
subgroup to predict outcomes for the majority subgroup, and hence the full cohort, was 
proposed.  Post discharge data generated in the community, and analysed ‘at Home 
Medicines Review’ (HMR) after GP consultation, was not available for the majority of 
patients in the CofCP cohort.   
 
Research utilising or trialling this method of predicting outcomes for a cohort of 
patients, and especially for those with cardiovascular disease, was not found in the 
literature.  Converse to this research, all articles retrieved from a search discussed the 
majority group as predictor for the minority group.1  However, it is suggested that the 
outcome of using this method of prediction in this research, has been successful.   
 
In the chapter studies the minority HMR Report group was identified as having a 
marked level of DRPs post discharge and a clearly demonstrated, ongoing exposure to PIP 
after GP consultation, post discharge.  Other than a predominance of males in the majority 
subgroup, this minority subgroup was shown to have no other statistically significant 
Can the CofC needs of a minority subgroup predict 
those of the majority subgroup? 
 
RESEARCH STRENGTHS and 
LIMITATIONS   
 
 Chapter 8 Synthesis of Concepts, Empirical Research and Data Analyses     Page 291 
 
differences in many important variables, to the majority non-HMR Report group.  Across 
this research the  HMR Report group was shown to be representative of the CofCP cohort.  
 
Hence, it was proposed that the majority non-HMR Report group would experience 
at least, the same high impact of DRPs and exposure to PIP as the HMR Report group after 
GP consultation in the community.  In addition, it was shown the majority of the patients 
(n=202) in the CofCP cohort were disadvantaged by not having the opportunity for 
resolution of their drug-related problems at medication review after discharge.   
 
All patients recruited into the CofCP were shown to have the same need for safer 
clinical  management  of  their  medications  and  improved  CofC starting at discharge and  
ongoing into the community.   
 
 
 
 
1 Lin RL. and Hastings CN.  Group Differentiated Prediction.  Appl  Psychol  
 
Measure 1984; 8:165-172. Doi: 10.1177/014662168400800205 
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RESEARCH STRENGTHS and LIMITATIONS continued 
 
8.8  LIMITATIONS TO GENERALISING THE DATA and PROCESS  
 
OUTCOMES 
 
 
8.8.1  DOCUMENTATION of HOME MEDICINES REVIEW (HMR) REPORTS 
 
It was found throughout all CofCP chapter studies that in general, documentation 
of drugs and diseases in HMR reports was inadequate,1 not necessarily inaccurate, for the 
information of GPs and for some data analyses.  This latter finding was in contrast to 
Australian research by Castelino et al. (2009) whose research also analysed the data in 
HMR reports.  That data was sufficiently well documented to enable Castelino et al. to 
conclude the majority of actions recommended by pharmacists in HMR reports were 
consistent with evidence based guidelines.2   
 
However, the CofCP finding of HMR report inadequacy was consistent with other 
research conducted in Australia in 2008 and in New Zealand (NZ) in 2010.  These 
researchers found GPs questioned the quality and usefulness of community pharmacists’ 
reporting and recommendations in medication reviews.  Difficulties were also reported by 
GPs, in accepting the encroachment of Pharmacists’ expertise on GPs prescribing 
experience and decisions.3-4    
 
8.8.2  PROVISION OF HOSPITAL DISCHARGE SUMMARIES 
It was routine ward practice, for the CofCP cohort, that hospital discharge summaries were 
not produced for  ‘Day Only’ (DO) patients regardless of their cardiovascular health status 
or complexity of their drug regimens.5  Data analysis in this CofCP research was not 
constrained as DO patient information was collected from medical records.  However, on 
discharge there were no readily transferable records of patients’ diseases, treatments, or 
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drug regimens recorded to show medication change, cancellation or continuation of pre-
existing drug prescriptions for these patients.   
 
In Ireland it was found the potential for reduced medication safety arising from 
inadequate discharge documentation, was consistent with outcomes of research on 
cardiovascular drugs conducted by Grimes et al. (2010) in Ireland.6  In Australia Wong et 
al. (2011) researched the barriers to effective discharge planning and concluded that 
inadequate documentation, poor communication and lack of coordination across various 
healthcare providers were barriers to quality discharge processes.7  In the context of this 
CofC research, the non-provision of discharge summaries was shown to be a barrier to 
safer clinical management of medicines and to the patients’ continuity of care post 
discharge.  
 
8.8.3  INFORMATION TRANSFER and HOSPITAL DISCHARGE PROTOCOLS  
This CofCP research found there was insufficient transfer of information to the patient in 
general and in particular, on the nature and aim of their discharge medications.5  For the 
CofCP cohort, there was no routine transfer of discharge information by the hospital to 
community pharmacies and hence, no transfer to accredited pharmacists.  Further, for 
those patients who received an HMR service, reliable transfer of medication information to 
accredited pharmacists from pharmacies and GPs was not routine.   
 
The CofCP research also showed the clinical management, patient education and 
reconciliation of discharge drugs by hospital medical, nursing and pharmacy staff was not 
co-ordinated for the CofCP cohort’s benefit.  Researchers from the USA (2010) 
investigated the key principles of making inpatient medication management and 
reconciliation, best practice.  They concluded that patient safety and patient centred care 
were the two principal drivers required.  These two drivers ensured patients received the 
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most appropriate management, information and medications regardless of when, where or 
by whom they were treated across the continuum of care.8-9   
 
8.8.4  INTEGRATION OF PATIENT CARE 
In their research on integration of patient care, Bryant et al. (2010) in NZ., 
investigated the expectation that pharmacists might be perceived as crossing a clinical 
boundary between the work of the GP and that of pharmacists.  Bryant et al. agreed with 
findings by Campbell et al. (2008) in Australia, and both concluded that GPs had high 
regard for pharmacists’ skills.  However, they also found GPs discriminated in support of 
activities that were acceptable to GPs, against those that encroached on GP’s territory.3-4 
 
This CofCP research also found the care necessary for the welfare of patients in the 
cohort was not integrated across healthcare disciplines or sustained for safe transfer from 
the hospital to the community.  In the past, Paul Lefkovitz (1995) expounded the need for 
‘a broad and fluid continuum of services for quality and efficient care’ (p260), and 
criticised the inequality of importance between tertiary and primary care.10  He recognised 
powerful systemic and healthcare practitioner attitudes as barriers to care.   
 
Lefkovitz extended his (mental health) findings to general hospital settings and 
presented an integrated continuum model of care.  His research showed that a chief 
challenge would be to maximise continuity and integration in a system without sacrificing 
care cohesion and the patients’ trust.10   
 
Recently, Béland and Hollander (2011) investigated the lack of integrated models 
of care for the chronically ill and frail elderly by interdisciplinary providers.  These 
researchers reviewed only models which espoused patient-centred care delivery and one 
Australian model was reviewed. 11-12  Béland and Hollander concluded that one common 
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characteristic required by all the models reviewed, was a coordinated continuum of 
integrated care for transition between different types of healthcare services.13  
 
Across the years Lefkovitz, Béland and Hollander (1995-2011) called for evidence 
of patients’ specific needs and the practice changes required to add to the quality, 
integration and continuity of patient care.  The implementation of this CofCP and data 
analyses have provided this evidence.    
 
The foregoing consideration of generalisation limitations was recorded in support 
of the following recommendations for transfer of research to practice.  In this CofCP 
research, it was found the inadequacy of data documentation, hospital protocols and 
healthcare practices in the community markedly reduced the quality and continuity of 
patient care investigated in this research. 
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8.9  RECOMMENDATIONS FOR PRACTISING INTEGRATED CARE   
 
 
 
 
8.9.1  RESEARCH OBJECTIVE 7)  Recommendations for transferring the research and 
process outcomes into practice. 
 
 
8.9.1.1 . TERTIARY CARE PRACTICE – IN THE HOSPITAL 
a)  Medical Staff 
 
 
• Documentation or supervision of patients’ drug regimens in discharge summaries 
by more senior members of the medical team or at least, pharmacist assistance in 
the process. 
• Provision of a discharge summary for all patients regardless of their diagnosis, 
clinical state; or length of stay; for both the patients’ GPs and community 
pharmacies. 
• Cardiovascular Patients: Patient focussed consideration in the prescribing or 
omission of antiplatelet or anticoagulant drugs or NSAIDs; especially clopidogrel 
and aspirin. 
• Recording on all discharge summaries – a request to the patients’ GPs for an HMR 
service referral for all patients. The request should appear automatically on the e-
template for discharge summaries in an ‘opt-out’ format which would require 
removal by the medical officer signing the discharge summary. 
 
 
 
How can CofC be integrated and practised, on and after 
discharge? 
 
 
RESEARCH TO PRACTICE 
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b)  Pharmacists  
• Support to the medical team recording drug regimens in discharge summaries. 
 
• For all patients, provision of a hardcopy list of all medicines and associated 
administration instructions for drugs prescribed on discharge 
 
• Cardiovascular Patients: Patient focussed reconciliation of discharge drugs for 
the timely identification of PIP antiplatelets, anticoagulants, or NSAIDs such as 
clopidogrel and aspirin.  
• Reconciliation of all discharge drugs, and identification of inadequacies in 
discharge summaries before dispensing prescribed discharge regimens. 
 
 
c)  Pharmacists and Nursing Staff 
 
• Certainty for the patient, and accountability for the overall integration of the 
patients’ needs at discharge. 
 
• Provision of clear verbal information to the patient, with emphasis on the aim of 
each drug,  alongside patients’ hard copy list and their discharge drugs,.  
 
8.9.1.2  PRIMARY CARE  PRACTICE – IN THE COMMUNITY 
 
d)  General Practitioners 
• Positive consideration of requests for medication review for all recently discharged 
patients. 
• Recording of  all currently prescribed drugs and the indicators for their prescription 
on medication review referral forms 
 
• A clear indication of dissatisfaction with inadequate HMR reports..  Closer liaison 
with community pharmacies and accredited pharmacists conducting medication 
reviews. 
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• Cardiovascular Patients: Post discharge, patient focussed drug reconciliation  of 
diagnosis indicated antiplatelets, anticoagulants, or NSAIDs such as clopidogrel 
and aspirin.  
 
8.10  FROM RESEARCH TO RESEARCH:  
 
RECOMMENDATIONS FOR INTERDISCIPLINARY CO-OPERATION: 
 
 
 
e) Investigation of general practitioners’ reasons for non-referral of chronically ill 
patients with cardiovascular disease,  for post discharge  medication review.   
 
f) Reproduction of the CofCP research design in a cohort large enough to control and 
test the practicality of the recommendations made for transfer into practice of the 
thesis research and process outcomes. 
 
g) Investigation of the clinical outcomes for patients with cardiovascular disease who 
were and who were not,  referred for post discharge medication review. 
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Figure 9.1 Thesis Conclusion
 
RESEARCH OBJECTIVES AND PRIMARY AIM 
 
 
CONCEPTS 
 
Continuity of Care (CofC) 
EMPIRICAL RESEARCH 
 
Continuity of Care Project (CofCP) 
 
DATA ANALYSIS 
 
 
Personal, clinical HRQL characteristics 
 
Number Drugs Prescribed – Polypharmacy 
 
Drug related Problems (DRP) 
 
Beers criteria – Basger indicators 
 
Potentially Inappropriate Prescribing (PIP) 
 
Prescribing frequencies – active ingredients 
 
Subgroup Comparisons – representativeness 
 
Cohort need for safer medication 
management and improved continuity of care 
 
 
 
STRENGTHS AND LIMITATIONS –  
 
RECOMMENDATIONS FOR RESEARCH TO 
PRACTICE CHANGE 
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THESIS    C O N C L U S I O N 
 
 
 
 
 
 
 
 
As shown in Figure 9.1, the synthesis of the concepts, empirical research, data analysis and 
consideration of the research limitations framed the recommendations for practice change. 
The objectives of the research were comprehensively met and, the primary aim of the 
research was successfully achieved.  
 
The need for safer clinical management of the CofCP cohort’s medications was shown in 
the identification of their exposure to polypharmacy, drug related problems (DRPs) and 
potentially inappropriate prescribing (PIP).  It was found for safer clinical management of 
medications, that evidence for the ‘potential’ and preventable aspect of  inappropriate 
prescribing was by far the most important.  That is, more important for the patients’ 
immediate and ongoing health and wellbeing than the delayed evidence of actual 
inappropriate prescribing.    
 
Post discharge medication review was shown to be beneficial to continuity of care 
for those patients referred for Home Medicines Review (HMR) service.  The service 
facilitated the post discharge identification and an opportunity for  resolution, of the 
minority subgroup’s DRPs and PIP.  The research showed PIP at hospital discharge was 
 
PRIMARY RESEARCH AIM 
 
To investigate the need for safer clinical 
management of medications for beneficial 
continuity and integrated patient care, on and after 
hospital discharge 
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perpetuated post discharge in the community, regardless of the tool used to identify it.  
Practice changes within, and between tertiary and primary healthcare sectors for the 
integration of patient care, were found to be essential.   
 
In achieving the primary aim of the research, it is concluded that all 281 patients in 
the CofCP cohort were disadvantaged by the lack of medication reconciliation on their 
discharge from hospital.  In addition, 202/281 patients were further disadvantaged by the 
lack of medication review after discharge.  The evidenced representativeness of the 
minority subgroup meant their  unacceptable level of DRPs and PIPs post discharge, could 
be predicted for the full cohort of patients.  That is, all patients in the CofCP cohort have 
been shown to need safer clinical management of their medications for beneficial 
continuity and integrated care, on and after their discharge.  
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